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ABSTRACT. 
Gamma oscillations, synchronous network activity between 30 and 100 Hz, have been linked 
to higher cognitive functions. Adenosine receptor modulation has been shown to alter 
cognitive function in animals and humans. In this thesis the effects of adenosine receptor 
modulation on in vitro and in vivo hippocampal gamma oscillations were investigated as well 
as the underlying mechanisms.  
A1-receptor activation selectively decreased gamma oscillations while blocking A1-receptors 
and activating A2A-receptors increased gamma oscillations. Increasing endogenous 
adenosine levels suppressed gamma oscillations while decreasing endogenous adenosine 
levels facilitated gamma oscillations in vitro. Sharp electrode current clamp and whole-cell 
voltage clamp experiments showed that A1-receptor activation hyperpolarised resting 
membrane potential, reduced firing rate and EPSP amplitude and shifted the IPSC reversal 
potential to more negative potentials. Blocking A1-receptors increased pyramidal cell 
excitability and increased excitatory synaptic transmission. The results in vivo were more 
ambiguous but A1-receptor activation decreased power in all frequency bands indicating that 
adenosine receptors can modulate hippocampal gamma oscillations in vivo. A1-receptor 
blockage had no consistent effect on in vivo hippocampal gamma oscillations.  
Adenosine receptors modulate gamma oscillations in rodent hippocampal slices but are 
difficult targets for developing treatments that have cognitive benefits because of their 
ambiguous effects in vivo. 
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CHAPTER 1: INTRODUCTION. 
 
1.1. Caffeine and cognition. 
Caffeine is the world‟s most widely used psychoactive substance, but unlike most other 
psychoactive substances caffeine is legal and readily available. Caffeine is present in a 
variety of foods people ingest every day, like coffee, tea, energy drinks and chocolate. 
Caffeine is best known for its stimulatory effects and warding off drowsiness and restoring 
alertness. At concentrations associated with normal coffee consumption (1-10 µM) caffeine 
increases cortical activation and sensory information processing (Fredholm et al., 1999). At 
concentration reached during normal coffee consumption, caffeine is a non-specific 
adenosine receptor antagonist. Blocking adenosine receptors has been shown to enhance 
cognitive function and skill performance during football (Foskett et al., 2009), increase 
memory retention through blockage of A2A-receptors (Kopf et al., 1999), facilitate memory 
through A1-receptors in the posterior cingulate cortex (Pereira et al., 2002) and prevent 
memory impairment after a convulsive episode in early life (Cognato et al., 2010). Caffeine 
has also been shown to alter dopaminergic transmission and locomotor behaviour in 
laboratory animals, positively affect mood in humans, change sleep patterns in laboratory 
animals and humans, and increase activity in neocortical areas and the hippocampus in 
laboratory animals and humans. For a review of all the effects see (Fredholm et al., 1999). 
The cognitive benefits of caffeine are more pronounced in aged humans (Ryan et al., 2002). 
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1.2. Age-induced cognitive changes and synaptic plasticity. 
Physiological ageing is associated with changes in the brain. A well described effect of the 
ageing brain is the appearance of memory deficits often involving the hippocampus (Lynch, 
2004;Rosenzweig and Barnes, 2003). Older mammals have particular trouble with spatial 
information processing (Bach et al., 1999;Lynch, 2004;Rosenzweig and Barnes, 2003). The 
decreased performance of aged mammals is most likely not due to general cell loss in the 
hippocampus (Rasmussen et al., 1996). Thus more subtle neuronal and network changes 
are likely to be responsible for age-induced memory deficits. Memory formation in the brain 
almost certainly involves some form of synaptic modification. The two main processes by 
which memory is thought be formed are long-term potentiation (LTP) and long-term 
depression (LTD). For a review on how LTP and memory are linked see Lynch, 2004. With 
ageing there is not a total loss of LTP but rather a reduction in LTP when low-intensity 
protocols are used (Rosenzweig and Barnes, 2003). At the same time aged rats have a lower 
threshold for induction of LTD (Rosenzweig and Barnes, 2003). Taking both findings together 
it seems that aged rats have an increased threshold for LTP making it more difficult to 
encode a memory. At the same time aged rats‟ decreased threshold for LTD could potentially 
make it easier to erase a memory (Rosenzweig and Barnes, 2003). There is a negative 
correlation between the performance of animals in spatial learning tasks and the amount of 
LTP that could be induced in vitro in slices made from the same animal (Bach et al., 1999). 
One of the ways to increase the performance of aged animals in memory tasks is treatment 
with the cyclic adenosine monophosphate (cAMP) phosphodiesterase inhibitor rolipram. This 
suggests that a decrease in cAMP and/or cAMP induced signalling is one of the mechanisms 
contributing to the age-related change in memory processes (Lynch, 2004). Most likely one 
of the main reasons aged mammals show cognitive decline is change in network connectivity 
and function. In the hippocampus there is not a loss of cells but a change in the amount of 
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functional synapses each axon makes (Rosenzweig and Barnes, 2003). Aged animals have 
reduced network function possibly affecting cognition (Vreugdenhil and Toescu, 2005). 
Aged animals show an increase in endogenous adenosine levels that tonically activate 
adenosine receptors (Sebastiao et al., 2000). This increase is most likely a result of altered 
localised synaptic modification of extracellular adenosine metabolism (Cunha, 
2001;Sebastiao et al., 2000). Increased adenosine A1-receptor activation through elevated 
ambient adenosine levels will suppress neuronal activity and decrease the efficiency of 
synaptic transmission. Adenosine is considered a suppressor of neuronal activity (Dunwiddie 
and Masino, 2001). Adenosine A1-receptor activation has been negatively linked to cognitive 
performance in rodent models (Corodimas and Tomita, 2001;Fredholm et al., 1999;Von 
Lubitz et al., 1993). Adenosine A1-receptor activation reduces cAMP levels through inhibiting 
adenylyl cyclase (AC) activity (Fredholm et al., 2001). This indicates that the age-related 
reduction in cAMP levels could partly be due to increased adenosine A1-receptor activation 
through increased ambient adenosine levels. This would fit well with the increased beneficial 
effect caffeine has on cognition in aged humans (Ryan et al., 2002). 
 
1.3. Regulation of adenosine levels in the brain. 
Adenosine is considered a neuronal activity suppressant substance and the adenosine levels 
in the brain are tightly regulated. The ambient adenosine levels in the rat brain are 
estimated to be around 40 nM in the extracellular space with elevation up to 460 nM 
(Ballarin et al., 1991). In hippocampal brain slices the ambient adenosine levels fall within 
the physiological range between 140 and 200 nM (Dunwiddie and Diao, 1994). 
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1.3.1. Adenosine sources.  
Adenosine can reach the extracellular space through two main mechanisms: formation 
through dephosphorylation of adenine nucleotides by ecto-nucleotidases, and release from 
the intracellular space through (equilibrium) transporters (see Figure 1.1). 
Virtually any adenine nucleotide can be dephosphorolated to 5‟-adenosine monophosphate 
(5‟-AMP) by ecto-nucleotidases, ecto-phosphodiesterases and apyrases. Subsequently 5‟-
AMP is dephysphorelated by 5‟-nucleotidase to adenosine. The ecto-enzymes involved in 
converting adenine nucleotides to adenosine are widespread throughout the brain and have 
a broad specificity (Dunwiddie and Masino, 2001). The process of converting adenine 
nucleotides to adenosine is generally rapid and takes less than a second (Dunwiddie et al., 
1997). There are many mechanisms by which adenine nucleotides are released into the 
extracellular space. One of such mechanisms is the co-release of adenosine triphosphate 
(ATP) with neurotransmitters, like acetylcholine, dopamine, serotonine and norepinephrine. 
The second mechanism by which adenosine can reach the extracellular space is by facilitated 
diffusion through equilibrium transporters (see Figure 1.1). In the brain the main transporter 
adenosine flows through in the equilibrative nucleoside transporter 1 (ENT-1) (Cunha, 
2001;Latini and Pedata, 2001). The ENT1 is widespread throughout the rat brain but has a 
relatively high density in the hippocampal region (Guillen-Gomez et al., 2004). These 
transporters are passive and equilibrate the adenosine concentration across cellular 
membranes. Due to the relatively high activity of the intracellularly located adenosine kinase 
the flow of adenosine is usually inwards. Adenosine can be formed intracellularly from 
adenosine monophosphate (AMP) by cytosolic 5‟-nucleotidase (see Figure 1.1). Under 
normal physiological conditions basal cytosolic AMP concentrations (0.1-0.5 mM) are not 
high enough to serve as a substrate for 5‟-nucleotidase (Km 1-14 mM) (Latini and Pedata, 
2001). The intracellular concentration of adenosine triphosphate (ATP) is about 50 times 
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higher than AMP. A small change in ATP catabolism can therefore induce a large increase in 
AMP concentration, which is then converted into adenosine. 
 
Figure 1.1. Overview of the most important pathways of adenosine production and 
metabolism. Adenosine kinase is the most active enzyme in metabolizing adenosine. 
Adenosine can be formed intra- and extracellular by 5‟-nucleotidases. Two inhibitors are 
indicated that are used in this thesis (see chapter 3). Abbreviations: 5-IT, 5-iodotubericidin; 
ADA, adenosine deaminase; ADP, adenosine diphosphate; ATP, adenosine triphosphate; 
cAMP, cyclic adenosine monophosphate; ENT-1, equilibrative nucleoside transporter 1; NBTI, 
S-(4-nitrobenzyl)-6-thioinosine; PDE, cAMP phosphodiesterase; SAH, S-adenosyl 
homocysteine. Figure inspired by Latini 2001. 
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The intracellular formation of adenosine from catabolism of cytosolic ATP can be seen as a 
very sensitive signal of metabolic rate or metabolic stress (Latini and Pedata, 2001). Under 
metabolic challenging conditions like hypoxia or ischemia extracellular adenosine levels 
increase rapidly (Dale et al., 2000;Latini et al., 1999;Winn et al., 1981). This increase in 
extracellular adenosine is due to increased formation of intracellular adenosine subsequently 
transported through equilibrative transporters to the extracellular space. This process is 
linked to the balance of energy supply and demand and thus cytosolic ATP degradation 
(Latini and Pedata, 2001). 
Another source of extracellular adenosine is released cAMP. Neurons can release cAMP 
through a non-specific energy dependent transporter. The released cAMP is then converted 
to 5‟-AMP by ecto-phosphodiesterase and subsequently to adenosine by 5‟-nucleotidase (see 
Figure 1.1). This suggests that neurotransmitters acting on metabotropic receptors coupled 
to AC could regulate extracellular adenosine levels by changing intracellular cAMP levels. 
Increased activity of metabotropic receptors can, through increased AC activity, increase 
cAMP levels which will be converted into adenosine eventually (Latini and Pedata, 2001). 
This process is not very rapid and unlikely to be the source of adenosine in acute metabolic 
challenging conditions like hypoxia, but prolonged neurotransmitter release could induce 
slow changes in intra- and/or extracellular cAMP and adenosine levels. This process could act 
as a fail-safe to keep neuronal activity from becoming excessive through suppressing 
neuronal activity by increasing adenosine levels.    
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1.3.2. Adenosine metabolism. 
The main mechanism by which adenosine is removed is through conversion by cytosolic 
adenosine kinase to 5‟-AMP (see Figure 1.1). When adenosine levels increase substantially 
adenosine deaminase (ADA) helps to clear adenosine by converting it to inosine. Under 
normal physiological conditions adenosine concentrations are in the nanomolar range which 
makes adenosine kinase the main adenosine sink. ADA will only start to help clear adenosine 
once levels rise to the micromolar range (Fredholm et al., 1999;Latini and Pedata, 2001). 
Adenosine kinase is the most important enzyme in clearing adenosine. Blocking adenosine 
kinase has a much bigger effect on adenosine release compared to ADA blockage (Lloyd and 
Fredholm, 1995). 
Another enzyme of importance in adenosine metabolism is S-adenosylhomocysteine 
hydrolase (SAH hydrolase). SAH hydrolase guards the equilibrium between S-
adenosylhomocysteine and adenosine + L-homocysteine. The activity of this enzyme does 
not depend on the adenosine concentration but rather the amino acid concentration. When 
L-homocysteine levels are low new amino acids are formed thereby also releasing 
adenosine. The reverse is also true, when L-homocysteine levels are high adenosine can be 
trapped inside the cell because it is converted to S-adenosylhomocysteine (Fredholm et al., 
1999;Latini and Pedata, 2001). 
 
1.4. Adenosine receptors. 
So far four distinct adenosine receptors have been cloned and characterised in the brain: A1-
receptors, A2A-receptors, A2B-receptors and A3-receptors (Fredholm et al., 2001). All four 
receptors subtypes are seven transmembrane domain receptors and G-protein coupled (see 
Table 1.1). The A1-receptor has the highest affinity for adenosine (~70 nM) and the A2A-
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receptor has an affinity for adenosine still in the nanomolar range (~150 nM). The A2B-
receptor and A3-receptor have an affinity for adenosine in the micromolar range (see Table 
1.1). With adenosine concentrations being between 40 and 460 nM in vivo (Ballarin et al., 
1991), ambient adenosine levels are high enough to activate both A1- and A2A-receptors. The 
effects of minor changes in ambient adenosine levels will therefore be dependent on the 
distribution of A1- and A2A-receptors within different brain structures. When adenosine levels 
rise substantially during pathological conditions the A2B- and A3-receptors will also be 
activated. Thus the A1- and A2A-receptors will be the most likely targets to prevent cognitive 
decline or boost cognitive function in similar ways as caffeine does. 
 
1.4.1. Adenosine receptor distribution within the brain and periphery. 
Adenosine receptors are prevalent throughout the central nervous system (see Table 1.1). 
Adenosine receptors are so common that you could almost say they are present on every 
cell. The A1-receptor is the most abundant receptor of all adenosine receptors in the brain. 
A1-receptors are present in virtually all brain areas with the highest levels in the 
hippocampus, cerebral and cerebellar cotex and certain thalamic nuclei (Fredholm et al., 
1999;Ochiishi et al., 1999). A2A-receptors are especially found in dopamine receptor (D1 and 
D2) rich regions of the brain (Fredholm et al., 2001). The highest concentration of A2A-
receptors is found in the caudate putamen, nucleus accumbens and the olfactory bulb. In 
the rest of the brain A2A-receptor mRNA is expressed in very low quantities but functional 
studies do show A2A-receptors are present in other brain areas. Most likely A2A-receptors are 
present in the hippocampus and cortex on neurons that project to these areas. A2A-receptors 
have been shown to exist on the terminals of striatopallidal GABAergic projections. The A2B-
receptor and the A3-receptor are expressed in low levels in most of the brain. There is an 
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intermediate expression of A3-receptors in the cerebellum and hippocampus (Fredholm et 
al., 2001). 
Adenosine receptors are also expressed in other organs besides the brain. The peripheral 
distribution of receptors can have important implication when it comes to possible side 
effects when using adenosine receptor acting drugs. A1-receptors are highly expressed in the 
heart, eye and adrenal glands, and also present in muscle tissue, the liver and colon. A2A-
receptors are highly expressed in the spleen and leukocytes, and also present in the heart 
and blood vessels. Data on the A2B- and A3-receptors is less clear because of the lack of 
specific ligands. A2B-receptors are thought to be present in the bladder and colon, and also 
present on blood vessel and in the eye. A3-receptors are expressed in the testis and mast 
cells and also present in the liver and thyroid. Some of the physiological effects of adenosine 
receptors are: reduced hart rate, decreased renal blood flow, immunosuppression, 
vasodilatation and alteration of pain perception (Fredholm et al., 2001;Fredholm, 2010). 
Though this is far from a complete list of physiological effects, it is clear that adenosine 
receptors can influence many processes in the body. 
 
1.4.2. Adenosine receptor distribution in the hippocampus. 
The hippocampal formation consists of three main subfields (see Figure 1.2): the dentate 
gyrus, the cornu ammonis 3 region (CA3) and the cornu ammonis 1 region (CA1). The CA2 
region is less well defined in the rat and will therefore not be mentioned any further in this 
thesis. The hippocampus is very structured with all the cell bodies arranged in one line 
(stratum pyramidale, see Figure 1.2). The CA3 area has excitatory projections to the CA1 
area (Schaffer-Collaterals). Where the CA3a and CA3b project to both the CA1 stratum 
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radiatum and stratum oriens the CA3c area projects only to the stratum radiatum (blue lines 
in Figure 1.2) (Freund and Buzsaki, 1996). 
 
Figure 1.2. Schematic representation of the hippocampus. The cellular layers are indicated 
by the thick grey lines. The excitatory projections from the CA3 area to the CA1 area 
(Schaffer-Collaterals) are depicted in blue.  
Abbreviations: CA1 = Cornu Ammonis 1, CA3 = Cornu Ammonis 3,  DG = dentate gyrus, S-
C = Schaffer-Collaterals, S-LM = Stratum Lacunosum Moleculare, SO = Stratum Oriens, SP 
= Stratum Pyramidale, SR = Stratum Radiatum. 
 
Because the experiments in this thesis are done in the hippocampus the adenosine receptor 
distribution within the hippocampus will be looked at in more depth in this section. The A1-
receptor has been studied most intensively and is most abundant within the hippocampus 
(see Table 1.1). Studies using mRNA show the highest A1-receptor expression in the 
granular layer of the dentate gyrus (DG) and the stratum pyramidale (SP) of the Cornu 
Ammonis (CA) (Swanson et al., 1995).  
In contrast to mRNA binding studies specific ligand binding studies showed higher density 
staining in the stratum oriens (SO), stratum radiatum (SR), and stratum lacunosum 
moleculare (SLM) (Ochiishi et al., 1999;Swanson et al., 1995). Both the cell bodies of 
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pyramidal cells and interneurons express in A1-receptors with no apparent discrimination 
between interneuron subtypes (Ochiishi et al., 1999). Even though staining of the cell bodies 
is less dense compared to axonal staining, individual neurons can be identified. One 
important difference between interneurons and pyramidal cells is that on inteneurons there 
are no A1-receptors present on axons (Ochiishi et al., 1999) while on pyramidal cells the 
axons show the highest density of A1-receptors (Swanson et al., 1995). The axons from and 
to the hippocampus express A1-receptors in varying densities. Figure 1.2.A gives a 
schematic overview of A1-receptor distribution in the hippocampus including the main 
incoming and outgoing hippocampal inputs colour coded for adenosine A1-receptor density. 
Projections from the DG to the CA3 area express A1-receptors in high density. The axons 
from CA3 pyramidal cells passing through the SP projecting to the CA1 (Schaffer-collaterals) 
have a high A1-receptor density which is maintained in the SR of the CA3 area but 
expression diminishes in the SR of the CA1 area. The axons going out of the CA1 also 
express A1-receptors abundantly, but not as dense as axons originating in the CA3 area. 
Radially oriented fibres in CA1, most likely fibres from the temporoammonic pathway, have 
a moderate A1-receptor density. Projections from the entorhinal cortex (perforant path) 
ending in the molecular layer of the dentate gyrus have a moderate density of A1-receptors, 
with projections ending in the outer molecular layer having a slightly higher density than 
projections ending in the inner molecular layer (Swanson et al., 1995). In the hippocampus 
adenosine receptors are not present on the dendritic tree (Ochiishi et al., 1999;Rebola et al., 
2003). A1-receptors are enriched in the active zone of the synaptic cleft on both the pre- and 
post-synaptic membrane (Figure 1.2.B). The plasma membrane outside the synaptic zone 
has some A1-receptor expression on the pre-synaptic membrane but not as much as along 
the axon or in the active zone of the synapse. On the post-synaptic membrane there is no 
further expression of A1-receptors (Ochiishi et al., 1999;Rebola et al., 2003). 
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The A2A-receptors mRNA expression pattern is strikingly similar to the expression of A1-
receptor mRNA in the hippocampus (Cunha et al., 1994;Sebastiao and Ribeiro, 1996). The 
biggest difference is the amount of expression between the two different receptors. Where 
A1-receptors are expressed abundantly A2A-receptors are rather sparse. Though A2A-
receptors are sparse in the hippocampus they are functional and shown to oppose A1-
mediated effects (Cunha et al., 1994;Sebastiao and Ribeiro, 1996). 
Adenosine receptors can also for heteromers with other receptor types. The A1-receptor and 
the A2A-receptor have been shown to form heteromers with group-I metabotropic glutamate 
receptors (Tabata et al., 2007). The A2A-receptor can also form heteromers with dopamine 
receptors and the expression patterns of dopamine receptors and A2A-receptors are strikingly 
similar (Fredholm et al., 1999;Tabata et al., 2007). 
 
1.4.3. Signalling through adenosine receptors. 
The A1-receptor is coupled to the pertussis toxin-sensitive G-Proteins (Gi1/2/3 and Go). The 
A2A-receptor is coupled to Gs and Golf G-proteins. Thus much of the effects of adenosine 
receptor activation can be predicted from what is known about G-protein signalling. The A2B-
receptor and A3-receptor are also G-protein coupled (see Table 1.1) but because their 
affinity for adenosine in very low and their distribution in the brain is sparse the focus in this 
thesis will be on the effects of A1- and A2A-receptors.  
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Figure 1.2. A1-receptor density in the hippocampal formation. A. Overview of axonal 
projections with known A1-receptor distribution from receptor labelling techniques. The 
cellular layer is indicated by the blue line and has a low density of A1-receptors. Projections 
from the entorhinal cortex ending in the molecular layer of the dentate gyrus (ML-DG) 
display A1-receptors with projections ending in the outer ML-DG having a higher density 
than projections ending in the inner ML-DG. The granule cell layer of the dentate gyrus (GC-
DG) has a low A1-receptor density which is confined to the fibres passing through the GC-
DG. Fibres from the DG projecting to the CA3 area through the Hilus have a high A1-
receptor density. The CA3 area shows high density A1-receptor in the stratum radiatum (SR) 
and stratum oriens (SO). In the stratum pyramidale (SP) the cell bodies have a low density 
A1-receptor while the fibres passing through the SP are dense in A1-receptor. The Schaffer-
collatterals projecting from CA3 to CA1 have a much lower A1-receptor density in the SR of 
the CA1 than the mossy fibre projections to the CA3 molecular layer. The radially oriented 
fibres showing moderate density of A1-receptor are most likely projections from the 
temporoammonic Pathway. The axons projecting from the CA1 SO are moderately high in 
A1-receptor density. Hippocampal A1-receptors seem to be confined mostly to axons and 
there is no evidence that A1-receptors are also displayed along the dendritic tree in any area 
of the hippocampus (Swanson et al., 1995) B. Schematic high magnification of the star in 
panel A. Though A1-receptors are not found on dendritic fibres they are enriched in nerve 
terminals on the pre and post synaptic membrane in the active zone. The pre-synaptic end 
of the synapse which comes from the axons also has A1-receptors on the rest of the 
terminal although not as dense as in the synaptic cleft. The display of A1-receptors on the 
post-synaptic membrane of the nerve terminal is confined only to the active zone and there 
are no A1-receptors on the rest of the dendrite (Rebola et al., 2003). Abbreviations: CA1 = 
Cornu Ammonis 1, CA3 = Cornu Ammonis 3, DG = Dentate Gyrus, H = Hilus, PP = Perforant 
Path, SLM = Stratum Lacunosum Moleculare, SO = Stratum Oriens, SP = Stratum 
Pyramidale, SR = Stratum Radiatum, TAP = Temporoammonic Pathway. 
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A1-receptor activation: inhibits AC activity thereby reducing cAMP levels; enhances several 
K+-channels function; inhibits several types of Ca2+-channels (N and Q type); and is 
positively coupled to phospholipase C and phospholipase D. A2A-receptor activation increases 
AC function thereby increasing cAMP levels and activates some voltage sensitive Ca2+-
channels (especially L-type channels) (Fredholm et al., 1999;Fredholm et al., 2001). 
Especially clear in the effect on cAMP levels A1- and A2A-receptors have partly opposing 
effects on a cellular level. This is important to keep in mind because both receptors are often 
co-expressed in the same brain areas and cells. The effect of non-specific agonists or 
antagonists can therefore depend on receptor distribution and possibly cellular location of 
the receptors. 
A1-receptors can also inhibit receptors directly through heteromer formation. In cerebellar 
Purkinje cells A1-receptors inhibit metabotropic glutamate receptors through a G-Protein 
independent pathway (Tabata et al., 2007).  
 
1.5. Effects of adenosine receptors on the brain function. 
Adenosine is not considered a neurotransmitter because it is not released in a classical Ca2+-
dependent fashion or stored in vesicles. There is also no evidence for synapses with 
adenosine as their primary neurotransmitter (Dunwiddie and Masino, 2001). Therefore 
adenosine is considered to have a neuromodulatory role. Adenosine receptors have been 
shown to alter the release of virtually every neurotransmitter system including, glutamate, 
gamma-aminubutyric acid (GABA), acetylcholine, norepinephine, 5-hydroxytryptamine (5-
HT), dopamine and others.  
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Though adenosine is not considered a neurotransmitter there is evidence that adenosine is 
released in an activity-dependent matter which is sensitive to TTX and Ca2+ (Wall and Dale, 
2007). 
 
1.5.1. Synaptic effects of adenosine receptors. 
Adenosine A1-receptors activation blocks neurotransmitter release in mainly excitatory 
synapses (Haas and Selbach, 2000;Yoon and Rothman, 1991). Inhibitory (GABAergic) 
synapses are not affected when monosynaptic stimulation is used, but polysynaptic 
inhibition is almost completely blocked by A1-receptor activation (Thompson et al., 1992). 
The reduction in synaptic signalling by A1-receptors is due to prevention of vesicles releasing 
their content. Adenosine receptors are perfectly placed to quickly and efficiently alter 
vesicular transmitter release because of their enrichment in the active part of the synapse 
(see Figure 1.2.B). Vesicular transmitter release is most likely inhibited via a direct effect on 
N-type Ca2+-channels through G-proteins independent from cAMP levels (Cunha, 2001;Wu 
and Saggau, 1994). Even though this process seems most important other effects of 
adenosine receptors on vesicle release have also been described. A1-receptors could also 
directly affect the affinity of the release apparatus for calcium (Scanziani et al., 1992), or 
directly affect the release apparatus itself (Capogna et al., 1996). 
Adenosine A2A-receptor activation has the opposite effect and facilitates synaptic 
transmission. An A2A-receptor antagonist facilitates GABA release from hippocampal axonal 
endings (Cunha and Ribeiro, 2000). As A2A-receptors are also G-protein coupled many 
pathways could be activated. Facilitated synaptic transmission through A2A-receptor 
activation is dependent on protein kinase C but not protein kinase A activation (Cunha and 
Ribeiro, 2000). Adenosine A2A-receptors also increase cAMP levels (Table 1.1) through 
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affecting AC activity. AC activation has also been shown to increase neurotransmitter release 
from excitatory synapses in the rat hippocampus (Chavez-Noriega and Stevens, 1994). A2A-
receptors can also facilitate synaptic transmission through activating P-type Ca2+-channels, 
thereby enhancing vesicle release (Cunha, 2001;Mogul et al., 1993).  
Adenosine receptors can influence synaptic transmission through changing vesicular 
transmitter release by influencing Ca2+-channel activity, and by cAMP dependent pathways. 
The effect of adenosine (non-specific agonist) will depend on receptor distribution as A1- and 
A2A-receptors have opposite effects on synaptic transmission. 
 
1.5.2. Cellular effects of adenosine receptors. 
One of the clearest effects of adenosine A1-receptor activation is a hyperpolarisation of the 
resting membrane potential in pyramidal cells (Greene and Haas, 1985), many other 
neurons and astrocytes (Hosli et al., 1987) and interneurons (Li and Henry, 2000). The A1-
receptor induced hyperpolarisation is caused by increased K+-current across the membrane 
(Alzheimer and ten Bruggencate G., 1991). As adenosine receptors signal through G-
proteins it is no surprise G-protein-coupled inwardly rectifying K+ (GIRK) channels are 
responsible for the A1-receptor induced hyperpolarisation (Chen and Johnston, 
2005;Takigawa and Alzheimer, 2002). Interestingly A1-receptor antagonists seem to not 
have any effect on resting membrane potential (Luscher et al., 1997). 
A1-receptor activation also increases accommodation of action potential firing during a 
prolonged depolarizing stimulus in CA1 pyramidal cells (Greene and Haas, 1985;Haas and 
Selbach, 2000). Also the slow afterhyperpolarization (AHP) is prolonged during adenosine 
application (Greene and Haas, 1985;Haas and Selbach, 2000). Both processes are under the 
control of AC activity which makes it likely adenosine receptors can influence them. 
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1.6. Gamma oscillations. 
Neuronal networks in the brain sometimes display patterns of oscillatory activity. Some 
structures in the brain generate these rhythms and can therefore be studied in vitro. Of 
particular interest are oscillations within the gamma frequency band (30-100 Hz). Gamma 
oscillations are linked to a variety of cognitive functions including sensory processing (Engel 
and Singer, 2001;Singer, 1993), memory (Fell et al., 2001;Herrmann et al., 2004) and 
selective attention (Fries et al., 2001). The strength of gamma oscillations may affect 
cognitive performance (Fuchs et al., 2007). In rodents gamma oscillations are prominent 
during explorative behaviour (Buzsaki et al., 2003;Csicsvari et al., 2003) and thought to 
contribute to encoding and retrieval of memory (Bauer et al., 2007;Montgomery and 
Buzsaki, 2007). Gamma oscillations are thought to transfer information between different 
brain areas. To transfer information from one area to another coupling and synchronization 
of the different areas seems very important (Fell et al., 2001;Jutras et al., 2009). To code 
information within a gamma oscillation two main mechanisms are proposed: spike timing 
and phase encoding. The discussion of these two mechanisms is outside the scope of this 
introduction but discussed in (Fries et al., 2007).  
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Figure 1.3 Simplified schematic drawing of a CA3 hippocampal network. The green 
triangular cells are principal cells and the orange round cell represents an interneuron.  
 
1.7. Hippocampal gamma oscillations. 
The hippocampus is an area involved in memory processing. Because of the distinct laminar 
cellular organization within its networks the hippocampus is a perfect area to study network 
oscillations. The hippocampus has a relatively simple neuronal organization where the cell 
bodies of principal cells are aligned in one layer (stratum pyramidale, SP, see Figure 1.2.A), 
with axons originating from one end (stratum oriens, SO) and the dendrites extending 
towards the other side (stratum radiatum, SR). The axons from the CA3 area project to ipsi-  
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and contra-lateral CA3 and CA1 cells, targeting both principal cells as well as GABAergic 
interneurons (Hajos and Paulsen, 2009). The principal cells are very uniform of character 
within the hippocampus, while there are a variety of GABAergic interneurons (Freund and 
Buzsaki, 1996). For gamma rhythm generation the perisomatic inhibitory interneuron 
(basket cells and axo-axonic cells) seems most important (Hajos and Paulsen, 2009). Figure 
1.3 is a schematic simplified drawing of how pyramidal cells and perisomatic interneurons 
are connected within the hippocampus. The key characteristic for a network to be able to 
generate gamma oscillations is the convergent input onto interneurons from pyramidal cells 
and the divergent output from interneurons to pyramidal cells. Because the network is 
organised in this way excitatory input from any pyramidal cell will cause the interneurons to 
inhibit all pyramidal cells. Thus any excitatory input onto pyramidal cells will only be 
effective during the time window of fading inhibition. Interneurons fire with a slight phase 
delay compared to principal cells after which the whole network is silenced and a new 
gamma cycle can be started (Hajos and Paulsen, 2009). The majority of the extracellular 
recorded signal is the rhythmic inhibitory post-synaptic potentials (IPSPs) caused by 
interneuron firing. This might seem slightly contradictory as the pyramidal cells are the main 
driving force behind the oscillatory activity. But because only a small portion of the 
pyramidal cells are active during a cycle their contribution to the extracellular field is rather 
small (Hajos and Paulsen, 2009). 
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1.7.1. Different models to study hippocampal gamma oscillations in vitro. 
Gamma oscillations revolve around principal cells that recurrently activate interneurons 
whereby the interneurons can synchronise the network. Most in vitro models increase 
excitatory drive to pyramidal cells which would lead to a more effective start of a gamma 
cycle. One way to increase excitatory drive to principal cells in the hippocampus is by 
activating cholinergic muscarinic receptors through carbachol (CCH) application (Fisahn et 
al., 1998). In making slices, cholinergic inputs from the medial septum/diagonal band are 
cut off. Adding CCH is a pharmacological way of restoring that input and is quite effective in 
generating gamma oscillations. 
Another way to induce gamma oscillations in the hippocampus is through activation of 
kainate receptors, possibly mimicking the loss of glutamatergic tone after slicing. Kainate 
receptors are widely expressed in the hippocampus. The GluR6 subunit is crucial for 
oscillation induction and increases excitatory drive to pyramidal cells and interneurons 
(Fisahn, 2005). 
Gamma oscillations can also be induced by activation of metabotropic glutamate receptors 
(Boddeke et al., 1997). This model differs slightly from the CCH model but also relies on 
increased activity of pyramidal cells (Boddeke et al., 1997). 
The last model discussed here is the spontaneous gamma oscillations in hippocampal slices. 
If slice quality is very high, hippocampal slices can display gamma oscillations without any 
pharmacological induction (Pietersen et al., 2009b;Trevino et al., 2007). Even though all 
previous models reliably induce gamma oscillations, there are differences between the 
involvement of different subsets of interneurons (Hajos et al., 2004;Middleton et al., 
2008;Palhalmi et al., 2004) and different contribution of recurrent excitation (Bartos et al., 
2007). 
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The different models could represent different in vivo processes within the hippocampus 
dependent on the input received. For instance, the spontaneous gamma oscillation could 
represent gamma oscillations found during rapid eye movement sleep (Montgomery et al., 
2008), while kainate (KA) and CCH models could be more a model for behaviour that 
increases glutamatergic or cholinergic receptor activation (e.g. exploration). 
In this thesis the spontaneous and KA-induced models of hippocampal gamma oscillations 
are used predominantly, but also some work is done in the CCH-induced model. 
 
1.8. Adenosinergic modulation of hippocampal gamma oscillations: from single cell to whole 
animal. 
This thesis will look at how adenosine receptors can influence hippocampal gamma 
oscillations in vitro, in vivo and look at the underlying cellular and network changes 
responsible for adenosine receptor modulation changes in hippocampal gamma oscillations. 
 
1.8.1. Can adenosine receptor modulation alter hippocampal gamma oscillations in vitro? 
In the first part of this thesis the role of adenosine receptor modulation on different in vitro 
models of hippocampal gamma oscillations will be investigated. Gamma oscillation strength 
has been linked to memory performance (Fuchs et al., 2007). The adenosine receptor 
antagonist caffeine has also been linked to increased memory performance (Fredholm et al., 
1999;Pereira et al., 2002). Taking both these facts together adenosine receptors could 
possibly affect memory performance through gamma oscillation strength modulation. 
Adenosine receptors are well placed to influence network activity through its various cellular 
and synaptic effects (see Table 1.1). Caffeine has been shown to increase KA-induced 
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hippocampal gamma oscillations in vitro (Pietersen et al., 2009a). Caffeine is a non-specific 
adenosine receptor antagonist and will activate both A1- and A2A-receptors in the 
hippocampus. A1-receptors are more abundant within the hippocampus than A2A-receptors 
(see Table 1.1) and caffeine has a higher affinity for A1-receptors (Fredholm et al., 1999). 
Thus it is more likely that the caffeine induced increase in gamma oscillations is an effect 
mediated through A1-receptor antagonism. A2A-receptors have the opposite effect on many 
signalling pathways (see Table 1.1) and can inhibit A1-receptor function directly (Cunha, 
2001). Therefore it is likely that drugs specific for the A2A-receptor have opposite effects 
compared to A1-receptor acting drugs.  
In chapter 2 the effects of specific and non-specific adenosine receptor acting drugs on 
different models of hippocampal gamma oscillations (spontaneous, KA-induced and CCH-
induced) will be described. It is hypothesised that the non-specific A1-receptor agonist 
adenosine will decrease gamma oscillation strength and the non-specific A1-receptor 
antagonist caffeine will increase gamma oscillation strength in all models. The specific A1-
receptor antagonist 8-CPT and specific A2A-receptor agonist CGS21680 are expected to 
increase gamma oscillation strength. 
To be able to say anything about whether or not natural fluctuations in ambient adenosine 
levels can influence cognitive function, endogenous adenosine levels are modulated in 
chapter 3. Intracellular adenosine breakdown is decreased by inhibiting adenosine kinase 
(see Figure 1.1) and expected to increase adenosine levels and thereby suppress 
hippocampal gamma oscillations. Because ambient adenosine levels in hippocampal slices 
are high enough to tonically activate adenosine receptors (Dunwiddie and Diao, 1994), 
reducing the extracellular adenosine concentration, by blocking the ENT-1 transporter and 
adding ADA, is expected to increase hippocampal gamma oscillations. 
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1.8.2. What cellular and synaptic changes underlie adenosinergic modulation of hippocampal 
gamma oscillation? 
After establishing the effects of adenosine receptor modulation on hippocampal gamma 
oscillations (chapter 2 and 3) the cellular and synaptic changes underlying these effects are 
explored. In chapter 4 and 5 the effects of A1-receptor agonists and antagonists on CA3c 
pyramidal neurons will be investigated. It is expected that A1-receptor activation will 
hyperpolarise neurons (Greene and Haas, 1985;Li and Henry, 2000) and inhibit excitatory 
input (Haas and Selbach, 2000;Yoon and Rothman, 1991). A1-receptor blockage will 
probably increase excitation but not depolarise the resting membrane potential (Luscher et 
al., 1997). Because gamma oscillations are mainly recorded IPSPs a closer look will be taken 
at polysynaptic and monosynaptic inhibition. A1-receptor agonists are expected to decrease 
polysynaptic inhibition but not mono-synaptic inhibition (Thompson et al., 1992). 
 
1.8.3. Does adenosinergic modulation have the same effect in vivo? 
To be able to say anything about whether or not adenosine receptors are a good target for 
prevention of cognitive decline or enhancement of cognitive function the results obtained in 
vitro have to be verified in vivo. Chapter 6 will look at the effects ventricular injected A1-
receptor acting drugs have on gamma oscillations in anaesthetised animals. It is expected 
that A1-receptor modulation will have similar effects on gamma oscillations in vivo. Because 
adenosine receptors are so widespread throughout the brain (see Table 1.1) other brain 
areas can have unexpected influences on the hippocampus. 
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Finally in the last chapter (chapter 7) the most important results will be summarised and 
discussed in relation to cognition. 
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Receptor 
subtype 
A1-receptor A2A-receptor A2B-receptor A3-receptor 
Adenosine 
affinity 
~70 nM ~150 nM ~5100 nM ~6500 nM 
G-protein 
coupling 
Gi1/2/3 / Go Gs / Golf /G15/16 Gs / Gq/11 Gi2/3 / Gq/11 
Effect of G-
protein 
coupling 
AC   cAMP , 
K+-channel 
function , 
Phospholipase C 
and D , Ca2+-
channel (N, Q 
type)  
 
AC   cAMP, 
Ca2+-channel (L-
type)  
AC   cAMP, 
phospholipase C 
 
AC   cAMP , 
phospholipase C 
, intracellular 
Ca2+  
Distribution 
in the brain 
High density: 
Hippocampus, 
cerebral and 
cerebellar cortex, 
certain thalamic 
nuclei 
 
Intermediate 
levels: other brain 
regions 
High density: 
caudate putamen, 
nucleus 
accumbens, 
tuberculum 
olfactorium), 
olfactory bulb 
 
Low density: Rest 
of the brain 
Low density: 
brain 
Intermediate 
density: 
cerebellum, 
hippocampus 
 
Low levels: most 
of the brain 
Synaptic 
effects 
Inhibits 
neurotransmitter 
release 
Facilitates 
neurotransmitter 
release 
Possibly 
facilitates 
neurotransmitter 
release 
Possibly inhibits 
neurotransmitter 
release 
Cellular 
effects 
Hyperpolarises 
resting membrane 
potential 
Depolarises 
resting membrane 
potential (in the 
presence of an A1-
receptor blocker 
Unknown unknown 
 
Table 1.1. Relevent facts of adenosine receptors . Abbreviations: AC, adenylyl cyclase; 
cAMP, cyclic adenosine monophosphate. 
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CHAPTER 2: MODULATION OF GAMMA OSCILLATIONS THROUGH ADENOSINE 
RECEPTORS. 
 
2.1. Introduction. 
In this chapter the effects of adenosine receptor acting drugs on hippocampal gamma 
oscillations in vitro will be investigated. Of the possible ways to investigate hippocampal 
gamma oscillations in vitro, three models were chosen: carbachol-induced (CCH), kainate-
induced (KA) and spontaneous. 
Local networks can generate rhythmic activity in interneurons at frequencies in the gamma 
band (30-100 Hz) through increased principal cell activity (Bartos et al., 2007). Multiple 
pyramidal cells converge their input onto interneurons, while the output of interneurons 
diverges onto multiple principal cells (see Figure 1.3). Because the network is setup in that 
way interneurons can synchronise principal cell activity, causing sustained rhythmic activity 
(Fisahn et al., 1998). Increases in gamma oscillations are seen during exploration behaviour 
in rodents (Buzsaki et al., 2003). Also higher cognitive processes like memory (Herrmann et 
al., 2004) and sensory information processing (Engel and Singer, 2001) have been linked to 
gamma oscillations. The strength of gamma oscillations may affect cognitive performance 
(Fuchs et al., 2007). 
Gamma oscillations can occur naturally in hippocampal slices (Pietersen et al., 
2009b;Trevino et al., 2007), and can be evoked by activation of muscarinic receptors 
(Fisahn et al., 1998) or activation of kainate receptors 
(Hajos et al., 2003). Gamma oscillations can be modulated by neurotransmitters like 
norepinephrine (Hajos et al., 2003). 
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Adenosine is a neuroprotective agent that increases strongly in extracellular concentration 
during pathological conditions like hypoxia (Frenguelli et al., 2003;Winn et al., 1981) and 
ischemia (Latini et al., 1999;Lloyd and Fredholm, 1995). Adenosine has been shown to 
reduce glutamate and acetylcholine neurotransmitter release through adenosine A1-receptor 
activation (Haas and Selbach, 2000). 
Caffeine is a non-specific adenosine receptor antagonist (Fredholm et al., 1999) and has 
been described to have cognitive enhancing effects in rodents and humans (Fredholm et al., 
1999;Hogervorst et al., 2008). One of the possible mechanism by which caffeine can 
enhance cognitive function is by increasing brain synchronicity within the gamma range. 
Caffeine has been shown to increase KA-induced gamma oscillations within the hippocampus 
in vitro (Pietersen et al., 2009a). First the effect of caffeine and adenosine on CCH-induced 
gamma oscillations will be investigated. The effect of different doses of adenosine on KA-
induced hippocampal gamma oscillations will be investigated. One dose of adenosine will be 
used in both other models as well. Further receptor specificity will be determined in KA-
induced gamma oscillations. We predict that caffeine will increase CCH-induced gamma 
oscillations and that adenosine will decrease gamma oscillations in all models in a dose 
dependent manner. The effect of the non-specific agonist adenosine is expected to mainly 
come from adenosine A1-receptor modulation, because the affinity for the A1-receptor is 
higher than for the other adenosine receptors (see introduction Table 1.1). As adenosine 
A2A-receptors oppose the effects of adenosine A1-receptors ((Fredholm et al., 2001), 
introduction Table 1.1) it is predicted that a specific adenosine A2A-receptor agonist will 
increase gamma oscillations. 
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2.2. Materials and methods. 
All experiments complied with the University of Birmingham ethical committee and all 
procedures were performed under the UK Animals (Scientific Procedures) Act 1986. 
 
2.2.1. Tissue preparation. 
Male C57BL/J6 mice (2-5 months) were anaesthetised by an intra-peritoneal injection of a 
ketamine (75 mg/kg) and medetomidine (1 mg/kg) mixture, and killed by cervical 
dislocation. Mice were used because work where this thesis is based on was done in mouse 
hippocampal slices. The brain was removed and chilled in an oxygenated sucrose based 
cutting solution containing (in mM): sucrose, 189; KCl, 2.5; NaHCO3, 26; NaH2PO4, 1.25; D-
glucose 10; MgCl2, 5; CaCl2, 0.1; pH 7.4. Using an Integraslicer (Campden Instruments, 
Loughborough, UK) 400 µm thick horizontal slices were made from the ventral hippocampus 
and put either in a Haas-type recording chamber at the interface between moist carbogen 
(95%, O2, 5% CO2) and artificial cerebrospinal fluid (aCSF, containing (in mM): D-glucose, 
10; NaHCO3, 26; NaCl, 125; KCl, 3; NaH2PO4, 1.25; CaCl2, 2; MgCl2, 1) at 32°C, or stored in 
a static interface type chamber containing aCSF at room temperature for later use. Fluid 
levels were kept relatively high in the recording chamber using a perfusion rate of 8±1 
ml/min minimizing gravitational pull onto the mesh but not submerging the slices. Slices 
were allowed to recover for 50 minutes before recordings started.  
 
2.2.2. Electrophysiological recordings. 
Local field potentials were recorded with aCSF-filled glass pipette recording electrodes (4-5 
MΩ) from stratum radiatum of the CA3c hippocampal area (Figure 2.1.A). Recordings were 
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amplified with Neurolog NL104 AC-coupled amplifiers (Digitimer Welwyn Garden City, UK) 
and band-pass filtered at 3-500 Hz. Noise locked to the powerline frequency 50 Hz was 
removed with Humbug noise eliminators (Digitimer Welwyn Garden City, UK). Subsequently 
the signal was digitised and sampled at 2 kHz using a CED-1401 interface (Cambridge 
Electronic Design, Cambridge, UK) and analyzed using Spike-2 software (Cambridge 
Electronic Design, Cambridge, UK).  
After one hour of recovery in the interface chamber, slices were selected for spontaneous, 
KA-induced or CCH-induced gamma oscillation experiments. Slices selected for spontaneous 
gamma oscillations had to fulfil the criteria: peak power in the gamma range > average 
power in the beta range. Figure 2.1.B shows a typical power spectrum of a KA-induced 
singular oscillation. The light grey area is the gamma range. The gamma band was set 
between 20 and 60 Hz (Fisahn et al., 1998) because recordings were made at 32°C, which 
shifts the frequency bands to lower frequencies compared to recordings at body temperature 
(Dickinson et al., 2003). To calculate the power within the gamma range, the power 
underneath the curve is averaged (shown for the gamma range). In spontaneous gamma 
oscillation experiments modulating drugs were added 60 minutes after slices were placed 
into the recording chamber. 
In slices not selected for spontaneous gamma oscillation experiments, gamma oscillations 
were induced by adding KA (50 nM) or CCH (5 µM) to the aCSF. The best predicable 
development for KA-induced and CCH-induced gamma oscillations was between 1h and 2h 
after application (Pietersen 2009 supplement). Adenosine receptor acting drugs were added 
to the aCSF 60 minutes after KA or CCH application. All modulating drugs were added for 20 
minutes. 
Drugs used were diluted from the following stock solutions: kainate (50 µM stock in water), 
carbachol (10 mM stock in water), caffeine (100 mM stock in water), adenosine (10 mM 
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stock in aCSF, or directly dissolved in aCSF at high concentrations), 8-cyclopentyl-1,3-
dimethylxanthine (8-CPT; 50 mM stock in dimethyl sulfoxide (DMSO)) and 4-[2-[[6-Amino-
9-(N-ethyl-b-d-ribofuranuronamidosyl)-9H-purin-2-yl]amino]ethyl]benzenepropanoic acid 
hydrochloride (CGS21680; 100 mM stock in DMSO). In experiments where drugs were 
dissolved in DMSO care was taken to add equal amounts of DMSO to the aCSF solution 
before and after drug application. CGS21680 was obtained from Tocris (Bristol, UK), all 
other drugs were purchased from Sigma (Poole, UK). 
 
Figure 2.1. Methods chapter 2. A. Schematic representation of the mouse hippocampus. 
The red dot indicates where field recordings were made. B. Power spectrum of a KA induced 
network oscillation. The light grey area indicates the gamma range. The dark grey area is 
the area under the curve from which the average is used as a measure of power within 
frequency bands. The dominant frequency is determined by the frequency which has the 
most power. C. Example of how autocorrelation was analyzed. Second peak amplitude was 
measured by taking the maximum deviation between the straddling troughs. 
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2.2.3. Analysis and statistics. 
Oscillation power was calculated from the recordings for four frequency bands (slow: 3-8 Hz, 
beta: 8-20 Hz, gamma: 20-60 Hz, fast: 60-100 Hz) using fast fourier transform (1 Hz bin 
size).  Data was analyzed in 30 seconds epochs. A power spectrum was made using a fast 
fourier transformation for every 30 seconds and used for further analysis. Due to the large 
variability of absolute power between individual slices, data was normalised to 5 minutes 
prior the start of modulating drug application or corresponding time in controls (see Figure 
2.2). The effect of adenosine receptor acting drugs was compared with time matched 
controls because the baseline progressively increased in the KA-induced and CCH-induced 
models. In the spontaneous model the baseline decreased over time.  
Figure 2.2. Effect of normalisation on gamma band power. There is a large variability 
between slices in the absolute gamma band power resulting in large error bars (dotted lines) 
in the average development over time (A). By normalising the gamma band power to five 
minutes before the point of drug injection (time = 0) the error bars are reduced (B). Even 
though the absolute power has a large variability the growth over time is very similar from 
slice to slice. The grey area in A indicates the data points used to normalise the average 
gamma band power.  
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Dominant frequency within the gamma range was determined from the power spectra (see 
Figure 2.1.B). If drug modulation caused the dominant frequency to shift outside the gamma 
range data was corrected and the peak in the beta range was taken as the dominant 
frequency. 
Autocorrelation is a measure of the regularity of an oscillation. The waveform is compared to 
itself and the better you can predict the value of the next cycle the bigger the value for the 
second peak will be. If a waveform is a perfect sinusoid the autocorrelation will be maximal. 
As a measure of autocorrelation the amplitude of the second peak in the autocorrelogram 
was calculated. The maximum deviation from an imaginary line between the straddling 
troughs was taken as the amplitude of the second peak (see Figure 2.1.C). 
For frequency band power and the amplitude of the second peak in the autocorrelogram 
statistical comparisons were made 20 minutes after drug application on the normalised drug 
induced changes and the normalised change over time in controls. Data acquired by 
undergraduate students Nisha Patel (8-CPT data) and Dominic Lancaster (CGS21680 data) 
were compared to their matched controls. Data acquisition done by Dominic Lancaster was 
co-supervised by me. For all other parameters statistical comparisons were made between 
the change after 20 minute of drug application and the time matched change in controls. All 
parameters were checked for normality using the Kolmogorov-Smirnov test in SPSS 15.0, 
and if data was normally distributed statistical comparison was made using a Student‟s t-
test. If data was not normally distributed the non-parametric Mann-Whitney U test was 
used. Data are expressed as means±standard error of the mean (s.e.m.). If the significance 
criterion was below 0.05, data were considered significantly different from controls. 
Numbers of observations (n, number of slices) are quoted in the Tables 2.1, 2.2 and 2.3. 
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2.3. Results 
 
2.3.1. The effect of caffeine and adenosine on CCH induced gamma oscillations. 
At concentrations reached through normal coffee consumption (1-10 µM) caffeine can 
antagonise adenosine A1-receptors and adenosine A2A-receptors (Fredholm et al., 1999). 
Caffeine has been shown to increase KA induced gamma oscillations in the hippocampus at 
similar concentrations (Pietersen et al., 2009a). To make sure this increase is not model 
specific the effects of 50 µM caffeine on CCH-induced gamma oscillations were investigated. 
Caffeine (50 µM) increased oscillation power in all frequency bands (see Table 2.1), example 
in Figure 2.3.A. The power spectrum (Figure 2.3.B) shows that caffeine increases the power 
before and around the dominant frequency. Also visible is an increase in power around 63 
Hz. This is double the dominant frequency and considered a harmonic. This is also visible in 
the raw traces as the trace recorded in the presence of caffeine has a more saw tooth like 
character than before caffeine was added. Oscillations induced by CCH have a very regular 
character, visible in the sharp peak in the power spectrum and the large second peak 
amplitude in the autocorrelogram. The average second peak amplitude was 0.80±0.05 
(n=18). There was no difference between controls and caffeine in the normalised second 
peak amplitude after 20 minutes of drug application (see Table 2.1). The average gamma 
band power was 76.2±16.8 µV2 (n=18), for the average of all other frequency bands see 
Table 2.1. Caffeine significantly increased the power in all frequency bands. The gamma 
band power increased to 3.08±0.28 (n=5) times the starting value (Figure 2.3.D), while 
controls only increased to 1.20±0.09 (n=6) times the starting value (Student‟s t-test, t4.9=-
6.8, p=0.002). Caffeine increased the beta band power  
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Figure 2.3. Effect of caffeine on CCH-induced gamma oscillations. A. Example traces before 
(black) and during caffeine (50 µM) application (20 minutes). Caffeine increased 
synchronous network activity B. Power spectrum before and after 20 minutes of caffeine 
application. Caffeine increased power in all frequency bands but mostly in the gamma band. 
C. Autocorrelogram from the same data as the power spectrum. Caffeine slightly increases 
the second peak amplitude. D.  Normalised development of CCH-induced gamma band 
power in aCSF (black lines, n=6) and in the presence of caffeine (green lines, n=5). Caffeine 
significantly increased normalised gamma power after 20 minutes (p=0.002) compared to 
controls.  
 
to 2.31±0.28 (n=5) times the starting value (Student‟s t-test, t4.3=-4.7, p=0.011), slow 
band power to 1.56±0.12 (n=5) times the starting value (Student‟s t-test, t9=-4.6, 
p=0.001) and fast band power to 3.06±0.20 times the starting value (Student‟s t-test, t9=-
8.8, p=0.000001), see Table 2.1 for control values. To test how the change in the gamma 
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range compares to the change in the beta range, the gamma/beta ratio is calculated by 
dividing the power in the gamma range by the power in the beta range. The gamma/beta 
ratio for CCH induced oscillations was 1.84±0.18 (n=18) before drug application. Caffeine 
increased the power in the gamma range increased more than the power in the beta range, 
but there was no significant difference between in change in gamma/beta ratio between 
controls and caffeine (see Table 2.1). The average dominant frequency in CCH-induced 
oscillations was 34.8±0.05 Hz (n=18). Caffeine shifted the dominant frequency down 
slightly (-1.38±0.66 Hz, n=5), but that shift was not significantly different from the shift in 
controls (-1.11±0.31 Hz, n=6). 
To find out if non-selective adenosine receptor agonists can decrease network oscillations, 
the effects of adenosine (50 µM) on CCH induced hippocampal gamma oscillations was 
investigated. Adenosine decreased oscillatory activity 20 minutes after application (Figure 
2.4.A). The power spectrum (Figure 2.4.B) shows a decrease in power specifically around 
the dominant frequency. Also notice the disappearance of the harmonic around 65 Hz after 
20 minutes of adenosine application. In contrast to caffeine adenosine does affect the 
regularity of the oscillation and decreases the second peak amplitude in the autocorrelogram 
(Figure 2.4.C). Striking is how quickly adenosine exerts its effects on gamma oscillations 
(Figure 2.4.D). Within one to two minutes after adenosine application the normalised 
average power in the gamma range decreased rapidly to a new steady level. Adenosine 
decreased the power within the gamma range to 0.61±0.12 (n=7) times starting values 
(Student‟s t-test, t11=3.8, p=0.003) after 20 minutes. The power in the fast band decreased 
to 0.60±0.11 (n=7) times the starting values (Student‟s t-test, t11=3.5, p=0.005). The 
normalised power within the beta and slow bands did decrease slightly but not significantly 
compared to the change in aCSF controls (see Table 2.1). The decrease in power was most 
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specific for the gamma range. Adenosine significantly decreased the gamma/beta ratio by -
0.59±0.29 (n=7),  
 
 
Figure 2.4. Effect of adenosine (50 uM) on CCH-induced gamma oscillations. A. Example 
traces before (black) and during adenosine (50 µM) application (20 minutes). B. Power 
spectrum before and after 20 minutes of adenosine application. Adenosine decreased power 
in the gamma range. C. Autocorrelogram from the same data as the power spectrum. 
Adenosine decreases the second peak amplitude significantly (p=0.001). D.  Normalised 
development of CCH-induced gamma band power in aCSF (black lines, n=6) and in the 
presence of adenosine (red lines, n=7). Adenosine significantly decreased normalised 
gamma power after 20 minutes (p=0.003) compared to controls. 
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while in aCSF controls specificity increased slightly, 0.19±0.10 (n=6) (Student‟s t-test, 
t11=2.4, p=0.035). The dominant frequency did shift down a little but the shift was not 
different from the change in control (see Table 2.1). Adenosine reduced the regularity of the 
oscillation, visible through decreased amplitude of the second peak in the autocorrelogram. 
The second peak amplitude decreased significantly to 0.69±0.03 (n=7) times the starting 
values (Student‟s t-test, t11=4.8, p=0.001). 
The non-selective adenosine receptor antagonist caffeine and the non-selective adenosine 
receptor agonist adenosine modulate CCH induced hippocampal network oscillations most 
powerfully within the gamma range.  
 
2.3.2. The effect of different adenosine concentrations on KA induced hippocampal network 
oscillations. 
To check if the reduction in CCH-induced hippocampal gamma oscillations is model-specific, 
the same adenosine concentration (50 µM) was also applied to KA-induced hippocampal 
gamma oscillations. Adenosine decreased KA induced gamma oscillations in a similar way as 
CCH induced gamma oscillations. Figure 2.5.A shows a reduction in signal amplitude 20 
minutes after adenosine application. The power spectrum shows a loss of power mostly 
within the gamma range (Figure 2.5.B) and a shift of the dominant frequency to lower 
values. The shift in dominant frequency is also visible within the autocorrelogram (Figure 
2.5.C) where the time to the second peak is increased. The amplitude of the second peak is 
reduced indicating a loss of regularity of the oscillation. The average power in the gamma 
band before drug application was 43.7±7.1 µV2 (n=30). Adenosine significantly decreased 
the power within the gamma band to 0.90±0.08 (n=9) times starting values (see Figure 
2.5.D). In aCSF controls the power in the gamma band increased to 1.42±0.03 (n=10) 
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times the starting values (Student‟s t-test, t17=6.5, p=0.000005). Adenosine also 
significantly decreased the power in the fast band to 0.92±0.06 (n=9) times starting values 
(Student‟s t-test, t17=7.0, p=0.000002). There was no significant difference between 
adenosine and controls for the slow and beta bands (see Table 2.2). The average 
gamma/beta ratio in KA induced gamma  
 
Figure 2.5. Effect of adenosine (50 µM) on KA-induced gamma oscillations. A. Example 
traces before (black) and during adenosine (50 µM) application (20 minutes). B. Power 
spectrum before and after 20 minutes of adenosine application. Adenosine decreased power 
in the gamma range. C. Autocorrelogram from the same data as the power spectrum. 
Adenosine decreases the second peak amplitude significantly (p=0.0002). D.  Normalised 
development of KA-induced gamma band power in aCSF (black lines, n=10) and in the 
presence of adenosine (red lines, n=9). Adenosine significantly decreased normalised 
gamma power after 20 minutes (p=0.000005) compared to controls.  
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oscillations was 0.98±0.05 (n=30). While there was hardly any change in gamma/beta ratio 
in controls (0.03±0.03, n=10) adenosine decreased gamma/beta ratio by -0.28±0.06 (n=9) 
(Student‟s t-test, t10.7=4.6, p=0.001). The dominant frequency before drug application was 
36.0±0.8 Hz (n=30). Adenosine significantly shifted the dominant frequency by -6.0±1.2 Hz 
(n=9), while in aCSF controls there was a slight increase by 0.5±0.9 Hz (n=10) (Student‟s t-
test, t17=4.5, p=0.0003). The average second peak amplitude in the autocorrelogram was 
0.34±0.02 (n=30). Adenosine significantly decreased the second peak amplitude to 
0.45±0.04 (n=9) times starting values (Mann-Whitney U-test, U=0.0, p=0.0002). All effects 
were reversed when adenosine was washed out. 
A very high concentration of 200 µM adenosine almost completely and reversibly blocked 
oscillatory activity within the hippocampal network in KA induced network oscillations 
(example in Figure 2.6.A). Where 50 µM adenosine decreased power mostly in the gamma 
band, a high dose of 200 µM adenosine wipes out almost all oscillatory activity. Strong 
reductions in power in the fast, gamma and beta bands (see power spectrum Figure 2.6.B) 
are observed. The oscillation is decreased so much that in 200 µM adenosine the 
autocorrelogram does not have a second peak within 100 ms. This indicated that the 
oscillation has a dominant frequency of below 10 Hz or that there was no dominant 
frequency at all. Adenosine decreased power in the gamma band to 0.13±0.07 (n=3) times 
starting values (Mann Whitney U-test, U=0.0, p=0.011), in the fast band to 0.28±0.12 
(n=3) times starting values (Mann Whitney U-test, U=0.0, p=0.011) and the beta band to 
0.56±0.04 (n=3) times starting values (Mann Whitney U-test, U=0.0, p=0.011). The power 
in the slow band did not change significantly different from controls (see Table 2.2). The 
oscillation became less specific for the gamma band as the specificity dropped by -
0.54±0.11 (n=3) (Mann Whitney U-Test, U=0.0, p=0.011). As there was no, or hardly any, 
second peak to measure in the autocorrelogram it is no surprise that adenosine decreased 
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the second peak amplitude to 0.02±0.02 (n=3) times starting values (Mann Whitney U-Test, 
U=0.0, p=0.011). In experiments where no second peak was visible in the autocorrelogram 
the peak amplitude was set to zero. With losing almost all power in the gamma and beta 
bands, adenosine shifted the dominant frequency by -13.5±2.4 Hz (n=3) (Mann Whitney U-
Test, U=0.0, p=0.011). 
 
 
Figure 2.6. Effect of adenosine (200 µM) on KA-induced gamma oscillations. A. Example 
traces before (black) and during adenosine (200 uM) application (20 minutes). B. Power 
spectrum before and after 20 minutes of adenosine application. Adenosine decreased power 
in the fast, gamma and beta bands. C. Autocorrelogram from the same data as the power 
spectrum. Adenosine decreases the second peak amplitude significantly (p=0.011). D. 
Normalised development of KA-induced gamma band power in aCSF (black lines, n=10) and 
in the presence of adenosine (red lines, n=3). Adenosine significantly decreased normalised 
gamma power after 20 minutes (p=0.0011) compared to controls.  
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With a high dose adenosine completely blocking all activity in the gamma range, the effects 
of a low dose (10 µM) of adenosine were investigated next. A low dose of adenosine (10 µM) 
decreased signal amplitude slightly (Figure 2.7.A). In the power spectrum a small decrease 
in power in the gamma band is visible (Figure 2.7.B). After 20 minutes of adenosine (10 µM) 
application the power hardly changed from starting values 1.00±0.04 (n=8), the power in 
aCSF controls increased to 1.42±0.03 (n=10) times starting values. Thus at 20 minutes 
after adenosine application 10 µM adenosine decreased gamma oscillations significantly 
(Student‟s t-test, U16=7.9, p=0.0000007). The fast band showed the same development as 
the gamma band (1.02±0.05, n=8) 20 minutes after drug application (Student‟s t-test, 
U16=6.7, p=0.000005). The slow and beta bands did not show any significant differences 
with the change in controls (see Table 2.2). With the power in the gamma range decreasing 
and the power in the beta range following the aCSF controls development, the specificity 
significantly decreased by -0.22±0.04 (n=8) (Student‟s t-test, U16=5.3, p=0.00007). The 
dominant frequency shifted significantly by -4.2±1.6 Hz (n=8) (Student‟s t-test, U16=2.7, 
p=0.015). Just like with the high and moderate dose of adenosine, 10 µM significantly 
decreased the second peak amplitude in the autocorrelogram to 0.56±0.05 (n=8) time the 
starting values (Mann Whitney U-test, U=1.0, p=0.001). 
Different doses of adenosine (10, 50 and 200 µM) decreased KA induced hippocampal 
network oscillations. Where the highest dose almost completely blocked all activity the lower 
doses were more specific for the gamma range. 
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Figure 2.7. Effect of adenosine (10 µM) on KA-induced gamma oscillations. A. Example 
traces before (black) and during adenosine (10 µM) application (20 minutes). B. Power 
spectrum before and after 20 minutes of adenosine application. Adenosine decreased power 
in the fast and gamma bands. C. Autocorrelogram from the same data as the power 
spectrum. Adenosine decreases the second peak amplitude significantly (p=0.001). D.  
Normalised development of KA-induced gamma band power in aCSF (black lines, n=10) and 
in the presence of adenosine (red lines, n=8). Adenosine significantly decreased normalised 
gamma power after 20 minutes (p=0.0000007) compared to controls. 
 
2.3.3. The effect of A1- and A2A-receptor modulation on KA induced hippocampal gamma 
oscillations. 
Caffeine is a non-selective adenosine receptor antagonist that powerfully increases gamma 
oscillations in the hippocampus. Adenosine A1-receptors are more abundant within the 
hippocampus than adenosine A2A-receptors (see introduction Table 1.1). This means that a 
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non-selective antagonist will activate both receptors but the effects seen are most likely 
caused by the A1-receptor. It is therefore expected that antagonizing the adenosine A1-
receptor will increase gamma oscillations. 
The selective adenosine A1-receptor antagonist 8-CPT (5 µM) increased KA-induced gamma 
oscillations in a similar way as caffeine. There is an increase in the oscillatory activity (Figure 
2.8.A). The power spectrum (Figure 2.8.B) there is an increase in power within the gamma 
range. The increase in the gamma range is mainly around the dominant frequency creating a 
sharp peak. Also visible is the appearance of a harmonic at double the dominant frequency 
(around 68 Hz) which increases the power in the fast frequency band. The power in the 
lower frequency bands also increases but not as much as in the gamma range. The 
appearance of a sharp peak in the gamma band already indicates that the oscillation became 
more regular. The increase in regularity is also visible through the increased second peak 
amplitude in the autocorrelogram (Figure 2.8.C). After 20 minutes  8-CPT significantly 
increased gamma band power to 3.96±0.91 (n=6) times starting values while aCSF controls 
only increased to 1.21±0.05 (n=10) times starting values (Student‟s t-test, U14=-5.0, 
p=0.013). The specific adenosine A1-receptor agonist N6-(2-phenylisopropyl)adenosine 
(PIA) has the opposite effect of 8-CPT and decreases KA-induced hippocampal gamma 
oscillations (Pietersen et al., 2009a). 
Adenosine A2A-receptors are less abundant in the hippocampus than A1-receptors but they 
are located at similar sites (see introduction, (Cunha et al., 1994;Sebastiao and Ribeiro, 
1996). Adenosine A2A-receptors have been shown to have the opposite effect of adenosine 
A1-receptors partly due to direct inhibition of A1-receptors (Lopes et al., 1999). To test 
whether adenosine A2A-receptors can modulate KA-induced gamma oscillations the 
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Figure 2.8. Effect of 8-CPT (5 µM) on KA-induced gamma oscillations. The data for this 
experiment were acquired by Nisha Patel. A. Example traces before (black) and during 8-
CPT (blue, 5 uM) application (20 minutes). 8-CPT increased synchronous network activity.  
B. Power spectrum before and after 20 minutes of 8-CPT application. 8-CPT increased power 
in the gamma band. C. Autocorrelogram from the same data as the power spectrum. 8-CPT 
increased the second peak amplitude. D.  Normalised development of KA-induced gamma 
band power in aCSF (black lines, n=10) and in the presence of 8-CPT (blue lines, n=6). 8-
CPT significantly increased normalised gamma power after 20 minutes (p=0.013) compared 
to controls. 
 
specific A2A-receptor agonist CGS21680 (20 nM) was added to the aCSF. CGS21680 slightly 
increased the amplitude of recorded network events (Figure 2.9.A). The power spectrum 
(Figure 2.9.B) shows a minor increase in power within the gamma range mainly around the 
dominant frequency. Also both lower frequency bands show a small increase in power in this 
example. The second peak amplitude in the autocorrelogram (Figure 2.9.C) increased 
- 45 - 
 
slightly. After 20 minutes the power within the gamma band was significantly increased to 
1.99±0.16 (n=8) times starting values while controls only increased to 1.27±0.05 (n=8) 
times starting values (Student‟s t-test, U14=-4.2, p=0.001). The adenosine A2A-receptor 
antagonist ZM241385 slightly reduced KA induced gamma oscillations (Pietersen et al., 
2009a). 
 
 
Figure 2.9. Effect of CGS21680 (20 nM) on KA-induced gamma oscillations. The data for 
this experiment were acquired by Dominic Lancaster. A. Example traces before (black) and 
during CGS21680 (purple, 20 nM) application (20 minutes). CGS21680 slightly increased 
synchronous network activity.  B. Power spectrum before and after 20 minutes of CGS21680 
application. CGS21680 increased power in the gamma band. C. Autocorrelogram from the 
same data as the power spectrum. CGS21680 marginally increased the second peak 
amplitude. D. Normalised development of KA-induced gamma band power in aCSF (black 
lines, n=8) and in the presence of CGS21680 (purple lines, n=8). CGS21680 significantly 
increased normalised gamma power after 20 minutes (p=0.001) compared to controls. 
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Both adenosine A1-receptor and A2A-receptor modulation alter KA induced hippocampal 
gamma oscillations. Where A1-receptor activation reduces gamma oscillations A2A-receptor 
activation slightly increases gamma oscillations. With the effects of A1-receptor modulation 
being much stronger, the effects of a mixed agonist or antagonist will be mainly due to the 
A1-receptor modulation. 
2.3.4. The effect of adenosine receptor modulation on spontaneous gamma oscillations. 
Adenosine levels in hippocampal slices in normal aCSF fall within the physiological range in 
vivo (Ballarin et al., 1991;Dunwiddie and Diao, 1994). To test if adenosine receptor 
modulation can also affect gamma oscillations under physiological conditions the effects of 
adenosine and 8-CPT were tested on spontaneous gamma oscillations.  
Similarly to the other models, adenosine (50 µM) decreased the oscillation amplitude (Figure 
2.10.A) and reduced the power within the gamma band mainly around the dominant 
frequency (Figure 2.10.B). The autocorrelogram (Figure 2.10.C) shows a slowing down of 
the oscillation and a reduction in regularity as a decrease in second peak amplitude. The 
average dominant frequency in spontaneous gamma oscillations was 32.2±1.0 Hz (n=15). 
In contrast to the KA and CCH induced models the power over time decreases in 
spontaneous oscillations. With the decrease in power the dominant frequency also slows 
down. As a consequence the change in dominant frequency caused by exogenous adenosine 
was not different from controls (see Table 2.3). The average second peak amplitude was 
0.35±0.04 (n=15). Due to the naturally slowing down of the oscillation the second peak 
amplitude was reduced to almost half the starting value in both adenosine and controls (see 
Table 2.3). Adenosine significantly decreased the power in all frequency bands (see Table 
2.3). Adenosine significantly decreased the power in the gamma band to 0.47±0.04 (n=6) 
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times starting values (Student‟s t-test, U13=3.1, p=0.008). The beta band was decreased to 
0.74±0.07 (n=6) times starting values, significantly different from controls (1.19±0.14, 
n=9) (Student‟s t-test, U13=2.5, p=0.026). The slow band significantly decreased to 
0.76±0.07 (n=6) times starting (Student‟s t-test, U13=2.4, p=0.015).  
 
Figure 2.10. Effect of adenosine (50 µM) on spontaneous gamma oscillations. A. Example 
traces before (black) and during adenosine (red, 50 µM) application (20 minutes). B. Power 
spectrum before and after 20 minutes of adenosine application. Adenosine decreased power 
in the gamma range. C. Autocorrelogram from the same data as the power spectrum. 
Adenosine decreases the second peak amplitude but the change was not significantly 
different from the change in controls. D.  Normalised development of spontaneous gamma 
band power in aCSF (black lines, n=9) and in the presence of adenosine (red lines, n=6). 
Adenosine significantly decreased normalised gamma power after 20 minutes (p=0.008) 
compared to controls. 
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The power in the fast band significantly reduced to 0.78±0.06 (n=6) times starting values 
(Mann Whitney U-test, U=9.0, p=0.034). The average gamma/beta ratio was 0.82±0.06 
(n=15). There was no difference between the change in gamma/beta ratio between controls 
and adenosine (see Table 2.3). 
Just as with KA-induced gamma oscillations 8-CPT increased the spontaneous oscillation 
power specifically in the gamma range. The raw traces show an increase in signal amplitude 
(Figure 2.11.A) after 20 minutes of 8-CPT (5 µM) application. The power spectrum shows an 
increase in power in all frequency bands but most noticeably around the dominant frequency 
(Figure 2.11.B), which falls within the gamma range. Also visible is the appearance of a 
small harmonic in the fast frequency band. With the specific increase in power around the 
dominant frequency the oscillations becomes more specific. This is visible in the 
autocorrelogram through increased second peak amplitude (Figure 2.11.C). The power in the 
gamma band rises rather quickly but contrary to the KA-induced model, in spontaneous 
oscillations the power does not keep increasing but goes down a bit and then levels off 
during 8-CPT application (Figure 2.11.D). After 20 minutes of 8-CPT application the power in 
the gamma band increased to 4.42±0.59 (n=7) times the starting values. This is a 
significant increase compared to controls as in aCSF controls the power decreases to 
0.80±0.04 (n=7) times the starting values (Student‟s t-test, U6.1=-6.1, p=0.001). 
Adenosine receptors can modulate gamma oscillations under condition where adenosine 
levels fall within the physiological range. 
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Figure 2.11. Effect of 8-CPT (5 µM) on spontaneous gamma oscillations. The data for this 
experiment were acquired by Nisha Patel. A. Example traces before (black) and during 8-
CPT (blue, 5 µM) application (20 minutes). 8-CPT increased synchronous network activity.  
B. Power spectrum before and after 20 minutes of 8-CPT application. 8-CPT increased power 
in the gamma band. C. Autocorrelogram from the same data as the power spectrum. 8-CPT 
increased the second peak amplitude. D.  Normalised development of spontaneous gamma 
band power in aCSF (black lines) and in the presence of 8-CPT (blue lines). 8-CPT 
significantly increased normalised gamma power after 20 minutes (p=0.001) compared to 
controls. 
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2.4. Discussion. 
Adenosine receptor modulation alters hippocampal network oscillations especially in the 
gamma range in three different types of models. Adenosine A1-receptor activation reduces 
gamma oscillations. It has been reported that the adenosine A2A-recepter antagonist 
ZM241385 slightly reduces gamma oscillation power (Pietersen et al., 2009a). Conversely, 
the adenosine A1-receptor antagonist PIA (Pietersen et al., 2009a) and A2A-receptor agonist 
CGS21680 increase gamma oscillation power. CGS21680 has a 180-fold greater affinity for 
A2A-receptors than A1-receptors (KD-value, 16 nM), (Jarvis et al., 1989) making a strong 
case that A2A-receptor agonists on their own can also increase hippocampal gamma 
oscillations. In the hippocampus non-selective adenosine agonists and antagonists seem to 
work mainly through the A1-receptor. Care has to be taken to extrapolate these results to 
other brain areas as adenosine receptor distribution might be different than in the 
hippocampus making it well possible that a non-selective agonist or antagonist can have the 
opposite effect as described in this chapter.  
The modulation of gamma oscillations by adenosine receptors is not model specific as in all 
three models investigated similar results were obtained. Even though there are differences 
between different models in physiological properties (Pietersen et al., 2009b), adenosine 
receptors can alter gamma oscillations in all models. This points to a general mechanism of 
action of adenosine receptor induced modulation of gamma oscillations. 
Adenosine activates both A1- and A2A-receptors, but A1-receptors are more abundant in the 
hippocampus (see introduction Table 1.1, (Fredholm et al., 2005) and adenosine has a 
higher affinity for the A1-receptor ((Dunwiddie and Masino, 2001), introduction Table 1.1). 
Even though A2A-receptors have the opposite effect of A1-receptors partly, through direct 
inhibition of A1-receptors (Lopes et al., 1999), the predominant effect of adenosine is a 
- 51 - 
 
decrease in gamma oscillation power through A1-receptor activation. Similarly the non-
selective antagonist caffeine will exert its effects mainly through the A1-receptor and 
increase gamma oscillation power at the concentration used in the described experiments. 
The strong increase of gamma oscillations caused by caffeine or the selective A1-receptor 
antagonist 8-CPT (8-CPT has a 1000-fold higher potency in the rat over A2A-receptors, KD-
value, 4 nM (Klotz, 2000)) indicates that ambient extracellular adenosine levels suppress 
gamma oscillations. Adenosine levels in the slice are estimated between 30 and 300 nM 
(Dunwiddie and Diao, 1994;Fredholm et al., 2001). With the high affinity of adenosine for 
the adenosine A1-receptor (Kd 10-70 nM, (Dunwiddie and Masino, 2001;Huber et al., 2001); 
introduction Table 1.1), ambient adenosine levels will be able to activate adenosine 
receptors and suppress of brain oscillations.  
Adenosine also acts as a neuroprotector (Cunha, 2001). Adenosine is released in high 
quantities during energy challenging circumstances like hypoxia (Frenguelli et al., 
2003;Winn et al., 1981). Like the high concentration of adenosine (200 µM), hypoxia quickly 
and dramatically reduces gamma oscillations (Fano et al., 2007;Huchzermeyer et al., 2008), 
most likely through increased adenosine levels (Pietersen et al., 2009a). With such a big 
influence on neuronal activity it is no surprise that adenosine levels are tightly regulated in 
the brain. Adenosine levels are kept in check by the intracellularly located adenosine kinase, 
which has a high affinity for adenosine (Dunwiddie and Masino, 2001;Lloyd and Fredholm, 
1995); see introduction. When adenosine levels rise substantially and adenosine kinase can 
not clear the excess adenosine, adenosine deaminase (ADA), which has a lower affinity for 
adenosine, helps to bring adenosine levels down to normal (Dunwiddie and Masino, 
2001;Lloyd and Fredholm, 1995). Because of this tight control of adenosine levels, rather 
high concentrations of exogenous applied adenosine need to be given to suppress gamma 
oscillations in vitro. The lower adenosine concentrations (10 and 50 µM) suppressed the 
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gamma band without significantly affecting the lower frequency bands. The change in fast 
frequency band power is linked to the gamma band power in almost all experiments. We 
take the gamma band from 20 to 60 Hz but very often the tail of the power in the gamma 
range is slightly beyond 60 Hz (see Figure 2.1.B). If we indeed are looking at the same 
event a reduction of power in the gamma range will then also reduce power within the fast 
band.  
At concentrations achieved by normal coffee consumption (1-10 µM) (Fredholm et al., 1999) 
caffeine increases hippocampal gamma oscillations in vitro via A1-receptor antagonism. 
Gamma oscillations have been linked to cognitive performance and thus could be one of the 
ways caffeine increases alertness and cognitive function (Fredholm et al., 1999;Lorist and 
Tops, 2003). Differences in adenosine receptor distribution between A1- and A2A-receptors 
can give mixed effects as A2A-receptor antagonists increase gamma oscillations (Pietersen et 
al., 2009a). Also numerous side effects can be a result of adenosine A2A-receptor activation 
(Fredholm et al., 1999). 
Adenosine levels fluctuate with neuronal activity (Dunwiddie and Masino, 2001) and 
circadian rhythm (Huston et al., 1996) which could have an effect on the amount of gamma 
oscillations possible at a given moment during the day. Thus during periods where 
adenosine levels are low cognitive function would be more efficient compared to periods 
where adenosine levels are high. The rise in adenosine levels during waking may not occur 
in all brain areas as some regional differences have been proposed (Haas and Selbach, 
2000). Adenosine levels increase with age through increased 5‟-nucleotidase activity 
(Mackiewicz et al., 2006;Sperlagh et al., 1997), which could have an effect on gamma 
oscillations strength within an aged brain. Increased adenosine levels could be partly 
responsible for the mild memory impairment associated with normal ageing. This is further 
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substantiated by an age-related decrease in gamma oscillations in the mouse hippocampus 
in vitro (Driver et al., 2007;Vreugdenhil and Toescu, 2005). 
Even a central nervous system specific A1-receptor antagonist is very likely to have many 
side effects due to the abundance of adenosine receptors throughout the brain (Fredholm et 
al., 1999). The best strategy for increasing gamma oscillations would be to find a compound 
that is an A1-receptor antagonist and an A2A-receptor agonist. Understanding more about the 
underlying mechanisms could possibly provide other targets to prevent cognitive decline 
with age or enhance cognitive performance. An alternate strategy for age associated 
memory impairment would be to reduce basal adenosine levels. 
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2.5. Future research. 
If controlling adenosine levels could be a potential therapeutic target it is important to 
investigate if changes in endogenous adenosine levels can modulate gamma oscillations. 
This will be done in the chapter 3. 
Adenosine A1-receptor activation has been shown to inhibit vesicle release which could be 
one of the ways gamma oscillations are suppressed. In chapter 4 and 5 the cellular and 
synaptic changes underlying the observed network changes through A1-receptor modulation 
will be investigated. 
In chapter 6 all the in vitro findings will be assessed in anaesthetised animals. 
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Parameter  Parameter 
value 
Control Adenosine 
(50 µM) 
Caffeine 
(50 µM) 
Model CCH CCH CCH CCH 
Normalised power n=18 n=6 n=7 n=5 
Gamma (20-
60 Hz) 
Mean 76.2 1.20 0.61 3.08 
 SEM 16.8 0.09 0.12 0.28 
Beta (8-20 Hz) Mean 41.5 1.09 0.85 2.31 
 SEM 8.9 0.05 0.10 0.28 
Slow (3-8 Hz) Mean 44.4 1.04 0.93 1.56 
 SEM 8.9 0.03 0.12 0.12 
Fast (60-100 
Hz) 
Mean 6.0 1.15 0.60 3.06 
 SEM 1.1 0.11 0.11 0.20 
 
ΔGamma/beta 
ratio 
Mean 1.84 0.19 -0.59 0.68 
 SEM 0.18 0.10 0.29 0.36 
 
Δdominant 
frequency (Hz) 
Mean 34.8 -1.11 -2.19 -1.38 
 SEM 0.5 0.31 0.81 0.66 
Normalised autocorrelation 
2nd peak 
amplitude 
Mean 0.80 1.08 0.69 1.24 
 SEM 0.05 0.03 0.07 0.09 
 
Table 2.1. Effect of adenosine receptors on CCH-induced hippocampal gamma oscillations. Bold numbers indicate 
significant differences (p<0.05) compared to controls. Power parameter value is in µV2. All other columns are normalized 
data. 
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Parameter  Parameter 
value 
Control Adenosine 
(10 µM) 
Adenosine 
(50 µM) 
Adenosine 
(200 µM) 
Control 8-
CPT 
(5 
µM) 
Control CGS21680 
(20 nM) 
Model KA KA KA KA KA KA KA KA KA 
Normalised power n=30 n=10 n=8 n=9 n=3 n=10 n=6 n=8 n=8 
Gamma (20-60 
Hz 
Mean 43.7 1.42 1.00 0.90 0.13 1.21 3.96 1.27 1.99 
 SEM 7.1 0.03 0.04 0.08 0.07 0.05 0.91 0.05 0.16 
Beta (8-20 Hz) Mean 42.5 1.33 1.27 1.17 0.56     
 SEM 5.9 0.04 0.08 0.09 0.04     
Slow (3-8 Hz) Mean 34.7 1.22 1.30 1.16 1.07     
 SEM 5.4 0.03 0.09 0.08 0.64     
Fast (60-100 
Hz) 
Mean 3.9 1.45 1.02 0.92 0.28     
 SEM 0.6 0.04 0.05 0.06 0.12     
 
ΔGamma/beta 
ratio 
Mean 0.98 0.03 -0.22 -0.28 -0.54     
 SEM 0.05 0.03 0.04 0.06 0.11     
 
Δdominant 
frequency (Hz) 
Mean 36.0 0.5 -4.2 -6.0 -13.5     
 SEM 0.8 0.9 1.6 1.2 2.4     
Normalised autocorrelation 
2nd peak 
amplitude 
Mean 0.34 1.06 0.56 0.45 0.02     
 SEM 0.02 0.11 0.05 0.04 0.02     
 
Table 2.2. Effect of adenosine receptors on KA-induced hippocampal gamma oscillations. Bold numbers indicate 
significant differences (p<0.05) compared to controls. Power parameter value is in µV2. All other columns are normalized 
data. 
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Parameter  Parameter 
value 
Control Adenosine 
(50 µM) 
Control 8-CPT (5 
µM) 
Model spontaneous Spontaneous Spontaneous Spontaneous spontaneous 
Normalised power n=15 n=9 n=6 n=7 n=7 
Gamma (20-
60 Hz 
Mean 4.0 0.80 0.47 0.80 4.42 
 SEM 0.6 0.08 0.04 0.04 0.59 
Beta (8-20 Hz) Mean 5.0 1.19 0.74   
 SEM 0.7 0.14 0.07   
Slow (3-8 Hz) Mean 6.1 1.19 0.76   
 SEM 0.7 0.14 0.07   
Fast (60-100 
Hz) 
Mean 0.3 1.10 0.78   
 SEM 0.1 0.15 0.06   
 
ΔGamma/beta 
ratio 
Mean 0.82 -0.25 -0.33   
 SEM 0.06 0.04 0.08   
 
Δdominant 
frequency (Hz) 
Mean 32.2 -6.5 -5.3   
 SEM 1.0 1.0 1.0   
Normalised autocorrelation 
2nd peak 
amplitude 
Mean 0.35 0.54 0.55   
 SEM 0.04 0.04 0.12   
 
Table 2.3. Effect of adenosine receptors on spontaneous hippocampal gamma oscillations. Bold numbers indicate 
significant differences (p<0.05) compared to controls. Power parameter value is in µV2. All other columns are normalized 
data. 
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CHAPTER 3: ENDOGENOUS ADENOSINE LEVELS MODULATE GAMMA OSCILLATIONS. 
 
3.1. Introduction. 
In the previous chapter the effects of exogenous adenosine and blockage of specific 
adenosine receptors on gamma oscillations showed that adenosine receptors are potent 
modulators of in vitro brain oscillations specifically in the gamma band. In this chapter the 
effect of endogenous adenosine levels on KA induced gamma oscillations are investigated. 
Ambient adenosine levels are estimated to be between 30 and 300 nM in hippocampal slices 
in vitro (Dunwiddie and Diao, 1994;Fredholm et al., 2001) which falls well within the 
physiological range measured in vivo. The adenosine concentration measured through 
microdialysis in awake rats in the extracellular space is 40 nM with elevation up to 460 nM 
(Ballarin et al., 1991). With the high affinity of adenosine for the adenosine A1-receptor (Kd 
10-70 nM, (Dunwiddie and Masino, 2001), introduction table 1.1), ambient adenosine levels 
will be able to activate adenosine receptors and give a constant suppression of brain 
oscillations. Adenosine levels fluctuate and follow a circadian rhythm (Fredholm et al., 
1999), which means that the amount of suppression can vary endogenous adenosine levels. 
Adenosine levels in the extracellular space in the brain are determined by the formation of 
adenosine from AMP through 5‟ ecto-nucleotidases, the breakdown of adenosine by ecto-
adenosine deaminase and transport of adenosine to the cytoplasm, usually through 
equilibrium nucleoside transporters, of neurons and glial cells (for review see (Dunwiddie 
and Masino, 2001)). Intracellular adenosine concentration is determined by influx from the 
extracellular space, production by 5‟ nucleotidases and removal by predominantly adenosine 
kinase. The intracellularly located adenosine kinase largely determines the adenosine 
concentration under normal physiological circumstances (Dunwiddie and Masino, 2001;Lloyd 
and Fredholm, 1995). Adenosine deaminase (ADA) has a low affinity for adenosine 
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(Fredholm et al., 1999;Latini and Pedata, 2001). When adenosine levels rise under energy 
demanding situations, like hypoxia or an epilepsy seizure, ADA will help break down the 
excess adenosine to bring adenosine concentrations back down to normal values. In this 
chapter production and breakdown of adenosine are modulated to alter ambient adenosine 
concentrations in order to see whether this affects gamma oscillations. First adenosine 
kinase is blocked using 5-iodotubericidin (5-IT, Ki-value 30 nM, see Figure 1.1), which will 
increase the intracellular adenosine concentration and subsequently the extracellular 
adenosine concentration will rise due to transport from the cytosol to the extracellular space 
through equilibrium transporters. The rise in extracellular adenosine is expected to suppress 
brain oscillations, specifically in the gamma band. To lower adenosine concentration we first 
need to make sure extracellular adenosine will not be replenished from the cytosol which 
means the equilibrium transporters need to be blocked. In the hippocampus the equilibrative 
nucleotide transporter 1 (ENT-1) is abundantly present and the major equilibrium 
transporter involved in regulating adenosine concentrations (Dunwiddie and Masino, 2001). 
After blocking ENT-1, ADA is added to decrease extracellular adenosine concentrations, 
which is predicted to increase brain oscillations, specifically in the gamma band.  
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3.2. Materials and methods. 
3.2.1. Tissue preparation. 
Slices were prepared via the same methods as chapter 2.  
3.2.2. Electrophysiological recordings. 
Recordings were done the same as in chapter 2. 
Drugs were diluted from the following stock solutions: 5-iodotubericidin (5-IT, 1 mM stock in 
DMSO), S-(4-nitrobenzyl)-6-thioinosine (NBTI, 100 mM in DMSO) and adenosine deaminase 
type 5 (ADA, 160 U/ml in 50% glycerol, 50 mM K2PO4). In experiments where ADA was used 
aCSF was made without K+ and a solution of 50% glycerol and 20 mM K2PO4 was added to 
the aCSF in the same volume as was needed to dilute to the used ADA concentration. In the 
ADA experiments NBTI was added 10 minutes before the point drugs were added in all 
experiments (i.e. 50 minutes after KA application). Washout was done in the presence of 
NBTI. 
3.2.3. Analysis and statistics. 
Statistical analysis was done via the same methods described in chapter 2. 
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3.3. Results. 
3.3.1. Increasing endogenous adenosine levels. 
All experiments are done using the KA-induced model of gamma oscillations. To increase 
endogenous adenosine levels adenosine kinase was inhibited by 5-IT. At high concentrations 
(1 µM) 5-IT almost completely blocked all oscillatory activity (see Table 3.1). At a low 
concentration of 0.1 µM, 5-IT showed a delayed effect. 5-IT was applied for 20 minutes, but 
its biggest effect was seen 10 minutes into washout (Figure 3.1.D). The raw trace shows a 
small reduction in signal size (Figure 3.1.A) after 20 minutes of 5-IT application. The 
accompanying power spectrum (Figure 3.1.B) shows a loss of the peak in the gamma band 
while there is a small increase in the beta band after 20 minutes. The power in the gamma 
band after 20 minutes of 5-IT application hardly changed from the start of drug application 
(1.02±0.09, n=6) while controls showed a steady growth to 1.28±0.03 (n=10) times the 
starting value. This was a significant difference between groups (Student‟s t-test, t5.7 =2.7, 
p=0.039). The normalised development over time shows that it takes a while for 5-IT to 
have its effect (Figure 3.1.D). For the first five minutes the 5-IT treated slices have the 
same development as controls. By the end of the 20 minute drug application the normalised 
power is reduced to starting values. The same downward trend continues while 5-IT is 
washed out and the biggest difference is around 30 minutes after drug application (which is 
10 minutes into washout). At 30 minutes the power in the gamma band is reduced to 
0.93±0.11 (n=6) times the starting value, while controls keep growing steadily to 
1.42±0.03 (n=10) the starting value (Student‟s t-test, t6 =4.4, p=0.005). At 30 minutes the 
normalised power in the slow and beta bands are not significantly different from controls 
(see Table 4.1), while the fast band power is reduced to 0.89±0.09 (n=6)  times the 
baseline. Significantly different from controls which show an increase to 1.45±0.04 (n=10)  
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Figure 3.1. Effect of increasing endogenous adenosine levels on KA induced gamma 
oscillations. A. Raw trace of one second before (black line) during 100 nM 5-IT application 
(red line, 20 minutes). 5-IT causes a small reduction in signal size. B. Power spectrum of 
300s before (black) and in the presence of 5-IT (red, 20 minutes). The peak in the gamma 
range reduces in size while the power in the frequencies below the peak increases slightly. 
The dominant frequency shifts to a slower frequency as well. Grey area indicates the gamma 
band. C. Autocorrelogram from the same data the power spectrum was taken. 5-IT reduces 
the amplitude of the second peak (red) after 20 minutes compared to before drug 
application (black). The shift in dominant frequency is also visible in the autocorrelogram 
through an increase in time to the second peak. D. Change of the normalised power in the 
gamma band. Data was normalised to 5 minutes before 5-IT application. Controls show a 
steady growth (black, n=10) while 5-IT (red, n=6) initially follows the control development 
it reduces the power in the gamma band. The downward trend continues even when 
washout has already started which causes the biggest effect to be around 30 minutes after 
drug application (10 minutes into washout). 
 
times starting values (Student‟s t-test, t14 =6.3, p=0.00002). In controls the power in all 
frequency bands grows at the same rate which creates a steady value for the gamma/beta 
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ratio. The average gamma/beta ratio was 0.98±0.08 (n=21). During 5-IT application the 
gamma band is affected much more than the beta band causing the change in gamma/beta 
ratio to become negative 30 minutes after application, -0.44±0.12 (n=6), which is a 
significant reduction in gamma/beta ratio compared to controls, 0.06±0.03 (n=10) 
(Student‟s t-test, t5.6 = 4.1, p=0.008). The average dominant frequency was 35.4±1.1 Hz 
(n=21). The loss of the peak in the gamma band shifts the dominant frequency by -
10.4±3.2 Hz (n=6) in 5-IT exposed slices. This is significantly different from controls as the 
change in dominant frequency in controls is 0.28±1.49 Hz (n=10), (Mann-Whitney U-test, 
U=5.0, p=0.007). The change in dominant frequency can also be seen in the 
autocorrelogram as the time of the second peak is later in the presence of 5-IT compared to 
before 5-IT was added. The autocorrelation also says something about the regularity of the 
oscillation. There is a clear reduction in the amplitude of the second peak in the presence of 
5-IT after 20 minutes (data from the same period as the power spectrum, Figure 3.1.C) 
indicating that the oscillation becomes less regular. The second peak reduces to 0.46±0.03 
(n=6) times the starting value 30 minutes after 5-IT application while in controls there is a 
small increase to 1.16±0.15 (n=10) times the starting value (Mann-Whitney U-test, U=0.0, 
p=0.001). 
The adenosine kinase blocker 5-IT decreased brain oscillations in the gamma band and the 
fast band, slowed down the oscillation and decreased regularity. 
 
3.3.2. Decreasing endogenous adenosine levels. 
To reduce endogenous adenosine levels ADA was added to the aCSF. ADA on its own gave 
varying results. In some slices ADA increased gamma oscillations, while in other slices ADA 
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decreased gamma oscillations. This average effect was non-significant increase with a large 
error bar (see Table 3.1). To prevent replenishment of adenosine from the cytosol, the 
 
 
Figure 3.2. Effect of decreased endogenous adenosine concentration on KA induced gamma 
oscillations. A. Raw trace before (black) and after 20 minutes NBTI (10 µM) + ADA (2 U/ml) 
(blue). NBTI+ADA increases signal size. B. Typical power spectrum of 300s before (black) 
and after 20 minutes NBTI + ADA (blue). Power increases in all frequency bands but mostly 
in the gamma range (grey area). The dominant frequency shifts slightly to slower 
frequencies. C. Autocorrelogram of the same data the power spectrum was taken. The 
oscillation becomes more regular visible in the increased amplitude of the second peak. D. 
Normalised gamma band power over time. Data was normalised to 300 seconds before drug 
application (grey area). NBTI + ADA increases the normalised gamma power to 2.25 times 
the starting value after 20 minutes of drug application (blue line, n=5) while controls 
increase to 1.29 times the starting value (black line, n=10). 
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equilibrium transporter ENT-1 was blocked by NBTI 10 minutes before ADA was applied. 
NBTI (10 µM) on its own did not change oscillatory activity in the hippocampal network (see 
Table 3.1). An increase in synchronous activity was observed in the raw data (Figure 3.2.A) 
in the presence of NBTI (10 µM) and ADA (2 U/ml) after 20 minutes. This is also visible in 
the power spectrum (Figure 3.2.B) through the increase of the peak in the gamma band. In 
the presence of NBTI and ADA the power in the gamma band increased to 2.25±0.19 (n=5) 
times the starting value after 20 minutes of drug application, which is a significantly bigger 
increase compared to controls, 1.29±0.03 (n=10) (Student‟s t-test, t4.1 = -4.9, p=0.007). 
The power in both the slow and beta bands did not significantly increase from controls (see 
Table 3.1). The power in the fast band did increase significantly more than controls to 
2.35±0.22 (n=5) the starting values (Student‟s t-test, t4.2 = -4.7, p=0.008), see Table 3.1. 
The power in the gamma band increased more than the power in the beta range visible 
through the increase in gamma/beta ratio. The gamma/beta ratio changed by 0.47±0.07 
(n=5) after 20 minutes of NBTI and ADA application, while in controls there is hardly any 
change, 0.03±0.03, (Student‟s t-test, t13 = -7.2, p=0.000007). The peak in the gamma 
band became sharper (Figure 3.2.B) making the oscillation more regular. This is reflected in 
the increased amplitude of the second peak in the autocorrelogram (Figure 3.2.C). The 
amplitude of the second peak increased to 1.48±0.1 (n=5) times its starting value while in 
significantly different from controls, 1.06±0.11 (n=10) times the starting value (Mann-
Whitney U-test, U=5.0, p=0.014). In the example power spectrum (Figure 3.2.B) a small 
shift in dominant frequency was observed. On average the dominant frequency shifts by -
2.14±1.42 Hz (n=5) after 20 minutes of NBTI and ADA application though this is not 
significantly different from the change in controls (see Table 3.1). 
ADA increased brain oscillations in the gamma band and fast band and increased the 
regularity of the oscillation.   
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3.4. Discussion. 
Modulation of endogenous adenosine levels powerfully affects in vitro gamma oscillations. 
Increasing extracellular adenosine levels by blocking adenosine kinase with 5-IT suppresses 
gamma oscillation power, distorts rhythmic activity by making the brain oscillation less 
regular and shifts the dominant frequency to a slower frequency. Decreasing adenosine 
levels by blocking ENT-1 and adding ADA to the aCSF increases gamma oscillations and 
increases rhythmic activity. 
 
3.4.1. Increasing adenosine levels. 
Applying a saturating dose of 5-IT (5 µM) to hippocampal slices increases basal adenosine 
concentrations by about 1 µM (Etherington et al., 2009). Applying a concentration of 1 µM 5-
IT already blocked almost all oscillatory activity within the hippocampal network. The low 
dose of 100 nM 5-IT slowly starts to reduce hippocampal brain oscillations, and prolonged 
application significantly decreased the power in the gamma band. As a high dose of 5-IT is 
able to increase the amount of extracellular adenosine by 1 µM it is expected that 100 nM 5-
IT will gradually increase adenosine concentration within the hundreds of nanomolar range. 
An increase of hundreds of nanomolar falls within the physiological variation in vivo (Ballarin 
et al., 1991). This means that natural variations in adenosine concentration can have a big 
impact on the amount of gamma oscillations. The effects of blocking adenosine kinase are 
strikingly similar to adding exogenous adenosine to the aCSF. When the increase in 
adenosine is small gamma oscillations are suppressed specifically. A big increase in 
adenosine levels, with 200 µM adenosine (Figure 2.6) or 1 µM 5-IT, blocks oscillations in all 
frequency bands ((Pietersen et al., 2009a), see table 3.1). The time course when using low 
concentrations of 5-IT is rather slow, probably because it takes some time for adenosine 
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concentrations to rise sufficiently high intracellularly and be transported to the extracellular 
space.  When 5-IT is washed out it takes a long time for the system to recover and 
suppression of gamma oscillations continues well in to the washout with the peak effect 
about 10 minutes into the washout which was about 30 minutes after drug application. 
Given enough time slices can recover from low doses of 5-IT. The cytosolic location of 
adenosine kinase is most likely the reason for the slow build up and recovery. When 
adenosine levels rise very quickly during abnormal physiological conditions like hypoxia 
(Frenguelli et al., 2003;Winn et al., 1981) a reduction in gamma oscillations in observed as 
well (Fano et al., 2007;Huchzermeyer et al., 2008). This reduction in gamma oscillations 
during hypoxia can be prevented by adding 8-CPT to the aCSF (Pietersen et al., 2009a). 
Adenosine can also be released in an activity-dependent manner (Wall and Dale, 2008). 
Though the precise mechanism is not yet clear it does mean that adenosine can reduce 
network activity through feed-back loops. When adenosine levels rise because the network is 
active, the release of adenosine can suppress the effectiveness of any subsequent 
neurotransmission until adenosine levels are brought back to normal.   
 
3.4.2. Decreasing adenosine levels. 
Both ADA (1-2U/ml) and the ENT-1 blocker NBTI (10 µM) on their own did not have a 
consistent effect on gamma oscillations. Blocking ENT-1 has been shown to have no 
influence on adenosine levels (Wall et al., 2007). In the presence of NBTI extracellular 
adenosine levels cannot be replenished from the cytosol, thus ADA can lower extracellular 
adenosine concentrations. Reducing adenosine levels by adding ADA to the aCSF very 
potently increased brain oscillations specifically in the gamma band. Due to the low affinity 
of ADA for adenosine (Dunwiddie and Masino, 2001) increasing gamma oscillations by 
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reducing adenosine levels with ADA is only feasible under circumstances where adenosine 
levels are relatively high. When adenosine levels are low ADA has a much smaller effect on 
gamma oscillations (Pietersen et al., 2009a). 
These results indicate that small fluctuations in adenosine levels can alter gamma 
oscillations and possibly also the cognitive functions related to gamma oscillations. With the 
increase in adenosine levels during ageing (Mackiewicz et al., 2006;Sperlagh et al., 1997) 
cognitive processes that decline during ageing could be boosted by lowering adenosine levels 
in the brain. 
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3.5. Future research. 
To be able to say something about using adenosine levels as possible cognitive enhancers 
the exact adenosine concentrations that influence gamma oscillations need to be known. It 
would be really interesting to see how the adenosine levels correlate with the reduction in 
gamma oscillations. Adenosine levels can be measured accurately in hippocampal slices 
using an adenosine probe (Etherington et al., 2009). A possible experiment would be to use 
the low dose of 5-IT used in this chapter (100 nM) while recording the adenosine 
concentration. Then a correlation between the extracellular adenosine concentration and the 
degree gamma oscillations are affected can be made. Because of the slow time course seen 
when applying low doses of 5-IT it is possible to accurately measure adenosine 
concentration and gamma oscillations power. If adenosine levels rise too quickly it will be 
hard to determine at which concentration adenosine will start to significantly change gamma 
oscillations in vitro. A similar experiment can be done using an ENT-1 blocker and ADA. If 
adenosine levels drop too quickly ADA concentrations can be increased incrementally to 
decrease adenosine levels more slowly. These findings will have to be confirmed in vivo 
before anything can be said about adenosine levels and adenosine receptors as cognitive 
enhancing agents.  
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parameter 
 
 parameter 
value 
 
control 
 
5-IT 
(100 
nM) 
control NBTI (10 µM) 
+ ADA (2 
U/ml) 
NBTI 
(10 
µM) 
 
ADA (1-
2U/ml) 
5-IT 
(1 µM) 
 
   30 min 30 min 20 min 20 min 20 min 20 min 20 min 
normalised power n=21 n=10 n=6 n=10 n=5 n=10 n=5 n=9 
gamma (20-60 
Hz) 
Mean 44.6 1.42 0.93 1.29 2.25 1.52 1.81 0.08 
 SEM 6.4 0.03 0.11 0.03 0.19 0.16 0.53 0.02 
beta (8-20 Hz) Mean 47.0 1.33 1.41 1.26 1.55 1.32 1.18 0.17 
 SEM 7.8 0.04 0.11 0.04 0.14 0.12 0.34 0.03 
slow (3-8 Hz) Mean 34.4 1.22 1.29 1.20 1.76 1.27 1.44 0.33 
 SEM 3.7 0.03 0.07 0.04 0.21 0.10 0.28 0.05 
fast (60-100) Mean 4.0 1.45 0.89 1.32 2.35 1.42 1.64 0.15 
 SEM 0.6 0.04 0.09 0.03 0.22 0.15 0.53 0.03 
 
Δgamma/beta 
ratio 
Mean 0.98 0.06 -0.44 0.03 0.47    
 SEM 0.08 0.03 0.12 0.03 0.07    
 
Δdominant 
frequency 
Mean 35.4 0.28 -10.4 0.5 -2.1    
 Sem 1.1 1.49 3.2 0.9 1.4    
normalised autocorrelation 
2nd peak 
amplitude 
Mean 0.32 1.16 0.46 1.06 1.48    
 SEM 0.03 0.15 0.03 0.11 0.10    
 
Table 3.1. Effect of changes in endogenous adenosine levels on gamma oscillations. Bold numbers indicate significant 
differences (p<0.05) compared to controls. NBTI was given 10 minutes prior to ADA application in the experiments using 
both drugs. 
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CHAPTER 4: ADENOSINE RECEPTOR MODULATION OF CELLULAR AND SYNAPTIC 
PROPERTIES. 
 
4.1. Introduction.  
The effects of adenosine receptor modulation on gamma oscillations recorded through field 
potentials in vitro have been investigated in the past two chapters. Adenosine A1-receptor 
agonists and A2A-receptor antagonists reduce gamma oscillation strength, while adenosine 
A1-receptor antagonists and A2A-receptor agonists increase gamma oscillation strength. The 
effect of a non-specific adenosine receptor agonist (adenosine) or antagonist (caffeine) will 
depend on receptor distribution and receptor density in the investigated brain area. Also 
modulation of endogenous adenosine levels has an impact on the recorded oscillation. 
Increasing adenosine levels decreases oscillation strength specifically within the gamma 
range, while decreasing adenosine levels has the opposite effect. 
In this chapter the cellular and synaptic changes that underlie the effects caused by 
adenosine receptor acting drug on gamma oscillations are investigated. Figure 4.1 is a 
simplified schematic drawing of the hippocampal network (an extension of the figure shown 
in the introduction, see Figure 1.3). One of the key features is the convergent input of 
pyramidal cells onto interneurons and the divergent output from interneurons to pyramidal 
cells. Adenosine receptors are widespread throughout the brain and present on both the pre- 
and postsynaptic membrane of pyramidal cells and interneurons (see figure 1.2). This 
means that adenosine receptors could possibly affect both inhibition and excitation within 
the hippocampal network. The numbers in Figure 4.1 show possible sites where adenosine 
receptors could modulate gamma oscillations. Several synaptic and cellular effects of 
adenosine A1-receptor activation 
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Figure 4.1. Simplified schematic drawing of a CA3c hippocampal network. The green 
triangular cells are pyramidal cells and the orange round cell represents an interneuron. The 
numbers indicate possible sites where adenosine receptor modulation can change cellular or 
synaptic properties that can underlie the changes observed in the field recordings. 1. cellular 
properties. 2. excitatory inputs. 3. inhibitory inputs. The lightning symbol represents 
antidromic stimulation of the Schaffer-collaterals.  
 
have already been described in literature. Adenosine has been shown to reduce excitatory 
synaptic activity in various brain areas including the hippocampus (Fredholm et al., 
1999;Haas and Selbach, 2000). There is evidence that adenosine A1-receptor activation 
inhibits primarily N-type Ca2+ currents (Mogul et al., 1993) and thereby vesicle release. A 
hyperpolarization of the post-synaptic membrane will also reduce the effect of the released 
neurotransmitters. Adenosine A1-receptors have been found to hyperpolarise the membrane 
potential of pyramidal cells (Haas and Selbach, 2000;Luscher et al., 1997) and interneurons 
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in the hippocampus (Li and Henry, 2000) through activating inward rectifying K+ currents 
(Haas and Selbach, 2000). In contrast to the reduction in excitation, adenosine does not 
seem to affect monosynaptic inhibition, while the polysynaptic IPSP was almost totally 
blocked (Thompson et al., 1992). 
In this chapter the effects adenosine and 8-CPT have on pyramidal cells in the hippocampus 
will be investigated. Adenosine and 8-CPT were chosen to be able to relate the findings in 
this chapter with the findings from the field recordings. The effects described in literature 
will be reproduced and subsequently a deeper look will be taken at other parameters that 
could underlie the changes observed in the previously described field recordings. Firstly, 
intrinsic properties will be studied. It is expected that adenosine will activate G-protein 
Inward Rectifying K+-channels (GIRK channels) and thereby increase the flow of K+ ions 
across the membrane causing a hyperpolarization of the membrane potential. Secondly, 
both excitatory and inhibitory synaptic properties will be looked at. It is expected adenosine 
will reduce excitatory synaptic transmission, though the underlying cellular mechanisms will 
not be studied. With inhibition being a very important feature of gamma oscillations a closer 
look will be taken at IPSPs, though literature predicts that adenosine receptor modulation 
does not affect inhibitory synapses.  
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4.2. Materials and methods.  
4.2.1. Tissue preparation. 
Male Sprague-Dawley rats (200 – 400 grams, from Charles-River, Margate, UK) were 
anaesthetised with a mixture of ketamine (75 mg/Kg) + medetomidine (1 mg/Kg) by i.p. 
injection. Rats were used instead of mice because the goal is to eventually do in vivo and 
behavioural experiments which are easier done in rats. Using a new technique seems a 
natural point to change the kind of animal used though the assumption is made there are 
not major differences in the hippocampal networks between rats and mice. The rat‟s blood 
was replaced via cardiac perfusion through the left ventricle with an oxygenated and chilled 
sucrose based solution containing (in mM): sucrose, 205; KCl, 2.5; NaHCO3, 26; NaH2PO4, 
1.25; D-glucose 10; MgCl2, 5; CaCl2, 0.1. Subsequently the rat was killed by cervical 
dislocation after which the brain was removed and kept cold in oxygenated sucrose solution. 
Using an Integraslicer (Campden Instruments, Loughborough, UK) 400 µm thick horizontal 
slices were made from the ventral hippocampus (coordinates from bregma: -7.5 till -5.0 
mm) and put either in a Haas-type recording chamber at the interface between moist 
carbogen (95%, O2, 5% CO2) and aCSF (containing (in mM): D-glucose, 10; NaHCO3, 26; 
NaCl, 125; KCl, 3; NaH2PO4, 1.25; CaCl2, 2; MgCl2, 1) at 32°C, or stored in a static interface 
type chamber containing aCSF at 21°C for later use. Fluid levels in the recording chamber 
were kept high using a perfusion rate of 8±1 ml/min minimizing gravitational pull onto the 
mesh, but making sure the slices were not submerged or started floating. All procedures 
were in accordance with the UK „Animals (Scientific Procedures) Act 1986‟, and the studies 
were approved by the Biomedical Ethics Review Sub-Committee.  
  
- 75 - 
 
4.2.2. Electrophysiological recordings. 
Intracellular recordings from CA3c pyramidal cells were made using sharp glass pipette 
recording electrodes filled with 3M potassium methylsulfonate (KCH3SO4, resistance >50 
MΩ). Electrodes were placed in stratum pyramidale of the CA3c area. Individual cells were 
not visualised. The membrane potential was amplified using an Axoclamp-2A amplifier (Axon 
Instruments, Burlingham, CA, USA) and a Neurolog NL106 DC amplifier (Digitimer, Welwyn 
Garden City, UK), low-pass filtered at 2 kHz and sampled at 10 kHz. The signal was then 
digitised and sampled by using a CED-1401 (Cambridge Electronical Design, Cambridge, UK) 
and analyzed using Signal 3 and Spike 2 software (Cambridge Electronical Design, 
Cambridge, UK). All cells were recorded in current clamp.  
Cells were bridge balanced and used for experiments when the resting membrane potential 
was stable and the cell needed less than 0.5 nA current to stay at -65 mV resting membrane 
potential, and had overshooting action potentials. Schaffer collaterals were stimulated by a 
0.1 ms square pulse using a bipolar twisted 50 µm diameter nickel/chromium wire (Advent 
Research Materials Ltd, Halesworth, UK) and a DS2A isolated stimulator (Digitimer). The 
stimulus electrode was placed on the border of CA3a and CA1. 
Drugs were diluted from the following stock solutions: adenosine (10 mM stock in aCSF), 8-
cyclopentyl-1,3-dimethyxanthine (8-CPT; 10 mM stock in 0.1 M NaOH). All drugs and aCSF 
salts were purchased from Sigma (Poole, UK). 
After running all protocols for the first time in normal aCSF (before phase) drugs were 
washed in for 10 minutes by adding them to the aCSF flowing in the system. If the cell was 
still healthy and the membrane potential was stable after the drugs were washed in, the 
same protocols were done in the presence of the added drug (drug phase). Once all 
protocols were run once again the drugs were washed out by changing to a fresh aCSF 
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solution. After 10 minutes of wash out the cell was checked to assess if it was still healthy, 
and if it was the protocols were done a third time (after phase).  
4.2.3. Analysis and statistics. 
Statistical comparisons were made between the change (drug phase – before phase) in aCSF 
controls and the change in cells treated with either adenosine or 8-CPT. The unpaired 
comparison was chosen over the paired comparison to make sure that any change occurring 
over time will not be mistaken for a change caused by adenosine or 8-CPT. Every variable 
was first analyzed for normality and any difference in starting value between groups. If data 
was normally distributed a Student‟s t-test was used for comparison while if data was not 
normally distributed a non-parametric equivalent was used. Unless stated otherwise, there 
was no difference in the starting values between the different treatment groups. Because 
the effects of adenosine on field potential were totally reversible (see chapter 2), the 
adenosine group was analyzed by calculating the “drug effect”. The drug effect was obtained 
by averageing the parameter values from the before and after phase and using that average 
in subsequent comparison and calculations. The change of the parameter was then 
calculated by subtracting the calculated average from the value obtained in the drug phase. 
Because the effects of 8-CPT on the field recording were not reversible, comparisons were 
made between the drug and before phase and the change was calculated by subtracting the 
before phase from the drug phase. All parameters were checked for normality using the 
Kolmogorov-Smirnov test in SPSS 15.0, and if data was normally distributed statistical 
comparison was made using a Student‟s t-test. If data was not normally distributed the non-
parametric Mann-Whitney U test was used. Data are expressed as means±standard error of 
the mean (s.e.m.). If the significance level was below 0.05, data were considered 
significantly different from controls. 
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4.3. Results.  
 
4.3.1. Intrinsic properties. 
Changes in passive cell properties can complicate interpreting results therefore it is 
important to check the stability of the cells parameters recorded.  
 
4.3.2. Cell resistance and capacitance. 
Negative current steps and positive current steps that did not elicit an action potential were 
used to calculate the slope resistance. Cells were kept at a membrane potential of -65 mV 
and the response to a 0.2 second current step was recorded. A typical response to a -0.5 nA 
current step is shown in Figure 4.2.A. To get the most accurate resistance measurement the 
response was fitted with single exponential fit using Signal software version 3.10 (CED). 
Using the equation: value = amplitude * e(-x/taum) + offset, three values are obtained from 
the fit: amplitude, membrane time constant (taum) and offset. The fit was measured 
between cursors 2 and 3 with cursor 1 (Figure 4.2.A) as a reference. Cursor 1 was placed at 
the start of the current step. To compensate for any bridge imbalance and to avoid inclusion 
of incompletely-compensated capacitance transient in the fit, cursor 2 was placed slightly 
after the start of the stimulus on the clearly exponential part of the response. Cursor 3 was 
placed at the end of the stimulus except in cases where the hyperpolarisation-activated cat-
ion current (Ih) caused an increase in membrane potential during the current step. In these 
cases cursor 3 was placed at the point just before the visible depolarization in membrane 
potential caused by Ih was observed. The amplitude is the deviation from baseline (in mV) 
induced by the current injected, the offset is the voltage to where the cell is polarised to (in 
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mV) and the taum is the time constant of the exponential decay to the offset. Cursor 3 was 
repositioned if unrealistic values were obtained. The taum should theoretically not change 
with different current injections in the same condition  
 
Figure 4.2. Slope resistance. A. Example of a response to a -0.5 nA current step. The 
response is fitted with a single exponential fit between cursors 2 and 3, after which 
membrane resistance (Rm) can be calculated (Rm=amplitude (mV) / current (nA)). B. Slope 
resistance is calculated from two -0.5 nA, two -1 nA and one 0.1 nA current steps via a 
linear fit (amplitude=slope resistance*current). 
 
because it is dependent on the cell resistance and cell capacitance which remain the same 
under the same experimental conditions. Therefore the tau is calculated by taking the 
average from all responses used in Figure 4.2.B. The average taum from all cells before any 
drugs was added was 41.5±2.4 ms (n=22).  No significant difference was found in the 
change in taum (Δtaum) between aCSF controls (2.1±3.0 ms, n=6) and adenosine (50 µM, -
5.7±3.0 ms, n=8) or aCSF controls (5.7±4.2 ms, n=6) and 8-CPT (5 µM, 2.2±3.6 ms, n=8 
see Table 4.1). The Δoffset was also not significantly different from controls in both 
adenosine and 8-CPT (not shown). As a measure of resistance the slope resistance was 
calculated using four negative current injections (two times -0.5 and two times -1.0 nA) and 
one positive current injection (0.1 nA). The amplitude was plotted against the size of the 
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current injection, see Figure 4.2.B. When the positive current injection caused the cell to fire 
an action potential, the response could not reliably be fitted with an exponential fit and was 
therefore not used. To calculate the slope resistance the amplitude of the response from the 
fit was set out against the current injected and subsequently fitted with a linear fit using 
with the formula: amplitude = slope resistance * current. The fit was forced through zero 
because a zero nA injection does theoretically not produce a deviation from baseline. The 
slope resistance had an average of 50.0±3.3 MΩ/nA (n=22) before any drugs were tested. 
The change in slope resistance (Δslope resistance) in cells treated with adenosine (-2.8±4.2 
MΩ, n=8) or 8-CPT (3.7±4.0 MΩ, n=8) was not different from the Δslope resistance in aCSF 
controls (1.1±2.7 MΩ, n=6) (see Table 4.1). 
The capacitance of a cell can be calculated by dividing the membrane time constant by the 
cells resistance. The capacitance is proportional to the surface area of the cell and is thus an 
indirect measure of cell size.  As you would not expect a cell to change its size during an 
experiment it is an important measure to check the condition of the recorded cell. The 
average membrane capacitance (Cm) of all cells recorded before drugs were tested was 
0.91±0.08 pF (n=22). The change in capacitance (ΔCm) with adenosine (-0.13±0.07 pF, 
n=8) and 8-CPT (-0.02±0.04 pF, n=8) did not differ significantly from the change in aCSF 
controls (0.08±0.12 pF, n=6, see Table 4.1).  
 
4.3.3. Action potential properties. 
From positive current steps that caused action potential firing, the action potential properties 
were measured. To make sure similar action potentials were compared the first action 
potential of the first current step that caused an action potential within 10 ms of the start of 
the current step was used to determine firing threshold (APthres), action potential upward 
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slope (APslope up) and action potential downward slope (APslope down). Figure 4.3.A.I shows a 
typical response of a cell that fires action potentials after a depolarizing current step (0.7 
nA). Very typical for CA3c neurons is that the action potential are grouped in the early part 
of the depolarizing current. From the first derivative of the original response, the maximum 
APslope up and the maximum APslope down (see Figure 4.3.A.II) were measured. Figure 4.3.B is 
an enlargement of the first action potential and its derivative (grey area in Figure 4.3.A). 
APslope up and APslope down are  
Figure 4.3. Action potentials. A.I. Example of a response to a 0.7 nA current step. Typical 
for Ca3c neurons is that the evoked action potentials are grouped in the early part of the 
depolarizing pulse. II. First derivative of the response in A.I. used to determine action 
potential slope up and slope down and where the action potential threshold was measured. 
B. Enlargement of the grey area in A. I. The first action potential cause by the 0.7 nA 
current step used in A. II. First derivative of the action potential in B.I used for measuring 
the up and downward slopes indicated by the vertical grey bars. The grey dotted line 
indicates the point where the first big change in membrane potential occurred. This is the 
start of the action potential and a measure for action potential threshold. Action potential 
threshold was taken from the same position from the original trace (A.I). 
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measured by taking the peak values, which correspond to the slopes of the action potential 
in the original recording. The average APslope up was 174±13 V/s (n=21). The change in 
APslope up (ΔAPslope up) with adenosine (6.1±5.0 V/s, n=8) or 8-CPT (-4.9±3.8 V/s, n=8) did 
not significantly differ from aCSF controls (2.9±2.2 V/s, n=6, see Table 4.1). APslope down had 
an average of -71±6 V/s (n=21) before drugs were tested and showed no significant 
difference in ΔAPslope down between treatments. The first big positive inflection of the first 
derivative corresponds to the start of the action potential, and was taken as APthres (see 
Figure 4.3.B). The average APthres was -53.9±1.0 mV (n=21) but no significant difference 
was observed in ΔAPthres between adenosine (-1.63±1.5 mV, n=8) or 8-CPT (-0.51±0.9 mV, 
n=8) compared to aCSF controls (-0.47±1.7 mV, n=6).  
 
4.3.4. Resting membrane potential. 
A possible way for adenosine receptors to affect gamma oscillations is by changing a cell‟s 
resting membrane potential (Vm). Figure 4.4.A shows a typical example of the effect of 50 
µM adenosine has on the membrane potential during wash in. The cell was held at a 
membrane potential of -65 mV before drugs were added. Adenosine hyperpolarised the CA3 
pyramidal cell resting membrane potential very quickly after application. Within a few 
minutes a new stable equilibrium was reached. The average Vm before drug application 
without injecting any current was -58.6±0.77 (n=22). Adenosine caused a significant 
hyperpolarisation compared to aCSF controls (Figure 4.4.B), ΔVm
 = -4.34±1.16 mV in 
adenosine (n=8), ΔVm = -0.49±0.88 mV in controls (n=6), Student‟s t-test, t12 = 2.5, 
p=0.029 (see Table 4.1). There was no difference in ΔVm between 8-CPT (-1.08±0.72 mV, 
n=8) and aCSF controls.  
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Figure 4.4. Resting membrane potential. A. Example of the effect of adenosine (50 µM) on 
membrane potential of a CA3 pyramidal cell during wash in. A quick hyperpolarisation is 
observed after adenosine application. The red horizontal bar indicates the time when 
adenosine (50 µM) was applied. B. Adenosine (50 µM, n=8) caused a significant 
hyperpolarisation to the resting membrane of CA3 pyramidal cells compared to controls 
(n=6), (p=0.029) while 8-CPT (5 µM, n=8) had no effect. 
 
 
4.3.5. Slow afterhyperpolarization. 
One of the mechanisms by which A1-receptor acting drugs could influence gamma 
oscillations is by changing the slow afterhyperpolarisation (AHPslow) seen after action 
potential firing. A typical example is shown in Figure 4.5.A where a CA3c pyramidal cell, kept 
at -65 mV, was given a 0.7 nA current injection causing the cell to fire a number of action 
potentials. The AHPslow was fitted with a single exponential fit: value = AHPmax * e(-x/AHPtau) 
+ offset.  From the fit three values were taken: amplitude (AHPmax), time constant (AHPtau) 
and offset. The fit was taken between cursors 2 and 3 with cursor 1 as a reference. Cursor 1 
was placed at the end of the current step, cursor 2 was placed approximately 50 ms after 
the trough and cursor 3 was placed at a time where it was clear the membrane potential had 
recovered back to baseline (see Figure 4.5.A). A response was refitted when the offset was 
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not within 1 mV of baseline values (the average of the 300 ms before the current injection) 
or if the AHPtau gave unrealistic values. The amplitude obtained from the fit is an 
overestimation of the real amplitude as signal software extrapolates the amplitude to the 
reference cursor (cursor 1 in Figure 4.5.A). A more realistic afterhyperpolarisation amplitude 
(AHPamp) was calculated from the values obtained from the fit using the equation above. To 
determine the time at which to calculate a realistic AHPamp all responses from all analysed 
cells were compared and 800 ms after the end of the current injection was chosen because 
all cells were definitely past the trough of the response at that time. As not every cell 
responds to current injections the same way it is hard to choose a response that is 
comparable from cell to cell. To obtain a more reliable measurement of the AHPslow the 
AHPamp was set out against the number of action potentials (Figure 4.5.B) and then fitted 
with a linear equation (AHPslow = y0 + AHPangle * number of AP). The fit angle (AHPangle) then 
captures all the responses from one cell in a single value. The value obtained from y0 was so 
small in every cell analyzed, that it was considered to be equal to 0. The average AHPangle 
was 1.7±0.3 mV/action potential (n=22) before drugs were added. The change in AHPangle 
(ΔAHPangle) did not differ significantly between groups (see Figure 4.5.C and Table 4.1). 
The AHPtau was calculated for every cell by averaging all the time constants from every 
response used in Figure 4.5.B that had action potentials. The AHPtau had an average value of 
1.3±01 s, n=22, but no significant differences were found in ΔAHPtau (see Table 4.1). The 
AHP in CA3c pyramidal cells in response to an action potential is large compared to CA1 
pyramidal cells (Greene and Haas, 1985). 
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Figure 4.5. Slow afterhyperpolarization (AHP). A. Typical response to action potential firing 
showing the slow AHP in a CA3c pyramidal neuron (0.7 nA current injection). The slow AHP 
was fitted with a single exponential fit to measure the amplitude and time constant.  B. 
Response effect relationship between AHP amplitude and number of action potentials. The 
data was fitted with a linear fit. The fit is not forced through zero because a depolarization 
without an action potential could also open a small amount of K+-channels and thereby 
create a small AHP. C. Change in AHPangle between drug and before phase. There is no 
significant difference between adenosine (n=8) or 8-CPT (n=8) groups and the control group 
(n=6). D. Relationship between the change in AHPangle and AHPangle before. There is a 
significant regression (p=0.031) between cells exposed to adenosine receptor activation or 
blockage showing that the starting value can influence whether or not an effect can occur. 
Red dots are cells exposed to adenosine and blue dots are cells exposed to 8-CPT. 
 
There were cells that already reached the maximum AHP amplitude after only two action 
potentials. It was expected from literature (see introduction) that adenosine increases AHP 
amplitude. Due to the big AHP before any drugs were added, the starting value can influence 
the change we can observe. If the AHP amplitude is already at its maximum there is little 
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room for adenosine to increase the response even further. To find out if the starting value 
had any influence on the observed change the ΔAHPangle was set out against the AHPangle in 
the before phase (see Figure 4.4.D) for all adenosine (red) and 8-CPT (blue) treated cells. 
There was a significant negative regression between the starting value and the change in 
AHPangle, Spearman‟s rho -0.538, p=0.031. This indicates that part of the variation seen can 
be explained by the variation in starting value.  
 
4.3.6. Signal variance. 
One of the noticeable things besides the obvious hyperpolarisation in Figure 4.5.A is the 
reduction in the size of the signal before and during adenosine application. To quantify the 
effect of adenosine receptor acting drugs on signal size, signal variance was calculated as 
the signal variance is proportional to signal power. The power in an electrical signal is 
defined as voltage * current (Power = V * I). The current is unknown but Ohm‟s law dictates 
that I = V / R (with R being the resistance). Inserting that into the previous formula gives: 
Power = V2 / R. As the cells resistance did not significantly change over time (see Figure 
4.6.B and Table 4.1) R can be seen as a constant which leaves us with: Power = V2. Signal 
software (CED) can calculate the signal standard deviation which once squared will give the 
Variance. At Vm the average signal variance was 1.04±0.17 mV
2 (n=22). Figure 4.6.A shows 
typical examples of all treatment groups. Just from looking at the raw data it becomes 
apparent that in aCSF controls (Figure 4.6.A.I) signal variation does not change while in cells 
exposed to 50 µM adenosine a reduction is signal variation (about 30%) is observed (Figure 
4.6.II). In cells exposed to 8-CPT there is an increase in signal variation which seems to be 
mostly an increase in big upward deflections (Figure 4.6.A.III). Adenosine significantly 
reduced the variance at resting membrane potential compared to aCSF controls, 
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ΔvarianceVm, adenosine (-0.34±0.10 mV
2, n=8), control (-0.07±0.01 mV2, n=6), (Mann-
Whitney U-test, U=6.0 and p=0.02 (see Table 4.1)), see Figure 4.6.B. The change in 8-CPT 
(5 µM, 0.24±0.14 mV2, n=8) did not differ significantly from the change in controls (-
0.05±0.11 mV2, n=6, see Table 4.1 and Figure 4.6.B). Because adenosine hyperpolarised 
resting membrane potential (see Figure 4.4.B), the significant change in ΔvarianceVm could 
be a result of a difference in resting membrane potential. At a more hyperpolarised Vm the 
same incoming current will be recorded as a smaller potential and thus reduce the variance. 
To have a more comparable value of the change in variance, the variance was calculated 
while the cell was held at -65 mV. Figure 4.6.C shows the raw traces (details as in Figure 
4.6.A) before and during drug application. While there is little difference between before and 
during drug traces in controls (Figure 4.6.C.I) and adenosine (Figure 4.6.C.II), the traces 
recorded in the presence of 8- CPT Figure 4.6.C.III) shows a clear increase in raw signal 
(about 3 times). The variance calculated at -65 mV had an average value of 0.57±0.1 mV2 
(n=22). The change in variance at -65 mV significantly increased in 8-CPT (0.67±0.31 mV2, 
n=8) treated cells compared to aCSF controls (0.07±0.10 mV2, n=6) (Mann-Whitney U-test, 
U=6.0, p=0.02, see Table 4.1) while the change in adenosine (-0.04±0.07 mV2, n=8) did 
not differ from the change in controls (0.04±0.11 mV2, n=6, see Table 4.1). 
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Figure 4.6. Signal Variance. A. Raw traces of the effect adenosine receptor acting drugs has 
on  signal size at Vm. Black lines represent traces before any drugs were added. I. Typical 
example of control data where aCSF was applied continuously. The grey line was taken at 
the time that corresponds to 20 minutes of drug exposure. II. Typical example of the effect 
50 µM adenosine on signal size. The red trace was taken 20 minutes after adenosine 
application. III. Typical example of the effect 5 µM 8-CPT has on signal size. The blue trace 
was taken 20 minutes after 8-CPT application. B. Difference between signal variance 20 
minutes after drug application and before drug application at Vm. Adenosine (50 µM, n=8) 
showed a significant decrease in signal variance (p=0.02) while 8-CPT (5 µM, n=8) was not 
significantly different from control data (n=6). C. Raw traces of the effect adenosine 
receptor acting drugs have on signal size while the membrane potential was kept at -65 mV. 
I, II, and III. Details same as in A. D. Difference between signal variance 20 minutes after 
drug application and before drug application at -65 mV. 8-CPT (5 µM, n=8) caused a 
significant increase in signal variance (p=0.02) while adenosine (50 µM, n=8) had no effect 
compared to the change in controls (n=6). 
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4.3.7. Firing rate. 
Firing rate was assessed at resting membrane potential. The average firing rate before drug 
application was 0.35±0.16 Hz, n=18. Figure 4.7.A shows every individual cell before and 
during drug application. In aCSF controls one cell increased its firing rate while the rest of 
the cells did not change its firing rate. All cells treated with 50 µM adenosine that had a 
firing rate above zero before drug application decreased their firing rate while the cells that 
had no firing rate before drug application in the same group did not change their firing rate. 
 
  
 
Figure 4.7. Firing rate. A. Firing rate before and during drug application. Individual cells are 
depicted and connected by lines. Horizontal bars indicate the group average. B. Difference in 
firing rate during and before drug application. Adenosine (50 µM, n=7) decreased firing rate 
significantly (p=0.037) while 8-CPT (5 µM, n=6) increased firing rate significantly (p=0.009) 
compared to controls (n=6). 
 
In the 8-CPT (5 µM) exposed group all cells increased their firing rate. The firing rate 
changed (Δfiring rate, see Figure 4.7.B) significantly after adenosine (50 µM) application (-
0.29±0.16 Hz, n=7), compared to controls (0.02±0.02 Hz, n=6), Mann-Whitney U-test, 
U=6.0 and p=0.037, (see Table 4.1). 8-CPT (5 µM) had the opposite effect and significantly 
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increased firing rate (0.16±0.03 Hz, n=6), Mann-Whitney U-test, U=5.0 and p=0.009 (see 
Table 4.1).  
 
4.3.8. Intrinsic properties conclusion. 
Of all the cellular parameters investigated adenosine significantly hyperpolarised the resting 
membrane potential, reduced signal variance at resting membrane potential and reduced 
firing rate. The changes in all these parameters fit well with the observed field effects and 
are likely to contribute to the reduction in oscillations specifically in the gamma range. On 
the other hand, 8-CPT significantly increased signal variance when cells were kept at -65 mV 
and increased firing rate. These effects are likely to contribute to the increase in 
hippocampal gamma oscillations described in the previous chapters (chapter 2 and 3).  
   
4.3.9. Synaptic properties. 
Adenosine receptors are also present on the pre- and post-synaptic membrane in the 
synaptic cleft (see Figure 1.2) and could therefore influence synaptic transmission directly. 
Both the inhibitory post-synaptic potential (IPSP) and excitatory post-synaptic potential 
(EPSP) were investigated.  
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4.3.10. Excitatory post-synaptic potentials (EPSPs). 
To investigate EPSPs cells were hyperpolarised to a membrane potential of -90 mV at the 
soma. This is close to the IPSC reversal potential (see Table 4.1) to minimise the influence 
of the IPSP on the change in potential after the stimulus, giving an as pure as possible EPSP. 
Figure 4.8.A shows a typical example of the response of a cell to an increasing Schaffer 
collateral stimulus. With increasing stimulus intensity the EPSP response increases in 
amplitude until eventually an action potential is evoked. As a measure of the EPSP size the 
upward slope is taken. To measure the EPSP slope the original trace is taken (Figure 4.8.B.I) 
and subsequently the first derivative was calculated (Figure 4.8.B.II). From the first 
derivative trace the first peak is taken as the maximum upward slope. Because the first 
derivative from the signal does not have a distinct single peak a horizontal cursor (grey 
dotted line) is used to measure the average peak. That value depicts the maximum change 
during the rising part of the EPSP which is a measure of the EPSP slope. If a stimulus evoked 
an action potential (see Figure 4.8.A) the EPSP slope was measured before the start of the 
action potential (Figure 4.8.B.III). The action potential is clearly visible in the very steep 
increase in the first derivative. The EPSP slope was plotted against the stimulus strength to 
obtain a stimulus-response curve (Figure 4.8.C). The data points were fitted with the 
sigmoidal function: amplitude=EPSPmax/1+(exp(-(S-ES50)/EPSPslope)), where EPSPmax is the 
fitted maximum EPSP amplitude, ES50 is the stimulus strength (S) required to reach half 
maximum effect and the EPSPslope is an inverse measure of the steepness of the curve. In 
control conditions, continuous aCSF, the response changed very little (see Figure 4.9.A). On 
the other hand 50 µM adenosine reduced the response (see Figure 4.9.B) while 5 µM 8-CPT 
increased the response (see Figure 4.9.C) to a Schaffer collateral stimulus of fixed stimulus 
strength. For cells treated with 8-CPT the after phase is not shown because 8-CPT does not 
wash out. The three values obtained from every fitted cell were averaged and used to 
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construct an average stimulus response curve, which gives an indication of the effects drugs 
have on the EPSP slope (Figure 4.9.B, D and F, for values see Table 4.1). In control there 
were no differences during the three recording phases (before, drug and after).  
 
 
Figure 4.8. Excitatory post-synaptic potential (EPSP) measured at -90 mV. A. Example of 
the responses to increasing Schaffer collateral stimulus (0, 2, 4, 6, 8, 10, 12, 15 and 20 V) 
at a membrane potential of -90 mV. With increasing stimulus strength the EPSP becomes 
bigger and the strongest two stimuli evoked an action potential. B. The upward EPSP slope 
is calculated for every individual response by taking the first derivative. I. The response to 
the 10 V stimulus in panel A. II. The first derivative of the response in panel B.I. The peak 
of the first derivative shows the maximum change and therefore the maximum EPSP slope. 
Because the response is noisy a horizontal cursor (grey dotted line) is used to determine the 
average peak. III. In responses where the stimulus evoked an action potential the slope 
was determined before the start of the action potential. The start of the action potential is 
clearly visible in the very steep change in membrane potential derivative. Again a horizontal 
cursor is used to determine the peak. C. A stimulus response curve is made from the 
stimulus intensity and upward EPSP slope and subsequently fitted with a sigmoidal function. 
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Figure 4.9. Excitatory post-synaptic potential (EPSP) measured at -90 mV. A. C. E. Typical 
examples of the response to a Schaffer collateral stimulation before, during and after drug 
application (aCSF control, adenosine (50 µM) and 8CPT (5 µM) respectively) of a single cell. 
Adenosine reduces the recorded response while 8-CPT increases the recorded response. 
Stimulus intensity 10, 15 and 8 V respectively. B. D. F. For every cell a stimulus response 
curve was made from which three values were derived (see Figure 4.8). From these values 
an average was calculated (n=6-8) and the curves shown in this figure are reconstructed 
sigmoidal curves from these average values. Adenosine reduced the fitted maximum and 
shifted the stimulus response curve to higher values while 8-CPT increased the fitted 
maximum. 
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The average fitted maximum EPSP slope was 7.27±0.76 V/s (n=22). Adenosine reversibly 
reduced the maximum EPSP slope (ΔEPSPmax = 2.64±0.53 V/s, n=8, Student‟s t-test, t10 = 
4.1, p=0.002) while 8-CPT increased the maximum EPSP slope (ΔEPSPmax = 1.84±0.49 V/s, 
n=8, Two sample Kolmogorov-Smirnov Test, Z=1.4, p=0.048), compared to controls 
(0.58±0.57 V/s, n=6), see Figure 4.10. The average EPSP ES50 was 7.8±0.4 V (n=22). For 
the unpaired comparison with controls, the adenosine induced shift in ES50 was not 
significant (Student‟s t-test, p=0.097). However a paired comparison between the before 
phase and the drug phase did reveal a shift to higher values during adenosine application 
(paired Student‟s t-test, t=3.7 p=0.011, n=8). The average slope was 1.92±0.22 (n=22) 
but showed no significant changes between groups.  
 
 
 
Figure 4.10. Change in EPSP fitted maximum in aCSF controls, adenosine (50 µM, n=8) 
and 8-CPT (5 µM, n=8). Adenosine significantly reduced the fitted maximum (p=.002) while 
8-CPT significantly increased the fitted maximum (p=0.048) compared to the change in 
controls (n=6). Functionally this means that the EPSP is reduced in adenosine and increased 
in 8-CPT treated cells. 
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Figure 4.11. Inhibitory post-synaptic potentials (IPSP) measured at -65 mV. A. Example of 
the response to increasing Schaffer collateral stimulation (0, 2, 4, 6, 8, 10, 12, 15, and 20V) 
at a membrane potential of -65 mV. The fast IPSP reaches its maximum quickly while the 
slow IPSP needs a stronger stimulus to reach its maximum. B. The response to the 10V 
stimulus from panel A. Fast and slow IPSP amplitude was measured by taking the average 
Vm before the start of the stimulus (baseline with a length of 0.3 s) and subtracting Vm at 
the cursors. To measure the fast IPSP the cursor (dotted grey line 1) was placed just before 
the trough which was usually 33 ms after the start of the stimulus. To measure the slow 
IPSP a cursor (dotted grey line 2) was placed 200 ms after the start of the stimulus. C+D. 
Stimulus response curve from the same data shown in panel A. Data was fitted with the 
same sigmoidal function as in Figure 4.8.C. The fast IPSP amplitude had a very small slope 
resulting in a sharp rising sigmoidal curve. The slow IPSP showed a more gradual profile. 
From the fits three values are taken: the fitted maximum, the half maximum value (ES50) 
and the slope. 
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4.3.11. Inhibitory post-synaptic potentials (IPSPs). 
To assess the effect of adenosine receptor acting drugs on IPSPs, a Schaffer collateral 
stimulus was given while the cells were kept at -65 mV. The individual responses to stimuli 
of increasing intensity are shown in Figure 4.11.A. Both the fast and slow IPSP were 
measured from the same responses (see Figure 4.11.B).  
 
4.3.12. Fast inhibitory post-synaptic potentials (fast IPSPs). 
The fast IPSP amplitude was measured just before the trough. To measure an as pure as 
possible fast IPSP amplitude, the potential just before the trough (approximately 33 ms after 
the stimulus) was subtracted from the baseline potential (the average of 300 ms before the 
stimulus). The fast IPSP amplitude was plotted against the stimulus intensity (Figure 
4.11.C). A sigmoidal function was used to fit the data: amplitude=fast IPSPmax/1+(exp(-(S-
fast IPSP ES50)/fast IPSPslope)). The fast IPSP amplitude as a function of stimulus intensity 
was fitted with a sigmoidal function with a very small slope. In aCSF controls the fast IPSP 
kinetics changed little over time (Figure 4.12.A). Adenosine (50 µM) reversibly increased the 
maximum fast IPSP amplitude (Figure 4.12.C) and reversibly reduced the EPSP amplitude 
just before the start of the IPSP. On the other hand 8-CPT (5 µM) did not change the IPSP 
amplitude but did increase the amplitude of the preceding EPSP (Figure 4.12.E). The 
average stimulus-effect relationships were constructed from the averaged three variables 
(Figure 4.12.B, D, and F). Adenosine reversibly increased the IPSP amplitude and shifted the 
whole stimulus response curve to higher values. The average fast IPSPmax was 9.91±0.60 
mV (n=22). The increase in fast IPSPmax during adenosine was greater than (about 5 times) 
the increase in controls (Figure 4.13.A), Δfast IPSPmax, adenosine = 2.73±0.53 mV, n=8, 
control = 0.51±0.37 mV, n=6, Student‟s t-test, t12 = -3.4, p=0.006, 
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Figure 4.12. Fast inhibitory post-synaptic potential (IPSP) measured at -65 mV. A. C. E. 
Typical examples of the response to a Schaffer collateral stimulus before during and after 
drug application (aCSF control, adenosine (50 µM) and 8CPT (5 µM) respectively) of a single 
cell. Adenosine reduced the EPSP visible right before the fast IPSP and increased the fast 
IPSP amplitude, while 8-CPT slightly increased the EPSP but does not affect the fast IPSP 
amplitude. Stimulus strength 10, 8 and 6 V respectively. B. D. F. For every cell a stimulus 
response curve was made from which three values were derived (see Figure 4.11). From 
these values an average (n=6-8) was calculated and the curves shown in this figure are 
reconstructed sigmoidal curves from the average values. Adenosine increased the fitted 
maximum and shifted the stimulus response curve to higher intensities while 8-CPT had no 
effect. 
- 97 - 
 
 
 
Figure 4.13. Significant changes in fast IPSP fitted curve values A. Change in fast IPSP 
fitted maximum in aSCF control (n=6), adenosine (50 µM, n=8) and 8-CPT (5 µM, n=8). 
Adenosine significantly increased the maximum IPSP amplitude (p=0.006) compared to the 
change in controls. 8-CPT had no effect on the IPSP maximum amplitude. B. Adenosine 
increased the ES50 significantly (p=0.016) while 8-CPT showed no significant difference from 
the change in aCSF controls. 
 
while the Δfast IPSPmax during 8-CPT (0.01±0.59 mV, n=8) did not significantly differ from 
controls (see Table 4.1). The average ES50 was 4.9±0.3 V (n=22). Adenosine shifted the 
ES50 by 0.69±0.16 V (n=8) while there was hardly any shift in control (0.07±0.14 V, n=6, 
see Figure 4.13.B, and Table 4.1), Student‟s t-test, t12 = -2.8, p=0.016. 8-CPT did not 
significantly shift the fast IPSP ES50 (0.26±0.17, n=8, see Figure 4.13.B and Table 4.1). The 
fast IPSP stimulus response curve had a steep slope, 0.45±0.8 (n=22). There was no 
difference in Δfast IPSPslope between adenosine or 8-CPT and controls. 
The fast IPSP reversal potential was analyzed. To calculate the fast IPSP reversal potential a 
stimulus that gave a clear IPSP response at -65 mV but did not cause an action potential to 
be generated was selected. This intensity was used to evoke synaptic potentials at varying 
Vm (-50 to -95 mV). Figure 4.14.A shows a typical example of the synaptic potentials evoked 
at different membrane potentials using the same stimulus intensity. The traces are zeroed to 
the start of stimulus for display purposes. The IPSP amplitude was calculated in the same 
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was as previously described (see Figure 4.11). The fast IPSP amplitude was plotted against 
the membrane potential (Figure 4.14.B) and fitted with a linear function. The reversal 
potential was calculated by solving the linear equation for y=0. The average fast IPSP 
reversal potential was -82.1±1.6 mV (n=22). 
 
 
Figure 4.14. IPSP reversal potential. A. Response to a Schaffer collateral stimulus at 
varying Vm. A voltage from the fast IPSP stimulus response curve (see figure 4.11) that did 
gave a clear IPSP at -65 mV but did not evoke an action potential was used. Cells were kept 
at a Vm between -95 and -50. The cursor (grey dotted line) shows where the IPSP amplitude 
was measured. B. The measured IPSP amplitude was plotted against Vm and fitted with a 
linear curve, the reversal potential was calculated by solving the linear equation for y=0. C. 
Change in reversal potential in aCSF controls (n=6), adenosine (50 µM, n=8) and 8-CPT (5 
µM, n=8). Adenosine makes the reversal potential significantly more negative compared to 
controls which show a small change towards zero (p=0.028). There was no significant 
change in IPSP reversal potential in cells exposed to 8-CPT. 
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Adenosine shifted the reversal potential by -2.28±0.69 mV, n=8, which was significantly 
different from the shift in controls, 0.42±0.85, n=6, Student‟s t-test, t11 = 2.5, p=0.032 
(see Table 4.1). There was no significant change in IPSP reversal potential in cells exposed 
to 8-CPT. 
 
4.3.13. Slow inhibitory post-synaptic potentials (slow IPSPs). 
The slow IPSP amplitude was measured 200 ms after the start of the stimulus (cursor 2 in 
Figure 4.11.B). To measure slow IPSP amplitude, the potential at 200 ms after the stimulus 
was subtracted from the baseline potential (the average of 300 ms before the stimulus). The 
slow IPSP amplitude was set out against the stimulus intensity (Figure 4.11.D). A sigmoidal 
function was used to fit the data: amplitude=slow IPSPmax/1+(exp(-(S-slow IPSP ES50)/slow 
IPSPslope)). The slow IPSP amplitude increased more gradually with stimulus intensity 
compared to the fast IPSP amplitude. Average stimulus-effect relationships were constructed 
for all treatment groups (Figure 4.15). The average slow IPSPmax was 9.94±0.76 mV and the 
slow IPSPslope was 1.33±0.26 (n=22). There was no significant difference in Δslow IPSPmax or 
Δslow IPSPslope between adenosine (n=7) or 8-CPT (n=6) and controls (n=6). The average 
slow IPSP ES50 was 7.23±0.56 V (n=22). Adenosine shifted the slow IPSP ES50 by 1.8±0.81 
V (n=7) which was significantly different from the change in controls, (0.185±0.38 V, n=6), 
Mann-Whitney U-test, U=7.0, p=0.028. There was no significant difference in Δslow ES50 
between 8-CPT (0.93±0.95 V, n=6) and control (0.16±0.42 V, n=6, see Figure 4.16 and 
Table 4.1).  
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There was no reliable measure of the slow IPSP reversal potential in the data recorded, thus 
the slow IPSP reversal potential was not analyzed.  
 
 
Figure 4.15. Slow inhibitory post-synaptic potential (IPSP) measured at -65 mV. A. B. C. 
For every cell a stimulus response curve was made from which three values were derived 
(see Figure 4.11). From these values an average (n=6-7) was calculated and the curves 
shown in this figure are reconstructed sigmoidal curves from the average values. Adenosine 
shifted the stimulus response curve to higher intensities while 8-CPT slightly increases the 
maximum. 
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Figure 4.16. Change in slow IPSP ES50 in aSCF control (n=6), adenosine (50 µM, n=7) and 
8-CPT (5 µM, n=6). Adenosine significantly increased the ES50 (p=0.028) compared to the 
change in controls thereby shifting the stimulus response curve to higher intensities. 8-CPT 
showed no significant difference from the change in aCSF controls. 
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4.4. Discussion.  
Cellular and synaptic responses to the adenosine receptor agonist adenosine and the specific 
adenosine A1-receptor antagonist were investigated. Adenosine (50 µM) hyperpolarised the 
resting membrane potential, decreased the signal variance at resting membrane potential, 
decreased the firing rate at resting membrane potential, decreased the EPSP amplitude, 
shifted the EPSP stimulus response curve to higher stimulus intensities, increased the fast 
IPSP amplitude, shifted the fast IPSP and slow IPSP stimulus response curve to higher 
stimulus intensities and made the fast IPSP reversal potential more negative. 8-CPT (5 µM) 
increased the signal variance when cells were kept at -65 mV, increased the firing rate at 
resting membrane potential and increased the EPSP amplitude.  
 
4.4.1. Intrinsic properties. 
It has been previously described in literature that adenosine increases the slow AHP duration 
in CA1 pyramidal cells (Greene and Haas, 1985). We found no difference in slow AHP 
duration in CA3c pyramidal cells. Very noticeable was the very large slow AHP, even after a 
single action potential in CA3c pyramidal cells, which was different from that in CA1 
pyramidal cells. There was a significant relationship between the value in the before phase 
and the drug induced change in AHP amplitude per action potential. In cells where only two 
action potentials already evoked maximum slow AHP amplitude there was little room for 
adenosine to increase the amplitude. We also found no difference in the slow AHP relaxation 
time constant, which is contradictory to what has been previously reported in literature 
(Greene and Haas, 1985;Haas and Selbach, 2000). One possible explanation could be that 
we compared the change in adenosine with the change in aCSF controls instead of paired 
comparisons from previous reports. However, also a paired comparison did not show 
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significant differences. Another difference with previous reports is that we compared the 
slow AHP per action potential, and not just one response. When considering the relevance of 
the slow AHP in CA3c pyramidal neurons for gamma oscillations, it is actually the slow AHP 
observed after one or two action potentials that can be of great influence on the oscillating 
network. That we found no significant prolongation of the slow AHP could also be down to a 
regional difference between CA3c and CA1 pyramidal cells within the hippocampus. This is 
unlikely as no difference in intracellular signalling mechanisms has been described between 
the two hippocampal regions. 
The lack of slow AHP prolongation characterised in CA3 pyramidal neurons can therefore not 
explain the adenosine-induced change in gamma oscillations observed. A more likely 
candidate is the resting membrane hyperpolarization caused by adenosine. Adenosine 
activates GIRK channels through the A1-receptor thereby increasing the K
+ conductance 
across the membrane, which leads to a hyperpolarization of the resting membrane potential 
(Alzheimer and ten Bruggencate G., 1991;Luscher et al., 1997;Takigawa and Alzheimer, 
2002). Adenosine levels in the slice are high enough for A1-receptor antagonists to increase 
brain oscillations specifically in the gamma range in vitro (see chapter 2 and 3), and fall 
within the physiological range (Ballarin et al., 1991;Dunwiddie and Diao, 1994;Fredholm et 
al., 2001). The lack of effect of 8-CPT on resting membrane potential is therefore 
unexpected. A possible explanation is that the open probability of GIRK channels under 
resting conditions at the soma is very small, while further away from the soma in the 
dendrites, in the apical dendrites, the open probability is higher (Chen and Johnston, 2005). 
It is therefore possible that blocking adenosine A1-receptors might depolarise the dendrites 
without a noticeable effect on the soma. Activating the adenosine A1-receptor will increase 
the GIRK channel open probability, including the channels at the soma, and thus enhance 
the K+ current, which leads to the observed hyperpolarization. The hyperpolarization of 
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pyramidal cells and also interneurons (Li and Henry, 2000) will reduce their firing rate. The 
activity within the network is thereby disrupted and the oscillation desynchronised. It will be 
harder for pyramidal cells to activate interneurons as the interneuron needs more 
depolarization which means fewer interneurons will be activated per cycle. The opposite is 
true for the increase in firing rate in the presence of 8-CPT. With an increased firing 
probability of pyramidal cells, more interneurons will be activated in the same cycle. This 
leads to increased synchronicity between cells which will be visible through larger field 
potentials.  
The decrease in signal variance measured at resting membrane potential was significantly 
reduced in the presence of adenosine. The hyperpolarization was mainly responsible for this 
change, as there was no significant difference compared to controls when the membrane 
potential was fixed at -65 mV. The reduction signal variance fits well with the decrease in 
gamma oscillations. 8-CPT increases signal variance while measured at a fixed membrane 
potential, but not at resting membrane potential. An increase in signal variance does fit 
nicely with increased network activity.  
 
4.4.2. Synaptic properties. 
Adenosine also decreased EPSP size significantly. This will be partly due to the 
hyperpolarization of the membrane, but adenosine also inhibits neurotransmitter release 
from the pre-synaptic terminal (Haas and Selbach, 2000;Yoon and Rothman, 1991) possibly 
through a PKC mediated process (Thompson et al., 1992). A reduction in neurotransmitter 
release from excitatory synapses will reduce the oscillation even more. Not only does 
adenosine reduce the amount of action potentials, adenosine also makes the vesicle release 
caused by action potential less effective. The shift of the stimulus response curve to higher 
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intensities caused by adenosine will have a noticeable effect on gamma oscillations. This can 
be explained by the hyperpolarization of the membrane potential and reduction of vesicle 
release. The increase in EPSP amplitude during 8-CPT will have a positive effect on network 
oscillations because cells are activated more easily by a stronger EPSP. This leads to 
increased synchronised interneuron activation causing a larger field potential. 
The most surprising finding in our data was the increased fast IPSP amplitude. The shift in 
the fast IPSP stimulus response curve to higher intensities is most likely due to the 
decreased efficacy of incoming EPSPs. In the presence of adenosine it will take more 
glutamatergic synapses to be active to cause a strong enough depolarization to activate the 
same amount of interneurons. The steepness of the fast IPSP stimulus response curve shows 
that it takes only the activation of a small portion of pyramidal cells to evoke an IPSP of 
maximum amplitude. This means that a shift in the stimulus response curve to higher 
intensities will have a dramatic effect on the amount of inhibition. If cells operate on the 
steep part of the curve in a normal functioning network than the presence of adenosine 
would cause a stimulus that would have been on the high end of the curve will now be on 
the bottom part of the curve. This will diminish the amount of synchronous inhibition in the 
network thereby reducing gamma oscillations. The adenosine induced shift in the slow IPSP 
stimulus response curve will be caused by a similar process. It is interesting to look at why 
the maximum fast IPSP is increased. Literature tells us that adenosine blocks the 
polysynaptic IPSP but that the monosynaptic IPSP is not affected (Thompson et al., 1992). 
There is a small but significant change in fast IPSP reversal potential to a more negative 
value. This change in fast IPSP reversal potential increases the driving force of the fast IPSP 
and can partly account for the increase in fast IPSP amplitude. If there is only an increase in 
inhibition it would be expected that gamma oscillations are increased as they are inhibition 
based (Fisahn et al., 1998;Fries et al., 2007). The fact that a decrease in gamma oscillations 
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is observed in the presence of adenosine indicates that the hyperpolarization of the resting 
membrane potential, and reduced effectiveness of excitatory inputs outweigh the increase in 
maximum fast IPSP amplitude. 
 
4.4.3. Modelling the significant findings. 
To find out whether the significant changes observed are sufficient to explain the increase in 
maximum fast IPSP amplitude, we modelled these changes in a computer model of a 
simplified model neuron using Neuron software (Michael Hines, John W. Moore, and Ted 
Carnevale, http://www.neuron.yale.edu/neuron/). The modelling is based on the 
“Interactions of synaptic potentials” tutorial from “Neurons In Action”, which models three 
independent synaptic inputs, one for the EPSP, one for the fast IPSP and one for the slow 
IPSP. The simulation models a single compartment cell with a resting membrane potential of 
-65 mV, at 32 °C, for which the leakage conductance is set at 0.001 S/cm2. First a control 
response is constructed to mimic the average response to Schaffer collateral stimulation in 
the before phase (black line in Figure 5.16.A.). The average response in the before phase 
and in the presence of adenosine (red line in Figure 4.17.A) were constructed from 
responses to a Schaffer collateral stimulus that evoked a maximal fast IPSP but not an 
action potential. The parameters used to mimic the response in the before phase are as  
followed:  
EPSP parameters: onset = 5 ms, Tpeak = 5 ms, gmax = 0.4 µS, e = 0 mV.  
Fast IPSP parameters: onset = 6 ms, Tpeak = 18 ms, gmax = 4 µS, e = -82 mV.  
Slow IPSP parameters: onset = 16 ms, Tpeak = 130 ms, gmax = 1.3 µS, e = -90 mV. 
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Figure 4.17. Modelling of the response to a Shaffer collateral stimulus at -65 mV. A. 
Average response of 7 cells before (black line) and during 50 µM adenosine (red line) to a 
Schaffer collateral stimulus that did not evoke an action potential. B. C. D. Black represents 
response in the before phase, yellow line represents response with changed parameters. B. 
First the EPSP conductance was reduced by half causing a reduction in the preceding EPSP 
and a shift of the response to the left but no change in amplitude. C. Then the fast IPSP 
reversal potential was set more negative by 2 mV causing a small increase in fast IPSP 
amplitude. D. The last change modelled was the shift in slow IPSP stimulus response curve 
by slightly decreasing the slow IPSP current. This made the response almost completely look 
like the recorded response indicating the observed changes are sufficient to explain the 
change in shape while adenosine is present. 
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Subsequently only the significant changes described in the result section are modelled. First 
the EPSP conductance was halved to model the change in EPSP amplitude. The EPSP 
preceding the IPSP was reduced and the hyperpolarizing line towards the fast IPSP 
maximum was shifted to the left (figure 4.17.B.). As this did nothing to the fast IPSP 
amplitude the change in fast IPSP reversal potential is added by changing the reversal 
potential to -84 mV (Figure 4.17.C). This increases the fast IPSP amplitude, which made the 
response almost look like the measured average in Figure 4.17.A. The only difference is that 
the modelled response stayed more hyperpolarised than the before response. The final 
change modelled was the shift in slow IPSP stimulus response curve by slightly reducing the 
conductance to 1.2 µS. With the changes in EPSP conductance, fast IPSP reversal potential 
and slow IPSP conductance the modelled synaptic response looks very similar to the 
recorded response in the presence of adenosine. This indicates that the observed changes 
described in this chapter are enough to explain the change in synaptic response induced by 
adenosine. 
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4.4.4. Conclusion. 
The changes observed in cellular and synaptic properties upon adenosine receptor 
modulation support the data from the field recordings in previous chapters. The reduction in 
gamma oscillations by adenosine are most likely mediated by a hyperpolarization of the 
resting membrane potential of pyramidal cells and interneurons (Li and Henry, 2000), a 
reduction in the effectiveness of EPSPs through prevention of vesicle release and a 
hyperpolarised membrane potential, and a reduced activation of interneurons with the same 
excitatory input. The maximum fast IPSP amplitude is increased through a shift of the fast 
IPSP reversal potential to a more negative potential, which should increase synchronicity 
and thereby increase gamma oscillations. A decrease in gamma oscillations is observed 
because the hyperpolarization of the resting membrane potential and the decrease in the 
effectiveness in EPSPs outweigh the increase in fast IPSP amplitude. The adenosine A1-
receptor antagonist 8-CPT probably increases gamma oscillations through increased 
pyramidal cell firing, and increased excitatory inputs to interneurons, resulting in more 
synchronous activity within the network as more interneurons will be activated at the same 
time leading to an increased gamma oscillation. 
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4.5. Future research.  
The experiments described in this chapter show that adenosine receptors can modulate 
gamma oscillations through cellular and synaptic processes. It would be interesting to find 
out what the contribution of each observed change is. Is it as simple as just hyperpolarizing 
the resting membrane potential, or do all observed effects have equal value? To find out we 
could assess the effect adenosine has on gamma oscillations in vitro in the presence of a 
GIRK-channel blocker. This would prevent the neurons from hyperpolarizing and thus we can 
see how much the cellular changes contribute to the observed modulation of gamma 
oscillations. 
It is also interesting to find out more about the lack of depolarization in the presence of 8-
CPT. Ambient adenosine levels are high enough to activate GIRK channels at our 
experimental conditions but under normal conditions somatic GIRK channels have a low 
open probability while this increases along the dendritic tree (Chen and Johnston, 2005). To 
find out more we could patch dendrites of CA3c hippocampal neurons and measure resting 
membrane potential and GIRK channel activity before and in the presence of 8-CPT. Another 
option would be to increase somatic GIRK channel activity by other means than activation 
adenosine A1-receptors and then apply 8-CPT.  
As membrane potential control over the whole cell is not great while using sharp electrodes 
some findings will be more credible if repeated under patch clamp conditions. The change in 
fast IPSP reversal potential is very small yet has quite a big effect. The prediction would be 
that in an isolated cell while using patch clamp recording we could get a better estimation of 
the shift in fast IPSP reversal potential. This will be looked at in the next chapter. We will 
also assess resting membrane potential and monosynaptic IPSC to confirm previous 
findings. 
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Parameter  Parameter 
value 
ΔaCSF Δadenosine 
(50 µM) 
ΔaCSF Δ8-CPT 
(5 µM) 
Intrinsic properties n=22 n=6 n=7-8 n=6 n=6-8 
Taum (ms) Mean 41.5 2.1 -5.7 5.7 2.2 
 SEM 2.4 3.0 3.0 4.2 3.6 
Slope resistance 
(MΩ) 
Mean 50.0 1.1 -2.8 2.2 3.7 
 SEM 3.3 2.7 4.2 3.5 4.0 
Cm (pF) Mean 0.91 0.08 -0.13 0.13 -0.02 
 SEM 0.08 0.12 0.07 0.11 0.04 
APslope up (V/s) Mean 174 5.3 6.1 2.9 -4.9 
 SEM 13 2.2 2.0 2.2 3.8 
APslope down (V/s) Mean -71 -0.5 -1.3 -0.5 2.8 
 SEM 6.0 0.9 0.9 1.2 1.1 
APthres (mV) Mean -53.9 -0.47 -1.63 -0.72 -0.51 
 SEM 1.0 1.7 1.5 2.7 0.9 
AHPtau (s) Mean 1.3 0.10 -0.09 0.18 0.04 
 SEM 0.1 0.07 0.09 0.11 0.19 
AHPangle (mV/action 
potential) 
Mean 1.7 -0.15 -0.07 0.09 -0.07 
 SEM 0.3 0.12 0.12 0.31 0.07 
Vm (mV) Mean -58.6 -0.49 -4.34 -0.49 -1.08 
 SEM 0.77 0.88 1.16 0.88 0.72 
VarianceVm (mV
2) Mean 1.04 -0.07 -0.34 -0.05 0.24 
 SEM 0.17 0.10 0.10 0.11 0.14 
Variance-65 (mV
2) Mean 0.57 0.04 -0.04 0.07 0.67 
 SEM 0.10 0.11 0.07 0.1 0.31 
Firing rate (Hz) Mean 0.35 0.02 -0.29 0.02 0.16 
 SEM 0.16 0.02 0.16 0.02 0.03 
 
Table 4.1. Sharps parameters. Change in intrinsic properties in the presence of aCSF, 
adenosine (50 µM) and 8-CPT (5 µM). Bold numbers indicate significant differences (p<0.05) 
compared to the change in controls. 
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Parameter  Parameter 
value 
ΔaCSF Δadenosine (50 
µM) 
ΔaCSF Δ8-CPT 
(5 µM) 
Synaptic properties n=22 n=6 n=7-8 n=6 n=6-8 
EPSP fit values 
EPSPmax (V/s) Mean 7.27 0.58 -2.64 0.52 1.84 
 SEM 0.76 0.57 0.53 0.54 0.49 
EPSPslope  Mean 1.92 0.08 -0.13 0.05 0.16 
 SEM 0.22 0.28 0.23 0.26 0.50 
EPSP ES50 (V) Mean 7.8 0.02 0.74 -0.22 0.64 
 SEM 0.4 0.4 0.2 0.3 0.4 
Fast IPSP fit values 
Fast IPSPmax 
(mV) 
Mean 9.91 0.51 2.73 1.50 0.01 
 SEM 0.60 0.37 0.50 0.80 0.59 
Fast IPSPslope Mean 0.45 -0.09 0.06 -0.09 0.04 
 SEM 0.08 0.04 0.04 0.04 0.16 
Fast IPSP ES50 
(V) 
Mean 4.9 0.07 0.69 -0.04 0.26 
 SEM 0.3 0.14 0.16 0.24 0.17 
Reversal 
potential (mV) 
Mean -82.1 0.42 -2.28 -0.83 0.55 
 SEM 1.6 0.85 0.69 1.17 2.18 
Slow IPSP fit values 
Slow IPSPmax 
(mV) 
Mean 9.94 0.44 -0.41 1.33 1.80 
 SEM 0.76 0.47 0.78 0.92 0.83 
Slow IPSPslope Mean 1.33 0.10 0.63 -0.04 -0.28 
 SEM 0.26 0.16 0.38 0.20 0.43 
Slow IPSP ES50 
(V) 
Mean 7.2 0.18 1.8 0.16 0.93 
 SEM 0.6 0.38 0.81 0.42 0.95 
 
Table 4.1 (continued). Sharps parameters. Change in synaptic properties in the presence 
of adenosine (50 µM) and 8-CPT (5 µM). Bold numbers indicate significant differences 
(p<0.05). 
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CHAPTER 5: ADENOSINE RECEPTOR MODULATION OF MONO-SYNAPTIC IPSCS. 
 
5.1. Introduction. 
The previous chapter showed that adenosine application unexpectedly increased the fast 
IPSP amplitude possibly through causing the fast IPSP reversal potential to become more 
negative. The unexpected finding that adenosine application increased IPSP amplitude, (see 
chapter 4) casted doubt on the previous reported finding that adenosine receptors do not 
affect inhibitory synapses (Thompson et al., 1992;Yoon and Rothman, 1991). Experiments in 
the previous chapter were done in slices without any additional pharmacological modification 
to suppress activity to mimic the same conditions used in field recordings. To get more 
insight into the mechanism underlying the increased IPSP amplitude, isolated mono-synaptic 
inhibitory postsynaptic current (IPSC) and the IPSC reversal potential will be investigated 
using patch clamp recordings. Using patch clamp allows for better voltage control of the 
neurons which together with pharmacological isolation of IPSCs will allow for proper 
assessment of the effect A1-receptor modulation has on IPSCs and IPSC reversal potential. 
Recordings were made in the CA1 area of the hippocampus because attempts to patch CA3c 
neurons failed. CA3c neurons are notoriously hard to patch and to be able to obtain useful 
data we moved to CA1. Thus we make the assumption that the location and actions of A1-
receptors are not different between the two areas. No differences have been described in 
literature in A1-receptor density or cellular location between CA3c and CA1 neurons (for 
receptor distribution see introduction Figure 1.2).  
It is predicted that the IPSC will not be altered by adenosine receptor modulation as it has 
been shown that mono-synaptic IPSPs are not affected (Thompson et al., 1992;Yoon and 
Rothman, 1991). It is predicted that the selective adenosine A1-receptor agonist CPA will 
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hyperpolarise the resting membrane potential. The A1-receptor antagonist 8-CPT is expected 
to not change the resting membrane potential because GIRK channels at the soma are have 
a low probability of being open at the membrane potential recorded (Chen and Johnston, 
2005). It is hard to predict what will happen to the IPSC reversal potential but if the results 
from the previous chapter are confirmed CPA will make the IPSC reversal potential more 
negative. If 8-CPT will have any effect on the IPSC reversal potential it is expected to make 
it more positive. 
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5.2. Materials and methods.  
 
5.2.1. Tissue preparation. 
Sprague-Dawley rats (17-32 days old, 40-170 grams, from Charles-River, Margate, UK) 
were anaesthetised with a mixture of ketamine (75 mg/kg) + medetomidine (1 mg/kg) by 
i.p. injection. The rat‟s blood was replaced via cardiac perfusion through the left ventricle 
with an oxygenated and chilled sucrose based solution containing (in mM): sucrose, 205; 
KCl, 2.5; NaHCO3, 26; NaH2PO4, 1.25; D-glucose 10; MgCl2, 5; CaCl2, 0.1. Subsequently the 
rat was killed by cervical dislocation after which the brain was removed and kept cold in 
oxygenated sucrose solution. Using an Integraslicer (Campden Instruments, Loughborough, 
UK) 250 µM thick horizontal slices were made from the ventral hippocampus (coordinates 
from bregma: -7.5 to -5.0 mm) and put either in a submerged recording chamber containing 
oxygenated aCSF (containing (in mM): D-glucose, 10; NaHCO3, 26; NaCl, 125; KCl, 3; 
NaH2PO4, 1.25; CaCl2, 2; MgCl2, 1) at 30°C, or stored in a static interface type chamber 
containing aCSF at 23°C for later use. All procedures were in accordance with the UK 
„Animals (Scientific Procedures) Act 1986‟, and the studies were approved by the Biomedical 
Ethics Review Sub-Committee.  
 
5.2.2. Electrophysiological recordings. 
Patch clamp recordings from CA1 pyramidal cells were made using glass pipette recording 
electrodes filled with internal solution (containing (in mM): KCH3SO4, 140; NaCl, 8; 4-(2-
Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 10; Mg-ATP, 2; Na-GTP, 0.3) with a 
pH of 7.4±0.1. The membrane potential was amplified using an Axoclamp-2A amplifier 
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(Axon Instruments, Burlingham, CA, USA) and a Neurolog NL106 DC amplifier (Digitimer, 
Welwyn Garden City, UK), low-pass filtered at 2 kHz and sampled at 10 kHz. The signal was 
then digitised and sampled by using a CED-1401 (Cambridge Electronical Design, 
Cambridge, UK) and analyzed using Signal 3 and Spike 2 software (Cambridge Electronical 
Design, Cambridge, UK). 
Cells were visualised using an infrared microscope. Before breaking through the cell 
membrane a seal resistance of at least 1 GΩ was made.  CA1 hippocampal cells were used 
for experiments when the resting membrane potential was stable and the cell needed less 
than 0.01 nA current to stay at -60 mV resting membrane potential, and had overshooting 
action potentials. Cells were bridge balanced in current clamp and access resistance was not 
allowed to vary more than 10% over the course of the experiment. When switching to 
voltage clamp recordings the cell was balanced again, to compensate for any action 
potentials as good as possible without running the risk of losing the cell, using gain, phase 
lag and anti-alias filter. Mono-synaptic IPSPs, recorded in voltage clamp, were evoked by 
stimulating the stratum pyramidale layer using a 0.1 ms square pulse via a concentric 
stimulating electrode (Harvard Apparatus Ltd, Kent, UK). The stimulus electrode was placed 
in stratum pyramidale less than 100 µm from the recorded cell.  
Drugs were diluted from the following stock solutions: DL-2-Amino-5-phosphonovaleric acid 
(APV, 25 mM), 1,2,3,4,-Tetrahydro-6-nitro-2,3-dioxo-benzo(f)quinoxaline-7-sulfonamide 
disodium salt hydrate (NBQX, 20 mM), adenosine (10 mM stock in aCSF), 8-cyclopentyl-1,3-
dimethyxanthine (8-CPT; 10 mM stock in 0.1 M NaOH), N6-Cyclopentyladenosine (CPA; 50 
µM stock in aCSF), -[2-[[6-Amino-9-(N-ethyl-b-d-ribofuranuronamidosyl)-9H-purin-2-
yl]amino]ethyl]benzenepropanoic acid hydrochloride (CGS21680; 100 mM stock in DMSO). 
All drugs and aCSF salts were purchased from Sigma (Poole, UK). 
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All experiments were done in the presence of AP-5 (25 µM) and NBQX (20 µM) to block 
excitatory synaptic activity. After running all protocols for the first time in normal aCSF 
(before phase) drugs were washed in for 10 minutes by adding them to the aCSF flowing in 
the system. If the cell was still healthy and the membrane potential was stable after the 
drugs were washed in, the same protocols were done in the presence of the added drug 
(drug phase). Once all protocols were run once again the drugs were washed out by 
changing to a fresh aCSF solution. After 10 minutes of wash out the cell was checked to 
assess if it was still healthy, and if it was the protocols were done a third time (after phase).  
 
5.2.3. Analysis and statistics. 
Statistical comparisons were made between the change (drug phase – before phase) in aCSF 
controls and the change in the presence of adenosine receptor acting drugs. The comparison 
between experiments (unpaired) was chosen over the comparison within experiments 
(paired) to make sure that any change occurring over time will not be mistaken for a change 
caused by adenosine or 8-CPT. Every variable was first analyzed for normality using the 
Kolmogorov-Smirnov test in SPSS 15.0, and any difference in starting value between 
groups. If data was normally distributed a Student‟s t-test was used for comparison while if 
data was not normally distributed a Mann-Whitney U-test was used. Unless stated 
otherwise, there was no difference in the starting values between the different treatment 
groups.  
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5.3. Results. 
 
5.3.1. Cellular properties. 
Figure 5.1.A gives a response of a CA1 pyramidal cell to a +0.5 nA and -0.5 nA current 
injection. The action potentials in CA1 pyramidal cells are not as grouped compared to CA3c 
cells (see Figure 4.4.A). This is most likely because the AHP in CA1 cells is not as strong as 
in CA3c cells. 
Figure 5.1. Patch-clamp cellular properties. A. Response to a -0.5 and +0.5 nA current 
injection. Contrary to CA3c cells action potentials are not grouped and the slow 
afterhyperpolarisation is a lot smaller. Action potentials are cropped. B. Change in 
membrane potential during drug wash in. Adenosine (p=0.035, n=6) and CPA (p=0.036, 
n=6) significantly hyperpolarised the membrane potential. 8-CPT (n=7) slightly increased 
resting membrane potential though not significantly different from controls (n=5). 
 
The slope resistance was calculated using the same methods described in chapter 4. The 
average slope resistance was 152±11 MΩ (n=27). In controls the slope resistance changed 
significantly over time (Student‟s paired t-test, p=0.001, n=5), while there was no 
significant difference between the before phase and drug phase in all the drug groups. As a 
consequence of the controls changing significantly over time all the changes in the drug 
groups are significantly different from the change in controls (64.1±7.2 MΩ, n=5, (Student‟s 
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t-test; adenosine (50 µM, 11.8±7.9 MΩ n=6), t9=4.8, p=0.001; 8-CPT (5 µM, 19.9±10.6 
MΩ, n=7), t10=3.2, p=0.01; Mann-Whitney U-test; CPA (50 nM, 10.7±13.8 MΩ, n=6), 
U=4.0, p=0.045). 
The average resting membrane potential before drug application was -60.9±0.6 mV (n=27). 
To measure the change in membrane potential cells were held at -60 mV. Then adenosine 
receptor modulating drugs were added to the aCSF. Three minutes after wash in, the 
membrane potential was measured again if the membrane potential was stable. The change 
in membrane potential during 50 µM adenosine application was -2.7±0.5 mV (n=6). This 
was significantly different from the change in controls (-0.1±0.8 mV, n=5), see Table 5.1 
and Figure 5.1.B (Student‟s t-test, t8=2.5, p=0.035). The adenosine A1-receptor agonist CPA 
(50 nM) significantly hyperpolarised the membrane potential by -3.8±1.2 mV (n=6) 
(Student‟s t-test, t8=2.5, p=0.036). The A1-receptor antagonist 8-CPT (5 µM, 0.9±0.5 mV, 
n=7) and the A2A-receptor agonist CGS21680 (20 nM, 0.7±0.2 mV, n=3) did not 
significantly change the resting membrane potential compared to controls (see Table 5.1).  
 
5.3.2. Inhibitory post-synaptic current (IPSC). 
The unexpected finding that adenosine application increased IPSP amplitude, (see Chapter 
4) casted doubt on the previous reported finding that adenosine receptors do not affect 
inhibitory synapses (Thompson et al., 1992;Yoon and Rothman, 1991). Figure 5.2.A shows 
the responses of a CA1 pyramidal cell to monosynaptic stimulation of increasing stimulus 
strength. To measure the IPSC amplitude the baseline (dotted line 1 in Figure 5.2.B) was 
subtracted from the maximum response (dotted line 2 in Figure 5.2.B). As the recordings 
were quite noisy the maximum was determined by estimating the average peak value with a 
cursor. The IPSC amplitude was set out against the stimulus strength and fitted with a 
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sigmoidal function, IPSC amplitude=IPSCmax/1+(exp(-(S-ES50)/slope)). IPSCmax is the fitted 
maximum IPSC amplitude, ES50 is the stimulus strength (S) required to reach half maximum 
effect and the slope is an inverse measure of the steepness of the curve (see Figure 5.2.C). 
The average IPSCmax was 0.2±0.02 nA (n=26) and the average ES50 was 21.9±1.5 V 
(n=26). There was no significant difference in the change in IPSCmax or ES50 between aCSF 
controls and adenosine 
 
Figure 5.2. Inhibitory post-synaptic currents (IPSCs). A. Responses of a CA1 pyramidal cell 
in the presence of APV (25 µM) and NBQX (10 µM), recorded in voltage clamp, to increasing 
mono-synaptic stimulation (0, 10, 15, 25, 35 ,55, 70 V). B. Response to the 55 V stimulus. 
IPSC amplitude was measured by subtracting the baseline (dotted line 1) from the peak 
current (dotted line 2). C. The IPSC amplitude was set out against the stimulus intensity and 
fitted with a sigmoidal curve. From the fits three values are taken: the fitted maximum, the 
half maximum value (ES50) and the slope. D. Change in fitted IPSC maximum in aCSF 
controls (n=5), adenosine (50 µM, n=6), 8-CPT (5 µM, n=6) and CPA (50 nM, n=6). There 
was no statistical significant difference between groups. 
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receptor modulating drugs (see Figure 5.2.D and Table 5.1). The average slope was 7.7±0.7 
(n=26). The change in slope was not different between controls and adenosine or CPA (see 
Table 5.1). 8-CPT changed the slope by 0.3±1.0 (n=6) which was significantly different from 
controls (-2.9±0.8, n=5) (Mann-Whitney U-test, U=4.0, p=0.045). CGS21680 also 
increased the IPSCslope slightly but significantly (0.6±0.1, n=3, Mann-Whitney U-test, U=0.0, 
p=0.025), though numbers in this group are low (n=3). 
 
5.3.3. IPSC reversal potential. 
In the previous chapter a minor but significant change in IPSP reversal potential was 
described. Here the reversal potential of the underlying current is investigated under better 
controlled conditions. Figure 5.3.A shows the responses to a sub-maximal stimulus at 
varying membrane potential. The stimulus chosen had to give a clear response in the 
stimulus response curve used to measure IPSC amplitude, but not cause a maximum IPSC. 
The IPSC amplitude was measured every 5 mV between -110 and -50 mV. To determine the 
IPSC reversal potential the IPSC amplitude was set out against the membrane potential. 
Under the assumption that the constant field theory can be applied and ion concentrations 
inside and outside are equal the relationship is predicted to be linear. All the cells recorded 
under our conditions showed a rectification from this predicted linear relationship. To obtain 
the most accurate measure of the IPSC reversal potential the data were fitted with a 3 
parameter exponential function (see Figure 5.3.B); IPSC amplitude=y0+a*exp(b*Vm). To 
calculate the reversal potential the equation was solved for amplitude=0. The average 
reversal potential was -70.3±1.0 mV (n=26). Adenosine and CPA made the IPSC reversal 
potential slightly more negative, while 8-CPT and aCSF controls made the IPSC reversal 
potential more positive (see Table 5.1). But there are no significant differences between 
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controls and adenosine receptor modulating drugs. There is a significant difference between 
the change caused by 8-CPT (4.4±1.5 mV, n=6) and change caused by CPA (-1.2±1.5 mV, 
n=6, Mann-Whitney U-test, U= 5.0, p=0.022). This indicates that adenosine A1-receptor 
activity can influence the IPSC reversal potential. A1-receptor and A2A-receptors often have 
opposite effects on second messenger pathways and thus cause opposite effects (Fredholm 
et al., 2001). The A2A-receptor agonist CGS21680 (20 nM) also causes a positive change in 
IPSC reversal potential (see Table 5.1) indicating a post-synaptic mechanism linked to both 
A1- and A2A-receptors could be involved in altering the reversal potential. Figure 5.3.D shows 
a scatter plot of the change in reversal potential against the change in resting membrane 
potential. There is a significant correlation through all data points (Pearson correlation 
coefficient = 0.476, p=0.019, n=26). Using a quick cluster analysis in SPSS 15 two clusters 
were identified. The open squares in Figure 5.3.D show cluster centres and the two clusters 
are separated by the dotted line. The left clusters contains mainly cells exposed to CPA and 
adenosine (A1-receptor agonist) while the right cluster mainly consists of cells exposed to 8-
CPT (A1-receptor antagonist). Thus, cells that have a large hyperpolarisation of the resting 
membrane potential are also likely to have a negative shift in the reversal potential.  
The current across a membrane is determined by the driving force and the conductance. To 
rule out that the change in IPSP amplitude is due to a change in membrane conductance the 
slope conductance was calculated. From the same plot where the IPSC reversal potential 
was calculated from (Figure 5.3.B) the slope conductance was calculated. The points above 
the reversal potential were fitted with a linear function (amplitude=y0+slope 
conductance*Vm). The average slope conductance was 0.51±0.05 µS (n=26). None of the 
adenosine receptor acting drugs changed the slope conductance significantly from starting 
values. There were no differences in the change in slope conductance between controls and 
the different adenosine receptor acting drug groups (see Table 5.1). 
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Figure 5.3. IPSC Reversal potential. Experiments were done in the presence of APV (25 µM) 
and NBQX (10 µM). A. Responses to mono-synaptic stimulation (40 V) at varying membrane 
potential. B. IPSC amplitude against membrane potential plot. All data points were fitted 
with a 3 parameter single exponential fit: IPSC amplitude=y0+a*exp(b*Vm). The reversal 
potential was calculated by solving the equation for IPSC amplitude =0. C. Change in 
reversal potential during aCSF (n=5), adenosine (50 µM, n=6), 8-CPT (5 µM, n=6) and CPA 
(50 nM, n=6). There was no significant difference between controls and drug groups. There 
was a significant difference in the change in reversal potential between 8-CPT and CPA 
(p=0.022). D. Scatter plot of the change in membrane potential and the change in reversal 
potential. There is a significant correlation through all data points (p=0.019, n=26). There 
are two clusters of points distinguishable. The open squares indicate cluster centres; the 
dotted line separates the two clusters. 
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5.4. Discussion. 
Adenosine A1-receptor activation significantly hyperpolarises the resting membrane potential 
and shifts the IPSC reversal potential to more negative potentials. Blocking the adenosine 
A1-receptor with 8-CPT has no significant effect on the resting membrane potential 
compared to the change in controls and makes the IPSC reversal potential more positive. 
The IPSC was not affected by any adenosine receptor modulation. 
In line with the results from chapter 4 the resting membrane potential was also 
hyperpolarised in patch recordings during A1-receptor activation. The selective A1-receptor 
agonist CPA also hyperpolarised the resting membrane potential. In patch recordings 8-CPT 
did show a change in the opposite direction but it was not significantly different from aCSF 
controls. This strengthens the idea proposed in the previous chapter that GIRK-channels 
have a very low open probability at the soma (see chapter 4 discussion) which makes 
recording a reduction in channel activity difficult.  
To shed more light on why the IPSP amplitude was increased the underlying current was 
investigated. Just as previously reported the conductance underlying the IPSC was not 
affected by adenosine receptor modulation (Thompson et al., 1992;Yoon and Rothman, 
1991). This finding is consistent with the fact that adenosine receptors are most likely not 
present on inhibitory pre-synaptic terminals (Thompson et al., 1992;Yoon and Rothman, 
1991). This leaves the question of how does adenosine increase the IPSP amplitude. In the 
previous chapter a shift of the IPSP reversal potential to more negative values by adenosine 
A1-receptor activation has been shown to be a likely candidate. Because the intracellular 
chloride concentration was clamped at 8 mM changes were expected to be small as only the 
extracellular Cl- concentration can vary. Though no significant differences between controls 
and adenosine receptor modulating drugs have been found in the change in reversal 
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potential, there was a significant difference between the specific A1-receptor modulating 
drugs CPA and 8-CPT. Together with the specific grouping of cells in the ΔVm and Δreversal 
potential plot (Figure 5.3.D) this can indicate that a shift in reversal potential can account 
for the increase in fast IPSP amplitude. In the model described in the discussion of chapter 4 
the shift in reversal potential was enough to account for the increase the fast IPSP 
amplitude. The fact that the change in membrane potential correlates with the change in 
reversal potential suggests a common second messenger pathway is involved. One possible 
mechanism by which A1-receptor modulation can hyperpolarise the membrane potential and 
shift the reversal potential is via modifying the AC, cAMP and PKA pathway through Gi/o 
signalling. Gi/o signalling modifies GIRK channel activity (Lei et al., 2003) and is also coupled 
to AC activity which can alter PKA activity through cAMP levels (Sebastiao and Ribeiro, 
2000). A reduction in cAMP levels and thereby reduced PKA activity through A1-receptor 
activation can lead to a reduced activity of the NKCC transporter (Haas and Forbush, III, 
1998;Sebastiao and Ribeiro, 2000). This in turn leads to a reduced Cl- uptake which 
increases the driving force for the fast IPSP through an increase in extracellular chloride. 
Thus A1-receptor activation can hyperpolarise the resting membrane potential and the shift 
the IPSP reversal potential via Gi/o signalling. 
In conclusion the findings in this chapter are in line with literature and the finding in the 
previous chapters. The increase in fast IPSP amplitude is most likely caused by a shift in 
reversal potential. An increase in inhibition would in theory be able to increase the power of 
an inhibition based network oscillation. This increase is unlikely to have an effect on the 
gamma oscillation as the other cellular and synaptic effects that suppress network activity 
outweigh the increase in driving force for IPSPs. 
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5.5 Future research. 
The fact that the experiments in this chapter were done in CA1 pyramidal cells instead of 
CA3c pyramidal cells does mean care has to be taken to make conclusions about the CA3c 
area. It would be good to repeat the shift in reversal potential in CA3c pyramidal cells in 
patch clamp recordings. 
There is little information on the cellular mechanism by which adenosine A1-receptor 
modulation can change the fast IPSP reversal potential. The proposed mechanism in the 
discussion is hypothetical and needs to be backed up by real data. One possible way would 
be to alter every step within the chain (cAMP, NKCC activity) and see whether or not this 
affects the reversal potential. 
Another useful tool to further investigate the change in reversal potential is using the 
perforated patch method. In perforated patch the chloride concentration inside the cell is 
unaltered by pipette solution and thus changes in chloride concentrations can be picked up 
easier. 
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Parameter  Parameter 
value 
ΔaCSF Δadenosine 
(50 µM) 
Δ8-
CPT 
(5 
µM) 
CPA 
(50 
nM) 
ΔCGS21680 
(20 nM) 
Intrinsic properties n=27 n=5 n=6 n=7 n=6 n=3 
Slope 
resistance 
(MΩ) 
Mean 150 64.1 11.8 19.9 10.7 40.2 
 SEM 11 7.2 7.9 10.6 13.8 11.4 
Vm (mV) Mean -60.9 -0.1 -2.7 0.9 -3.8 0.7 
 SEM 0.6 0.8 0.5 0.5 1.2 0.2 
 
IPSC fitted values n=26 n=5 n=6 n=6 n=6 n=3 
IPSCmax (mV) Mean 0.20 -0.02 -0.04 0.00 0.00 0.02 
 SEM 0.02 0.03 0.02 0.02 0.02 0.03 
slope Mean 7.7 -2.9 -5.9 0.3 0.7 0.6 
 SEM 0.7 0.8 2.4 1.0 2.0 0.1 
ES50 (V) Mean 21.9 -1.9 -7.7 0.0 1.4 1.5 
 SEM 1.5 2.3 2.6 1.7 3.9 1.5 
Reversal 
potential 
(mV) 
Mean -70.3 1.9 -1.1 4.4 -1.2 3.0 
 SEM 1.0 1.5 1.4 1.5 1.5 1.3 
Slope 
conductance 
(µS) 
Mean 0.51 0.02 0.04 0.00 0.01 0.19 
 SEM 0.05 0.06 0.08 0.08 0.02 0.11 
 
Table 5.1. Patch parameters. Change in intrinsic and synaptic properties in the presence of 
aCSF, adenosine (50 µM), 8-CPT (5 µM), CPA (50 nM) and CGS21680 (20 nM). Bold 
numbers indicate significant differences (p<0.05) compared to the change in controls. Bold 
and underlined numbers within are significantly different from each other but not from the 
change in controls. 
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CHAPTER 6: ADENOSINERGIC MODULATION OF HIPPOCAMPAL GAMMA 
OSCILLATIONS IN VIVO. 
 
6.1. Introduction. 
In the previous chapters it has been shown that adenosine modulates brain oscillations most 
specific for the gamma range in vitro. In vivo gamma oscillations (30-100 Hz) are associated 
with a variety of cognitive functions including memory (Fell et al., 2001;Herrmann et al., 
2004) and sensory processing (Engel and Singer, 2001;Singer, 1993). In rodents an 
increase in hippocampal gamma oscillation power is observed during explorative behaviour 
(Buzsaki et al., 2003;Csicsvari et al., 2003). Adenosine receptor modulation is able to alter 
cognitive function (Fredholm et al., 1999) including memory (Kopf et al., 1999;Pereira et al., 
2002). However there is little direct evidence showing that adenosine receptor modulation 
alters cognitive function through changing gamma oscillations. There are some clues that 
adenosine receptors can alter cognitive function through affecting gamma oscillations. With 
age there is a decrease in hippocampal gamma oscillations in rodents (Vreugdenhil and 
Toescu, 2005). This could be related to the increase in ambient adenosine levels with age 
(Sebastiao et al., 2000). This makes it quite possible that changes in adenosine levels or 
receptor function can underlie the age-related decrease in memory function. 
To have an indication whether adenosine receptor modulation is a possible target for 
preventing cognitive decline or increasing cognitive function, the in vitro results have to be 
verified in vivo. In slice experiments many brain regions that project to the hippocampus are 
cut off during slice preparation. Because adenosine receptors are abundantly expressed 
throughout the brain (see table 1.1), projections to the hippocampus from other brain areas 
can have unexpected effects on gamma oscillations in vivo. Because the in vitro experiments 
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showed that the A1-receptor is most effective in modulating hippocampal gamma oscillations 
(see chapter 2 and 3), the selective A1-receptor agonist CPA and the selective A1-receptor 
antagonist 8-CPT were used in the experiments in this chapter. In this chapter the effect of 
the A1-receptor agonist CPA and the A1-receptor antagonist 8-CPT on in vivo hippocampal 
gamma oscillations will be investigated in an anaesthetised animal. It is predicted that A1-
receptor modulation has similar effects as seen in in vitro experiments (see chapter 2 and 3) 
where activating A1-receptors will decrease gamma oscillation strength and inhibiting A1-
receptors will increase gamma oscillation strength.  
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6.2. Materials and methods.  
 
6.2.1. Animal preparation. 
Male Sprague-Dawley rats (250-400 grams, from Charles-River, Margate, UK) were 
anaesthetised by an i.p. urethane (1.25 g/kg) injection. When needed an i.p. injection of a 
mixture of ketamine (75 mg/kg) + medetomidine (1 mg/kg) was given to keep the animal 
well anaesthetised. Urethane is not suitable as a top-up anaesthetic because its effects are 
not immediate. After the urethane injection the rat was left alone for at least 45 minutes to 
allow the animal to be properly anaesthetised. The animal‟s skull was shaved and if needed 
a ketamine-medetomidine mixture was given before the animal was put into a stereotactic 
frame. Once in the stereotactic frame the eyes were lubricated to prevent them from drying 
out and the animal was set up with a breathing monitor and a heart rate and blood oxygen 
monitor. The animal was kept warm with an electrical heating pad and the temperature was 
monitored via a rectal probe. The animal was covered with bubble wrap to reduce heat loss 
as much as possible. The animal‟s temperature was kept at 36.5±0.5 °C and blood oxygen 
levels, measured at the foot, were kept between 80 and 90 %. If blood oxygen levels 
dropped below 80% extra oxygen was given via a small tube aimed at the rat‟s nose. The 
pedal reflex test, pressure on the rat‟s hind limb that causes retraction of the paw if not 
properly anaesthetised, was tested every 10 minutes and if needed a quarter dose of 
ketamine medetomidine mixture was given to make sure the animal was well anaesthetised. 
The skull was exposed and a small window perpendicular to the line bregma – interaural was 
made at the recording site on one side of the brain. For the ventricular injection of drugs a 
single burr hole was made. All procedures were in accordance with the UK „Animals 
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(Scientific Procedures) Act 1986‟, and the studies were approved by the Biomedical Ethics 
Review Sub-Committee. 
 
6.2.2. Electrophysiological recordings. 
Recordings from the CA3c (coordinates from bregma (Paxinos and Watson, 1998): anterior-
posterior (AP); -3.8, medio-lateral (ML); 3.5/-3.5, dorso-ventral (DV); -3.5) and the CA1 
(coordinates from bregma (Paxinos and Watson, 1998): AP; -3.8, ML; 2.4/-2.4, DV; -2.2) 
area of the hippocampus (see Figure 6.1) were made using  bipolar twisted Teflon-coated 
wire electrodes (Nickel (80%)/Chromium (20%), 0.05 mm, Advent Research Materials Ltd, 
Eynsham, Oxford, England, UK). The electrode was strengthened with a thin coating of nail 
varnish to prevent them from bending while lowered into the brain. One of the electrodes 
was cut shorter so the two ends could straddle the stratum pyramidale (distance between 
the two ends: 0.4 mm). Recordings were amplified using Neurolog NL104 AC-coupled 
amplifiers (Digitimer Welwyn Garden City, UK) and band-pass filtered at 3-2000 Hz. Noise 
locked to the powerline frequency 50 Hz was removed with Humbug noise eliminators 
(Digitimer Welwyn Garden City, UK). Subsequently the signal was digitised and sampled at 5 
kHz using a CED-1401 interface (Cambridge Electronic Design, Cambridge, UK) and 
analyzed using Spike-2 software (Cambridge Electronic Design, Cambridge, UK). 
Drugs were injected using a 10 µl Hamilton syringe (Hamilton Company, Reno, Nevada, 
USA) in the third ventricle (coordinates from bregma: AP; -0.8, ML; 1.3, DV; -3.5). The 
Hamilton syringe was inserted under a slight angle (see Figure 6.1) to prevent possible 
damage to a major artery running over the injection site.  
Drugs were diluted from the following stock solutions: 8-cyclopentyl-1,3-dimethyxanthine 
(8-CPT; 10 mM stock in 0.1 M NaOH), N6-Cyclopentyladenosine (CPA; 50 µM stock in sterile 
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aCSF). Drugs were diluted so that the injection volume was between 1 and 3 µl. The 
concentration used was aimed to be around 100 times higher than the receptor saturation 
concentration in vitro. All drugs were purchased from Sigma (Poole, UK).  
 
Figure 6.1. Recording and injection site in the hippocampus used in in vivo experiments. 
The two red lines indicate the position of the bipolar recording electrodes targeting the CA3c 
and CA1 area of the hippocampus. The electrode was aimed so that the ends of the bipolar 
electrode were straddling the stratum pyramidale. The purple line represents the Hamilton 
syringe used to inject drugs into the third ventricle. The blue dot indicates a stimulation site 
used in pilot experiments to find the optimal recording site. 
 
6.2.3. Electrode placement. 
The aim of this study was to investigate the influence of adenosinergic modulation of gamma 
oscillations in the hippocampus. It was less important to record from the exact same spot in 
the hippocampus than to record a good signal from the CA3c and CA1 area. To test whether 
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the stereotaxic placement of the recording electrode in CA3c was correct (straddling stratum 
pyramidale) the dorsal hippocampal commissure (coordinates from bregma (Paxinos and 
Watson, 1998): AP;-4.5, ML; 0.3/-0.3, DV;-2.4, see Figure 6.1) was stimulated with a 
bipolar electrode (identical to the recording electrodes). As soon as the longest tip of the 
electrode passed the stratum pyramidale any stimulus given at the dorsal hippocampal 
commissure will invert at the recording site. Using this technique for both CA3c and CA1, the 
coordinates found were very similar from experiment to experiment (n=9). Thus it was 
chosen to place the electrodes without relying on the stimulus in all subsequent 
experiments. Electrodes were lowered slowly to the pre-defined coordinates and if there was 
a good signal that had a measurable power in the gamma range (30-100 Hz) within 0.2 mm 
of the depth aimed for, that position was taken. For electrodes recording from the CA1 area 
it meant that when power in the gamma range would increase the hippocampus was 
reached. For the CA3c area the electrodes must first pass through the CA1 area (see Figure 
6.1). Power in the beta and gamma range would increase while passing through the CA1 
area, to then disappear while in the molecular layers to emerge again when approaching the 
CA3c area. Variation in this area was also kept within 0.2 mm of the targeted coordinates. 
The placement of the Hamilton syringe was tested in one of the pilot experiments via 
dissection of the brain, making sure the predetermined coordinates were correct. 
 
6.2.4. Analysis and statistics. 
Data was analyzed in 5 minute epochs just before and 30 minutes after drug injection. 
Oscillation power was calculated from the recordings for four frequency bands (slow: 3-13 
Hz, beta: 13-30 Hz, gamma: 30-100 Hz, fast: 100-250 Hz) using fast fourier transform (1 
Hz bin size). Average power was calculated from the unfiltered power spectrum only 
correcting for line noise if the Humbug was unable to filter all line noise out. 
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Data was filtered using the phase-true-FIR filter. Figure 6.2 shows the effect of filtering for 
different frequency bands has on the recordings and accompanying power spectra. A one 
second recording of the hippocampal CA3c area before any drugs were injected in the 
ventricle was used (see Figure 6.2.A and B). A low pass filter (13 Hz cut-off) selected all the 
slow waves and effectively removed all faster activity (see Figure 6.2.C and D). A band-pass 
filter (FIR, >30 Hz and <100 Hz) was used to extract the gamma band waveform from the 
original recording (see Figure 6.2.E). The power spectrum made from the filtered gamma 
oscillations shows that filtering was successful and selective (see Figure 6.2.F). The fast 
frequencies were filtered out using a high pass filter (>100 Hz) effectively removing all the 
low and gamma waveforms (see Figure 6.2.G and H). 
Markers were placed on gamma troughs (from the filtered data) that were clear gamma 
cycles with a size of at least 30% of the maximum amplitude. Single units were determined 
by filtering the original recording with a high pass filter above 300 Hz. Subsequently, an 
event was determined to be a single unit if the amplitude of that event was greater than 
three times the signal standard deviation. Signal standard deviation was calculated for every 
5 minute epoch separately. Only the negative deflecting deviations were marked as single 
units even though in theory a single unit can also be seen as a positive deflection dependent 
on electrode position. As the recordings were made bipolar the sign of the recorded event 
depends on the relative location of the cell in comparison to the poles of the recording 
electrode. 
Data was analyzed using non-parametric tests because numbers were low. Data are 
expressed as means±standard error of the mean (s.e.m.). 
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Figure 6.2. Effect of filtering data on recordings. Original data recorded from the CA3c area 
of the hippocampus (A) was filtered using a low pass (C, <13 Hz), band pass (E, 30-100 Hz) 
and high pass (G, >100 Hz) filter. The accompanying power spectra (B, D, F, H 
respectively) show the effect each type of filtering has on the recorded signal. Power spectra 
are shown with a logarithmic scale because the proportion of power in the lower frequencies 
is much higher in in vivo recordings. The gamma band is indicated by the light grey area. 
The filtered signals are very clean and narrow for their frequency bands indicating the right 
settings were used.  
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6.3. Results. 
 
6.3.1. The effect of lightened anaesthetic on hippocampal gamma oscillations. 
To assess whether or not a rat is experiencing pain during the experiment the standard 
pedal reflex test is commonly used. When a rat responds to a squeeze in the paw by pulling 
its leg towards it abdomen extra anaesthesia is required. In pilot experiments sometimes a 
quick and substantial rise in gamma oscillation strength in the hippocampus was observed 
that was responsive to a ketamine medetomidine mixture top-up. The increase in power 
within the gamma band occurs before any pedal reflex can be observed. If no additional 
anaesthetics were given the animal would start to respond to the pedal reflex test within the 
next 15 minutes. Figure 6.3 shows the effect of lightened anaesthetics on hippocampal 
gamma oscillations in CA3c. When anaesthetics are lighter there is an increase in 
synchronous activity visible in the unfiltered raw trace (Figure 6.3.A). There is an increase in 
power in the gamma range with a distinct hump appearing in the power spectrum (Figure 
6.3.B). Within five minutes the power increased approximately 5-fold in this example (Figure 
6.3.C). After a top-up of anaesthetic the power returned back to baseline within five 
minutes. This finding complicates the analysis of the in vivo recordings. Because there was 
no marker besides the increase in gamma activity that indicated the anaesthetic were 
lightened care was taken in selecting experiments for analysis to only select those 
experiment were the level of anaesthesia were similar. If there was doubt about the level of 
anaesthesia around the time measurements are taken the experiment was rejected. 
Consequently the numbers in this chapter are rather low. The pedal reflex test is a 
commonly used test to get an indication of anaesthesia depth. The pedal reflex was tested 
every 10 minutes though after observing the increase in gamma oscillations during lightened  
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Figure 6.3. Effect of lightened anaesthetic on hippocampal gamma oscillations. A+B. Raw 
traces (A) and accompanying power spectrum (B) for the CA3c area at baseline (black), 
light anaesthetic (blue) and after anaesthetic top-up (purple). Lightened anaesthetic 
increased power in the gamma range in the CA3c area visible by the appearance of a hump 
in the gamma range as well as increased synchronous network activity in the raw trace. C. 
Time course of the change in average gamma power during lightened anaesthetic. There is a 
5-fold increase in average gamma power within a few minutes that disappears just as fast 
when an anaesthetic top-up is injected (arrow).  
 
anaesthetics, anaesthesia top-up was given as soon as an unusually large increase in 
gamma activity was observed.  
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6.3.2. Description of the in vivo gamma oscillation. 
There is a distinguishable difference between the oscillation in the CA3c and the oscillation in 
the CA1 area of the hippocampus in vivo in our experiments.  In most cases the power in 
the CA1 area decreases steadily with frequency within the gamma range. In the CA3c area 
there is often a shoulder at the start of the gamma range after which the power declines 
steadily with frequency. Figure 6.4.A shows the power of simultaneous recorded oscillations 
in CA3c and CA1 that nicely illustrate the difference in power distribution. To quantify this 
difference the gamma/beta ratio is calculated by dividing the power in gamma by the power 
in beta for both areas. The gamma/beta ratio is significantly greater in CA3c (0.26±0.04, 
n=6) than the gamma/beta ratio in CA1 (0.18±0.03, n=6, see Tables 6.2 and 6.3, Figure 
6.4.B; Student‟s paired t-test, t=2.8, p=0.038). 
 
 
Figure 6.4. Difference in power spectrum between CA3c and CA1. A. Power spectrum from 
simultaneous recorded CA3c (red) and CA1(blue). CA1 shows a steady decline with 
increasing frequency within the gamma band. CA3c first has a shoulder after which power 
declines with increasing frequency. B. Gamma/beta specificity in the CA3c and CA1 area 
during simultaneous recordings. The specificity for each area is connected with a line. The 
mean±SEM are given by a dot with error bars. The specificity is significantly lower 
(p=0.027, n=6) in the CA1 compared to CA3c.  
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As recordings were made simultaneously the phase relationship between CA3c and CA1 can 
be investigated using cross-correlation. In most experiments there was a good phase 
relationship between filtered gamma of CA3c and CA1 (see Table 6.1). Figure 6.5.A shows a 
1 second epoch of filtered gamma in CA3c and CA1. The peaks and troughs occur within a 
few milliseconds of each other on a large portion of the cycles. The cross-correlation of the 
same animal has a cross-correlation maximum of 0.58. The lag of the peak of the cross-
correlation (Figure 6.5.B) is slightly positive indicating that the peak in the CA1 area is 
slightly after the peak in the CA3c area. The CA3c area leads the CA1 area in 5 out of 6 
experiments (average 1.27±0.63 ms (n=6, n.s.). 
 
Figure 6.5. Cross correlation between CA3c and CA1. A. Example of one second filtered 
gamma traces from which cross-correlation is calculated. The peaks and troughs in both 
areas occur within milliseconds of each other for a large proportion of the gamma cycles. B. 
Cross-correlation between CA3c and CA1 calculated from traces band pass filtered for 
gamma. The peak is positive indicating that CA3c peaks earlier than and possibly leads CA1. 
The high peak indicates that Ca3 and Ca1 are phase coupled. 
 
Gamma power fluctuates strongly in both CA1 and CA3c. To find out whether the power 
fluctuations between CA3c and CA1 is related the root mean square amplitude of the filtered 
gamma was calculated and then filtered with a low pass filter (FIR cut-off 13 Hz). Figure 
6.6.A shows the CA3c filtered gamma waveform (I), the root mean square amplitude of the 
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signal (II) and the low pass filtered waveform of the root mean square amplitude modified 
waveform (III). The root mean square modification inverts the troughs after which a low 
pass filter describes the fluctuation in gamma power. A waveform correlation between CA3c 
and CA1 is made on the low pass filtered waveform comparing the fluctuation in power over 
time of the gamma oscillation in both areas (Figure 6.6.B). The power in CA3c is high at the 
same time the power in CA1 is high. This example shows that there is a correlation between 
the power in CA3c and CA1 with a cross-correlation maximum of 0.37. On average the 
correlation maximum is 0.24±0.07 (n=5, see Table 6.1).  
Figure 6.6. Root mean square amplitude. A. Traces of filtered gamma (I), the root mean 
square amplitude (II) and the low pass filtered waveform of the root mean square amplitude 
(III) recorded in the CA3c area. The root mean square amplitude modification inverts the 
troughs after which a low pass filtered waveform becomes an good indicator of the power 
fluctuation over time. B. Cross-correlation between the power fluctuation in CA3c and CA1. 
There is a sizeable correlation between the powers in both areas. 
 
Because a wide spectrum of frequencies is recorded single units can be picked up. Recorded 
waveforms are high pass filtered for all frequencies above 300 Hz (Figure 6.7.A top). Any 
event that is bigger than three times the standard deviation (indicated with the grey line) is 
regarded as a single unit. The average single unit waveform in the CA3c of 1 experiment is 
shown in Figure 6.7.B. There is a distinctive average single unit visible showing the selected 
events are mostly single units. To determine if single units are related to the phase of the 
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gamma oscillations the timing of single units to gamma troughs (Figure 6.7.A bottom) was 
calculated. In four out of six experiments the intervals of single units to the gamma troughs 
are uniformly distributed (example in Figure 6.7.C, One sample Kolmogorov-Smirnov Test, 
Z=0.6, p=0.881) within the gamma oscillation. In two out of six experiments there is a non-
uniform distribution of the single units (example in Figure 6.7.D, One sample Kolmogorov-
Smirnov Test, Z=1.8, p=0.004). There is concentrated firing of the cells recorded just before 
the trough of the gamma peak in this experiment. 
 
Figure 6.7. Event correlation in CA3c. A. Trace high pass filtered (>300 Hz, top trace) with 
corresponding gamma (bottom trace). Any event with an amplitude falling through three 
standard deviations (grey line) is taken as a single unit. B. Average waveform from selected 
events. A clear single unit is visible in the middle with little activity next to it. C. Spike 
distribution relative to the gamma trough. This example shows a uniform distribution. D. 
Example of an experiment whit a non-uniform distributed spike distribution. Spikes are 
concentrated just before the trough of the gamma oscillation. 
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6.3.3. The effects of A1-receptor modulation on in vivo gamma oscillations. 
Because A1-receptors are distributed widely throughout the brain an injection into the 
ventricle is likely to affect other brain areas besides the hippocampus as well. Injecting the 
A1-receptor agonist CPA into the ventricle decreases heart rate and breathing rate. Care was 
taken to keep the blood oxygen levels above 80%. 
Due to the low numbers (n=3) in these experiments it is hard to make any definite 
conclusions on the effect of A1-receptor modulation on in vivo gamma oscillations. There are 
some interesting observations that do provide good clues to what possible effect A1-receptor 
modulation can have on in vivo gamma oscillations. Though not significant all rats injected 
with CPA (2 µg/kg) show a reduction of the power in all frequency bands in CA3c and CA1 
30 minutes after injection (see Tables 6.2 and 6.3). Figure 6.8. A and B shows an example 
of the change of in vivo brain oscillations in CA3c and CA1 after ventricular CPA (2 µg/kg) 
injection. In this example there is a clear reduction of power in the CA3c area while in the 
CA1 area the decrease is less pronounced. The power after 8-CPT (300 µg/kg) injection has 
a less consistent effect compared to the effect of CPA. On average there is an increase in 
power in all frequency bands in both CA3c and CA1 after 8-CPT injection (see Table 6.2 and 
6.3). The effect is less consistent because in one experiment both CA3c and CA1 show a 
reduction in power within the gamma range. In the example shown in Figure 6.8 C and D an 
increase in gamma power in the CA3c area (C) but a reduction in the CA1 area (D) is 
observed. 
All the other parameters described did not show any consistent effects and thus speculation 
about the possible influence A1-receptor modification would not be justified. The mean and 
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SEM of the cross-correlation, RMS-amplitude and spike distribution are summarised in 
Tables 6.2 and 6.3. 
 
Figure 6.8. A1-receptor modulation of oscillation power in vivo. A + B. Brain oscillations 
recorded in an anesthetised animal from the CA3c (A) and CA1 (B) region of the 
hippocampus (black lines). CPA (2 µg/kg) consistently reduced the power in all frequency 
bands in both areas (red lines). The power on the y-scale is on a logarithmic scale because 
the power in the lower frequencies is very high. C + D. Brain oscillations recorded in an 
anesthetised animal from the CA3c (C) and CA1 (D) region of the hippocampus (black lines). 
8-CPT (300 µg/kg) did not have a consistent effect on brain oscillations (blue lines). In this 
example the power in the CA3c area is increased in the gamma range, but reduced in the 
CA1 area. The power on the y-scale is on a logarithmic scale because the power in the lower 
frequencies is very high. 
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6.4. Discussion. 
Compared to in vitro recordings the oscillation recorded in vivo has a lot more power in the 
lower frequency bands. This is probably due to projections into the hippocampus from other 
brain areas that are severed when cutting slices. For instance, the hypothalamus and the 
septum project to the hippocampus with a theta range frequency (Kirk and Mackay, 2003). 
The oscillation in the CA3c area of the hippocampus measured in vivo has a higher 
gamma/beta ratio compared to the CA1 area. There is a small (not significant) phase lead of 
the CA3c area over the CA1 area and the power in both areas is also coupled. CA3c 
pyramidal neurons project to the stratum radiatum of the CA1 area while there are few 
projections from CA1 to CA3c. Thus it is likely that the CA3c influences the phase and 
possibly power of the gamma oscillation recorded in CA1. The linking of the two different 
areas in the hippocampus could serve as a means to transmit information between areas 
(Fries et al., 2007). In most experiments the timing of presumed single units was uniformly 
distributed compared to gamma troughs. In the few experiments that did have a non-
uniform spike distribution the resulting figure (Figure 6.7.D) is what you would expect for 
gamma oscillations (Fries et al., 2007). 
The increase in gamma band power during lightened anaesthetics was quite surprising. It 
could be that the type of anaesthesia used suppresses gamma oscillations and that what is 
recorded when the animal is deeply anaesthetised is a suppressed version of normal gamma 
oscillations. But if we compare the power spectrum during lightened anaesthetic with 
previously published in vivo recordings in freely moving animals (Buzsaki et al., 2003) the 
power in the gamma band is a lot higher. Thus it seems unlikely that the gamma recorded 
during lightened anaesthetic is the true gamma signal. It is more likely that it is a reaction 
to non-specific sensory stimuli reaching the cortex even though no pedal reflex was present. 
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Care was taken that in all experiments animals were anaesthetised to the standards required 
by the UK „Animals (Scientific Procedures) Act 1986‟ and the Biomedical Ethics Review Sub-
Committee. If it were the case that in the present experimental setup the gamma recorded 
is a suppressed version, one must be very careful in interpreting the results. Gamma 
oscillations in a freely moving animal might then respond in different ways that would not be 
picked up while looking at the suppressed version under anaesthetics.  
No definite conclusions can be drawn about the influence of A1-receptor modulation on in 
vivo gamma oscillations because the study was underpowered. The injection of A1-receptor 
agonist CPA did however have a very consistent effect by reducing the power in all 
frequency bands in all experiments. This general suppression is quite different from the 
change observed in vitro (chapter 2) where A1-receptor activation suppresses gamma band 
activity more specifically. The decrease in power in all frequency bands looks similar to a 
very high dose of adenosine in vitro which suppresses most oscillatory activity. The 
concentration CPA injected into the ventricle was about 100 times the receptor saturation 
concentration which could indicate a very high dose was used. However injections with a 5 
times lower concentration did not suppress network activity in any frequency bands (not 
shown). Another option is that because CPA was injected into the ventricle the incoming 
inputs from other brain areas are also suppressed. With the widespread distribution of A1-
receptors and the ventricle being connected to the septum it is likely that activity in the 
septum will also be suppressed. Suppression of the septum would cause a reduction of the 
theta range input to the hippocampus which would reduce the power in the lower frequency 
bands. Thus it looks like A1-receptor activation can also reduce gamma oscillations in vivo 
but in a less specific way. 
The A1-receptor antagonist 8-CPT did not show any consistent effect. The concentration used 
for 8-CPT (300 µg/kg) cannot easily be increased. 8-CPT cannot be dissolved in a higher 
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concentration than used which would leave as only option to increase the injection volume. 
Increasing the injection volume is not preferable because it will add more pressure to the 
brain of the rat and possibly displace all the aCSF in the ventricle. A better solution would be 
to use a different A1-receptor antagonist that can be injected using a small volume. The 
concentration 8-CPT used is at least 100 times higher than the receptor saturation 
concentration used in vitro. The fact that there is little effect of the 8-CPT injection with such 
high concentrations could also indicate that adenosine levels are low under the recording 
conditions. If ambient adenosine levels are low during anaesthesia experiments, 8-CPT will 
not be able to increase gamma oscillations.   
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6.5. Future research. 
As the study presented in this chapter was underpowered one should first increase the 
number of observations as to be able to draw better conclusions. Given the fact that gamma 
oscillations can increase substantially during lightened anaesthetics it is probably preferable 
to immediately investigate the effects of adenosine receptor modulation on gamma 
oscillations in freely moving animals. If the findings of the freely moving animal experiments 
are in line with previous result it would be interesting to investigate the role of A1-receptors 
and gamma oscillations in behavioural tasks relating behavioural performance to gamma 
oscillation strength modified by adenosine receptors. Both gamma oscillations strength (Fell 
et al., 2001;Herrmann et al., 2004) and A1-receptor modulation (Corodimas and Tomita, 
2001;Hauber and Bareiss, 2001) have been linked to increased cognitive function but there 
is no research yet linking both in the same experiment.  
The present study can be improved by injecting A1-receptor acting drugs more localised. The 
ventricle was chosen because the whole hippocampus could then be targeted. The reduction 
in the low frequency bands indicates brain areas projecting to the hippocampus are also 
suppressed by ventricular injection. A more localised injection will remove the change in 
activity of brain areas that project to the hippocampus. 
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Parameter  Parameter 
value 
before CPA (2 
µg/kg 
Before 8-CPT (300 
µg/kg) 
CA3c-CA1 n=6 n=3 n=3 n=3 n=3 
Cross-correlation 
Peak Mean 0.32 0.50 0.45 0.15 0.14 
 SEM 0.09 0.07 0.10 0.06 0.05 
Peak, time 
(ms) 
Mean 1.27 1.45 0.10 1.09 
3.30 
 SEM 0.63 0.80 0.81 1.13 2.96 
RMS amplitude  n=5 n=3 n=3 n=2 n=2 
Peak Mean 0.24 0.32 0.25 0.12 0.12 
 SEM 0.07 0.08 0.13 0.03 0.03 
Peak, time 
(ms) 
Mean 1.16 2.47 1.40 -0.80 
-5.8 
 SEM 1.56 2.43 1.93 0.40 7.0 
 
Table 6.1. Cross-correlation and RMS amplitude relationships between CA3c and CA1. 
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Parameter  Parameter 
value 
before CPA (2 
µg/kg 
CPA 
normalised 
Before 8-CPT 
(300 
µg/kg) 
8-CPT 
normalised 
CA3c n=6 n=3 n=3 n=3 n=3 n=3 n=3 
Power 
Gamma (30-
100 Hz 
Mean 13.1 21.2 15.3 0.66 5.1 
7.3 1.7 
 SEM 7.9 15.7 11.2 0.09 1.5 1.0 0.5 
Slow (3-13 
Hz) 
Mean 409.6 751.5 160.6 0.55 67.7 
89.3 1.2 
 SEM 295.5 564.8 86.4 0.24 24.7 44.8 0.3 
Beta (13-30 
Hz) 
Mean 60.1 102.4 38.8 0.48 17.8 
24.5 1.6 
 SEM 35.8 67.6 21.0 0.08 8.1 6.7 0.4 
Fast (100-250 
Hz) 
Mean 0.36 0.47 0.30 0.68 0.25 
0.39 1.6 
 SEM 0.15 0.31 0.18 0.04 0.04 0.00 0.2 
   
Gamma/beta 
ratio 
Mean 0.26 0.19 0.30  0.32 
0.34  
 SEM 0.04 0.02 0.10  0.05 0.08  
Spike distribution   
Z-value Mean 1.13 1.17 1.90  1.10 1.24  
 SEM 0.20 0.34 0.71  0.29 0.38  
 
Table 6.2. Effect of A1-receptor modulation on in vivo hippocampal (CA3c) gamma oscillations. Bold numbers indicate 
significant differences (p<0.05) between CA3c and CA1 (Table 6.3). 
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Parameter  Parameter 
value 
before CPA (2 
µg/kg 
CPA 
normalised 
Before 8-CPT 
(300 
µg/kg) 
8-CPT 
normalised 
CA1 n=6 n=3 n=3 n=3 n=3 n=3 n=3 
Power 
Gamma (30-
100 Hz 
Mean 14.1 10.1 4.3 0.63 18.0 
32.7 2.09 
 SEM 5.8 6.6 1.5 0.16 10.4 22.4 1.37 
Slow (3-13 
Hz) 
Mean 324.3 441.6 45.9 0.32 207.1 
493.4 2.26 
 SEM 169 351.2 10.7 0.17 75.7 253.4 0.98 
Beta (13-30 
Hz) 
Mean 76.7 70.3 28.2 0.65 83.2 
119.4 1.84 
 SEM 30.5 39.1 3.3 0.24 55.5 59.0 1.01 
Fast (100-250 
Hz) 
Mean 0.17 0.12 0.05 0.58 0.22 
0.29 1.23 
 SEM 0.05 0.06 0.01 0.17 0.08 0.12 0.22 
   
Gamma/beta 
ratio 
Mean 0.18 0.13 0.15  0.23 
0.24  
 SEM 0.03 0.02 0.04  0.04 0.07  
   
Z-value Mean 0.76 0.75 0.77  0.70 0.63  
 SEM 0.09 0.17 0.13  0.13 0.07  
 
Table 6.3. Effect of A1-receptor modulation on in vivo hippocampal (CA1) gamma oscillations. Bold numbers indicate 
significant differences (p<0.05) between CA1 and CA3c (Table 6.2). 
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CHAPTER 7: ADENOSINERGIC MODULATION OF HIPPOCAMPAL GAMMA 
OSCILLATIONS: FROM SINGLE CELL TO WHOLE ANIMAL. 
 
7.1. Can adenosine receptor modulation alter hippocampal gamma oscillations in vitro? 
Applying exogenous adenosine decreases hippocampal gamma oscillations in all of the in 
vitro models used. A high dose of adenosine decreases oscillatory activity in all frequency 
bands while a lower dose is specific for the gamma band. Adenosine suppresses gamma 
oscillations through A1-receptor activation. A2A-receptor activation moderately increases 
gamma oscillations. Blocking A1-receptors increases hippocampal gamma oscillations more 
potently than A2A-receptor activation. 
Fluctuating endogenous adenosine levels influence gamma oscillation strength in vitro. 
Increasing adenosine levels by blocking adenosine breakdown decreases gamma band 
activity specifically. Interestingly it is estimated that the increase in adenosine levels falls 
within the natural fluctuation observed in vivo. This makes a strong case that fluctuating 
adenosine levels can determine gamma oscillation strength in vivo. Decreasing adenosine 
levels by facilitating adenosine break-down has the opposite effect and increases gamma 
oscillations. 
 
7.2. What cellular and synaptic changes underlie adenosinergic modulation of hippocampal 
gamma oscillations? 
Adenosine decreases hippocampal gamma oscillations by hyperpolarising the resting 
membrane potential and inhibiting excitatory synaptic transmission through presynaptic 
receptors. Adenosine also increases the maximum IPSP amplitude most likely by increasing 
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the driving force through a shift of the IPSP reversal potential to a more negative potential. 
Monosynaptic inhibition is not altered by adenosine receptor modulation suggesting 
adenosine receptors are not present on inhibitory synapses. Increased strength of inhibitory 
synapses is more likely to increase gamma oscillations but adenosine has the opposite 
effect. Thus, the increase in driving force for inhibition is outweighed by the reduction in 
excitation and hyperpolarisation of the membrane potential.  
Blocking A1-receptors increases hippocampal gamma oscillations by facilitation of excitatory 
synapses and increasing principal cell excitability. By increasing principal cell excitability and 
making excitatory synapses more effective, more interneurons will be activated per gamma 
cycle resulting in an increase in the extracellular recorded signal.  
 
7.3. Does adenosinergic modulation have the same effect in vivo? 
Due to a small number of observations no definite conclusions can be drawn about the effect 
of A1-receptor modulation on in vivo gamma oscillations. However, A1-receptor activation did 
reduce the strength of the oscillation in all frequency bands in every experiment. This is 
quite different from the in vitro situation as there the suppression is more specific for the 
gamma band. This difference is most likely due to suppression of inputs from other brain 
regions projecting to the hippocampus. Blocking A1-receptors did not have any consistent 
effect on in vivo hippocampal gamma oscillations.  
 
7.4. Implications of this study. 
With the very clear effects of adenosinergic modulation of hippocampal gamma oscillations 
in vitro adenosine receptors seem like a good target to alter cognitive performance related 
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to gamma oscillations. However, the results in vivo are ambiguous indicating that a lot more 
work has to be done to find a suitable drug. Gamma oscillations are probably still a good 
target for treating memory deficiency or prevent memory decline during old age. Gamma 
oscillation strength has been linked to cognitive performance in rodents (Fuchs et al., 2007) 
making it likely that adenosinergic modulation of gamma oscillations can affect cognitive 
function. Among the drugs currently used to treat memory related diseases are 
cholinesterase inhibiters that prevent the breakdown of acetylcholine. Carbachol, used to 
induce hippocampal gamma oscillations in vitro, and acetylcholine target the same 
metabotropic receptors which is a good indication that gamma oscillations can be a viable 
target for treating memory deficiency. With the widespread distribution of adenosine 
receptors throughout the brain and their strong homology between different brain structures 
(Fredholm et al., 2001) adenosine receptor acting drugs are very likely to have many side 
effects. However if drugs can be designed to target specific areas in the brain adenosine 
receptors are a good candidate to modulate brain function. Both the A1-receptor and the A2A-
receptor have been shown to prevent cognitive impairment or increase cognitive function in 
rodents (Cognato et al., 2010;Hauber and Bareiss, 2001;Pereira et al., 2002). To maximise 
a drug‟s potential to increase gamma oscillations and possibly cognitive function using 
adenosine receptors, the compound used should ideally be an A1-receptor antagonist and an 
A2A-receptor agonist.  
In the case of old age dementia preventing the increase in adenosine levels with age can be 
a promising strategy. 
In conclusion adenosine receptors modulate gamma oscillations in vitro very effectively but 
are difficult targets for developing new treatments that have cognitive benefits because of 
their ambiguous effects in vivo. If brain areas can be targeted specifically adenosine 
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receptors are a good possible target to develop therapies for treating cognitive deficiencies 
linked to a reduction in gamma oscillation strength.  
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